#BEGIN_DRUGCARD DB03247

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
146-17-8

# ChEBI_ID:
17621

# Chemical_Formula:
C17H21N4O9P

# Chemical_IUPAC_Name:
{[(2R,3R,4R)-5-{7,8-dimethyl-2,4-dioxo-2H,3H,4H,10H-benzo[g]pteridin-10-yl}-2,3,4-trihydroxypentyl]oxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Vitamin B Complex

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Riboflavin Monophosphate

# HET_ID:
FMN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H21N4O9P/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H,20,25,26)(H2,27,28,29)/t11-,12-,14-/m1/s1

# InChI_Key:
InChIKey=FVTCRASFADXXNN-YRGRVCCFSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00061

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3247

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
456.3438

# Molecular_Weight_Mono:
456.104614802

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1SZF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.78

# Predicted_LogS:
-2.8

# Predicted_Water_Solubility:
6.68e-01 g/l

# Primary_Accession_No:
DB03247

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5702760

# PubChem_Substance_ID:
46507603

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01458

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=CC2=C(C=C1C)N(C[C@@H](O)[C@@H](O)[C@H](O)COP(O)(O)=O)C1=NC(=O)NC(=O)C1=N2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:04 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
POR

# Phase_1_Metabolizing_Enzyme_1_ID:
4120

# Phase_1_Metabolizing_Enzyme_1_Name:
NADPH--cytochrome P450 reductase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>NADPH--cytochrome P450 reductase
MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWV
VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPF
IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
YIKKLMTKGRYSLDVWS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P16435

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
AE001825

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
DR_A0214

# Drug_Target_10_Gene_Sequence:
>603 bp
TCAGCCGAGCAGCTTCGCCGTCAACTCCACCTGCCGCCTGACCTGATGGCGGATGCTCGC
CCGGTCATTCTCCAGCAGCGGCTGGCCGTTGGCGGTTACGCTCGCGCCGTAGGGGTTGCC
ACCGGACTTGAAAATCACCTCGTCGGTGTAGCCGGGAGGCGTCAGAACCGCGCCCCAGTG
CATCGCCGTCATGTACAGCGTTTGCAGGGTAGTTTCCTGGCCGCCGTTGACATTCTGGGC
CGAAGTCATTGCGCTGAAGGTCTTGTTCGCCAGTTTGCCGCTTGACCACAGGCCGCCGAG
GGTGTCGATGAACGCCCGCATCTGGCTCGTCGCGCCGCCGAAACGGGTGGGCGAGCTGAA
CACGATGGCTTCGGCCCATTCGAGGTCGGCGGGGGTCGCCTCTGGTACGTCTTTCATCGC
CTCGATGTTGGCTTTCCAGGCGTCCTGGCCGTCAATCACGTCTTGCGGAGCAGTTTCGCG
CACCTTGAGCAGCCGCACCTCGGCCCCGGCGGCGCGGCCCGCCTCGGCGGCTTCCTGGGC
CATGGCGTAGCCGGTGCCGGTGCTGGAATAAAAGACGATGGCGAGCTTGACAGGAGCGGT
CAT

# Drug_Target_10_General_Function:
Involved in FMN binding

# Drug_Target_10_General_References:
10567266	White O, Eisen JA, Heidelberg JF, Hickey EK, Peterson JD, Dodson RJ, Haft DH, Gwinn ML, Nelson WC, Richardson DL, Moffat KS, Qin H, Jiang L, Pamphile W, Crosby M, Shen M, Vamathevan JJ, Lam P, McDonald L, Utterback T, Zalewski C, Makarova KS, Aravind L, Daly MJ, Minton KW, Fleischmann RD, Ketchum KA, Nelson KE, Salzberg S, Smith HO, Venter JC, Fraser CM: Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1. Science. 1999 Nov 19;286(5444):1571-7.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
5197

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
21298

# Drug_Target_10_Name:
Trp repressor binding protein WrbA, putative

# Drug_Target_10_Number_of_Residues:
200

# Drug_Target_10_PDB_ID:
1YDG

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_10_Protein_Sequence:
>Trp repressor binding protein WrbA, putative
MTAPVKLAIVFYSSTGTGYAMAQEAAEAGRAAGAEVRLLKVRETAPQDVIDGQDAWKANI
EAMKDVPEATPADLEWAEAIVFSSPTRFGGATSQMRAFIDTLGGLWSSGKLANKTFSAMT
SAQNVNGGQETTLQTLYMTAMHWGAVLTPPGYTDEVIFKSGGNPYGASVTANGQPLLEND
RASIRHQVRRQVELTAKLLG

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Not Available

# Drug_Target_10_SwissProt_ID:
Q9RYU4

# Drug_Target_10_SwissProt_Name:
Q9RYU4_DEIRA

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
5.27

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
M59426

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
fldA

# Drug_Target_11_Gene_Sequence:
>531 bp
ATGGCTATCACTGGCATCTTTTTCGGCAGCGACACCGGTAATACCGAAAATATCGCAAAA
ATGATTCAAAAACAGCTTGGTAAAGACGTTGCCGATGTCCATGACATTGCAAAAAGCAGC
AAAGAAGATCTGGAAGCTTATGACATTCTGCTGCTGGGCATCCCAACCTGGTATTACGGC
GAAGCGCAGTGTGACTGGGATGACTTCTTCCCGACTCTCGAAGAGATTGATTTCAACGGC
AAACTGGTTGCGCTGTTTGGTTGTGGTGACCAGGAAGATTACGCCGAATATTTCTGCGAC
GCATTGGGCACCATCCGCGACATCATTGAACCGCGCGGTGCAACCATCGTTGGTCACTGG
CCAACTGCGGGCTATCATTTCGAAGCATCAAAAGGTCTGGCAGATGACGACCACTTTGTC
GGTCTGGCTATCGACGAAGACCGTCAGCCGGAACTGACCGCTGAACGTGTAGAAAAATGG
GTTAAACAGATTTCTGAAGAGTTGCATCTCGACGAAATTCTCAATGCCTGA

# Drug_Target_11_General_Function:
Involved in FMN binding

# Drug_Target_11_General_References:
1999390	Osborne C, Chen LM, Matthews RG: Isolation, cloning, mapping, and nucleotide sequencing of the gene encoding flavodoxin in Escherichia coli. J Bacteriol. 1991 Mar;173(5):1729-37.
7961651	Jenkins CM, Waterman MR: Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities. J Biol Chem. 1994 Nov 4;269(44):27401-8.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9119004	Ponstingl H, Otting G: NMR assignments, secondary structure and hydration of oxidized Escherichia coli flavodoxin. Eur J Biochem. 1997 Mar 1;244(2):384-99.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9416602	Hoover DM, Ludwig ML: A flavodoxin that is required for enzyme activation: the structure of oxidized flavodoxin from Escherichia coli at 1.8 A resolution. Protein Sci. 1997 Dec;6(12):2525-37.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
5198

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
19737

# Drug_Target_11_Name:
Flavodoxin-1

# Drug_Target_11_Number_of_Residues:
176

# Drug_Target_11_PDB_ID:
1AHN

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_11_Protein_Sequence:
>Flavodoxin-1
MAITGIFFGSDTGNTENIAKMIQKQLGKDVADVHDIAKSSKEDLEAYDILLLGIPTWYYG
EAQCDWDDFFPTLEEIDFNGKLVALFGCGDQEDYAEYFCDALGTIRDIIEPRGATIVGHW
PTAGYHFEASKGLADDDHFVGLAIDEDRQPELTAERVEKWVKQISEELHLDEILNA

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Low-potential electron donor to a number of redox enzymes (Potential). Involved in the reactivation of inactive cob(II)alamin in methionine synthase

# Drug_Target_11_SwissProt_ID:
P61949

# Drug_Target_11_SwissProt_Name:
FLAV_ECOLI

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
3.98

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
AB047343

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
fni

# Drug_Target_12_Gene_Sequence:
>1050 bp
GTGACTCGAGCAGAACGAAAAAGACAACACATCAATCATGCCTTGTCCATCGGCCAGAAG
CGGGAAACAGGTCTTGATGATATTACGTTTGTTCACGTCAGTCTGCCCGATCTTGCATTA
GAACAAGTAGATATTTCCACAAAAATCGGCGAACTTTCAAGCAGTTCGCCGATTTTTATC
AATGCAATGACTGGCGGCGGCGGAAAACTTACATATGAGATTAATAAATCGCTTGCGCGA
GCGGCTTCTCAGGCTGGAATTCCCCTTGCTGTGGGATCGCAAATGTCAGCATTAAAAGAT
CCATCAGAGCGTCTTTCCTATGAAATTGTTCGAAAGGAAAACCCAAACGGGCTGATTTTT
GCCAACCTGGGAAGCGAGGCAACGGCTGCTCAGGCAAAGGAAGCCGTTGAGATGATTGGA
GCAAACGCACTGCAGATCCACCTCAATGTGATTCAGGAAATTGTGATGCCTGAAGGGGAC
AGAAGCTTTAGCGGCGCATTGAAACGCATTGAACAAATTTGCAGCCGGGTCAGTGTACCG
GTCATTGTGAAAGAAGTCGGCTTCGGTATGAGCAAAGCATCAGCAGGAAAGCTGTATGAA
GCTGGTGCTGCAGCTGTTGACATTGGCGGTTACGGGGGAACAAATTTCTCGAAAATCGAA
AATCTCCGAAGACAGCGGCAAATCTCCTTTTTTAATTCGTGGGGCATTTCGACAGCTGCA
AGTTTGGCGGAAATCCGCTCTGAGTTTCCTGCAAGCACCATGATCGCCTCTGGCGGTCTG
CAAGATGCGCTTGACGTGGCAAAGGCAATTGCGCTGGGGGCCTCTTGCACCGGAATGGCA
GGGCATTTTTTAAAAGCGCTGACTGACAGCGGTGAGGAAGGACTGCTTGAGGAGATTCAG
CTGATCCTTGAGGAATTAAAGTTGATTATGACCGTGCTGGGTGCCAGAACAATTGCCGAT
TTACAAAAGGCGCCCCTTGTGATCAAAGGTGAAACCCATCATTGGCTCACAGAGAGAGGG
GTCAATACATCAAGCTATAGTGTGCGATAA

# Drug_Target_12_General_Function:
Involved in catalytic activity

# Drug_Target_12_General_References:
8760912	Sorokin A, Azevedo V, Zumstein E, Galleron N, Ehrlich SD, Serror P: Sequence analysis of the Bacillus subtilis chromosome region between the serA and kdg loci cloned in a yeast artificial chromosome. Microbiology. 1996 Aug;142 ( Pt 8):2005-16.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
5199

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
37221

# Drug_Target_12_Name:
Isopentenyl-diphosphate delta-isomerase

# Drug_Target_12_Number_of_Residues:
349

# Drug_Target_12_PDB_ID:
1P0N

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF01070	FMN_dh

# Drug_Target_12_Protein_Sequence:
>Isopentenyl-diphosphate delta-isomerase
MTRAERKRQHINHALSIGQKRETGLDDITFVHVSLPDLALEQVDISTKIGELSSSSPIFI
NAMTGGGGKLTYEINKSLARAASQAGIPLAVGSQMSALKDPSERLSYEIVRKENPNGLIF
ANLGSEATAAQAKEAVEMIGANALQIHLNVIQEIVMPEGDRSFSGALKRIEQICSRVSVP
VIVKEVGFGMSKASAGKLYEAGAAAVDIGGYGGTNFSKIENLRRQRQISFFNSWGISTAA
SLAEIRSEFPASTMIASGGLQDALDVAKAIALGASCTGMAGHFLKALTDSGEEGLLEEIQ
LILEELKLIMTVLGARTIADLQKAPLVIKGETHHWLTERGVNTSSYSVR

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Catalyzes the 1,3-allylic rearrangement of the homoallylic substrate isopentenyl (IPP) to its allylic isomer, dimethylallyl diphosphate (DMAPP) (By similarity)

# Drug_Target_12_SwissProt_ID:
P50740

# Drug_Target_12_SwissProt_Name:
IDI2_BACSU

# Drug_Target_12_Synonyms:
EC 5.3.3.2
IPP isomerase
Isopentenyl pyrophosphate isomerase

# Drug_Target_12_Theoretical_pI:
6.64

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Not Available

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
X60110

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
nox

# Drug_Target_13_Gene_Sequence:
>618 bp
ATGGAGGCGACCCTTCCCGTTTTGGACGCGAAGACGGCGGCCCTAAAGAGGCGTTCCATC
CGGCGTTACCGGAAGGACCCCGTACCCGAGGGGCTTCTCCGGGAAATCCTCGAGGCCGCC
CTCCGGGCGCCCTCGGCCTGGAACCTCCAGCCCTGGCGGATCGTGGTGGTGCGGGACCCC
GCCACCAAACGGGCCCTGAGGGAGGCGGCCTTCGGCCAGGCCCACGTGGAGGAGGCCCCC
GTGGTCCTGGTCCTCTACGCCGACCTCGAGGACGCTCTCGCCCACCTGGACGAGGTCATC
CACCCCGGGGTCCAGGGGGAAAGGCGTGAGGCGCAGAAGCAGGCCATCCAACGGGCCTTC
GCCGCCATGGGGCAAGAGGCGCGAAAGGCCTGGGCCTCCGGGCAGAGCTACATCCTCTTG
GGCTACCTCCTTCTCCTCCTGGAGGCTTATGGCCTCGGAAGCGTCCCCATGCTGGGGTTT
GACCCCGAGAGGGTGAGGGCGATCCTGGGGCTTCCTTCCCGCGCCGCCATCCCCGCCCTG
GTGGCCTTGGGCTACCCGGCGGAGGAGGGCTACCCCTCCCACCGCCTGCCCCTGGAGCGG
GTGGTCCTCTGGCGCTAG

# Drug_Target_13_General_Function:
Involved in oxidoreductase activity

# Drug_Target_13_General_References:
1577004	Park HJ, Kreutzer R, Reiser CO, Sprinzl M: Molecular cloning and nucleotide sequence of the gene encoding a H2O2-forming NADH oxidase from the extreme thermophilic Thermus thermophilus HB8 and its expression in Escherichia coli. Eur J Biochem. 1992 May 1;205(3):875-9.
1577005	Park HJ, Reiser CO, Kondruweit S, Erdmann H, Schmid RD, Sprinzl M: Purification and characterization of a NADH oxidase from the thermophile Thermus thermophilus HB8. Eur J Biochem. 1992 May 1;205(3):881-5.
8436145	Park HJ, Kreutzer R, Reiser CO, Sprinzl M: Molecular cloning and nucleotide sequence of the gene encoding a H2O2-forming NADH oxidase from the extreme thermophilic Thermus thermophilus HB8 and its expression in Escherichia coli. Eur J Biochem. 1993 Feb 1;211(3):909.
8846223	Hecht HJ, Erdmann H, Park HJ, Sprinzl M, Schmid RD: Crystal structure of NADH oxidase from Thermus thermophilus. Nat Struct Biol. 1995 Dec;2(12):1109-14.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
5200

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
22731

# Drug_Target_13_Name:
NADH dehydrogenase

# Drug_Target_13_Number_of_Residues:
205

# Drug_Target_13_PDB_ID:
1NOX

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_13_Protein_Sequence:
>NADH dehydrogenase
MEATLPVLDAKTAALKRRSIRRYRKDPVPEGLLREILEAALRAPSAWNLQPWRIVVVRDP
ATKRALREAAFGQAHVEEAPVVLVLYADLEDALAHLDEVIHPGVQGERREAQKQAIQRAF
AAMGQEARKAWASGQSYILLGYLLLLLEAYGLGSVPMLGFDPERVRAILGLPSHAAIPAL
VALGYPAEEGYPSHRLPLERVVLWR

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Can oxidize either NADH or NADPH with a preference for NADH. Can catalyze electron transfer from NADH to various electron acceptors which include, in addition to molecular oxygen, cytochrome c, 2,6 dichlorphenolindophenol, methylene blue, ferricyanide or P-nitroblue tetrazolium

# Drug_Target_13_SwissProt_ID:
Q60049

# Drug_Target_13_SwissProt_Name:
NOX_THET8

# Drug_Target_13_Synonyms:
EC 1.6.99.3
H(2)O(2)-forming NADH oxidase
NADH:oxygen oxidoreductase

# Drug_Target_13_Theoretical_pI:
9.31

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasm

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
Not Available

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
D21804

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
DvMF_2023

# Drug_Target_14_Gene_Sequence:
>369 bp
ATGCTGCCGGGTACATTTTTCGAAGTGCTGAAGAACGAAGGGGTCGTGGCCATCGCCACC
CAGGGCGAGGACGGACCGCATCTCGTCAACACCTGGAACAGCTACCTGAAGGTGCTGGAC
GGCAACCGCATCGTGGTGCCCGTGGGGGGCATGCACAAGACCGAGGCCAACGTTGCCCGC
GACGAACGGGTGCTGATGACTCTGGGCAGTCGCAAGGTGGCGGGTCGCAACGGGCCGGGC
ACGGGCTTCCTGATCCGGGGCTCTGCGGCGTTCCGCACCGATGGGCCGGAGTTCGAGGCC
ATCGCCCGTTTCAAGTGGGCCCGCGCGGCCCTGGTGATCACCGTGGTGTCGGCGGAGCAG
ACCCTGTAG

# Drug_Target_14_General_Function:
Involved in FMN binding

# Drug_Target_14_General_References:
10713530	Suto K, Kawagoe K, Shibata N, Morimoto Y, Higuchi Y, Kitamura M, Nakaya T, Yasuoka N: How do the x-ray structure and the NMR structure of FMN-binding protein differ? Acta Crystallogr D Biol Crystallogr. 2000 Mar;56(Pt 3):368-71.
8119891	Kitamura M, Kojima S, Ogasawara K, Nakaya T, Sagara T, Niki K, Miura K, Akutsu H, Kumagai I: Novel FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F). Cloning and expression of its gene in Escherichia coli. J Biol Chem. 1994 Feb 25;269(8):5566-73.
9406543	Liepinsh E, Kitamura M, Murakami T, Nakaya T, Otting G: Pathway of chymotrypsin evolution suggested by the structure of the FMN-binding protein from Desulfovibrio vulgaris (Miyazaki F) Nat Struct Biol. 1997 Dec;4(12):975-9.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
5201

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
13137

# Drug_Target_14_Name:
FMN-binding protein

# Drug_Target_14_Number_of_Residues:
122

# Drug_Target_14_PDB_ID:
1FLM

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_14_Protein_Sequence:
>FMN-binding protein
MLPGTFFEVLKNEGVVAIATQGEDGPHLVNTWNSYLKVLDGNRIVVPVGGMHKTEANVAR
DERVLMTLGSRKVAGRNGPGTGFLIRGSAAFRTDGPEFEAIARFKWARAALVITVVSAEQ
TL

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Functions as a redox protein with a potential of -325 mV

# Drug_Target_14_SwissProt_ID:
Q46604

# Drug_Target_14_SwissProt_Name:
FMNB_DESVM

# Drug_Target_14_Synonyms:
Not Available

# Drug_Target_14_Theoretical_pI:
9.94

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Not Available

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
Not Available

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
AE016877

# Drug_Target_15_GenBank_ID_Protein:
Not Available

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
BC_1844

# Drug_Target_15_Gene_Sequence:
>603 bp
ATGTCAGCAACTACAACAAACTTAAAAGAAGCAATCGTGAACCGCCGTTCAATTCGTAAA
GTAACAAAAAACGATGCAATTACGAAAGAAAGAATTGAAGAAGTGTTAAAAACAGCTTTA
CACGCACCAACATCTTTCAATATGCAAAGTGGTCGTATGGTTGTATTAATGGATGGAGAG
CATGAAAAGTTTTGGGATATCGTTAAAGAAACACTAAGAGCACGCGTACCAGCAGAAAAC
TTTGAAGCGACTGTAGAAAGACTAAAAGGCTTCCATGCAGGTGTAGGAACAGTTCTATTC
TTTGAAGATCAAGCAACTGTAGAAAAAATGCAAGAAAATGCCCCATTATACAAAGATCAG
TTCCCATTCTGGTCTCATCAAGGAAATGCGATGTTACAACATACTGTGTGGATGCTATTA
TCTGCTGAAGGAATTGGGGCGTCATTACAACATTACAACCCAATCGTAGATGCTGAAGTG
AAAGAAACTTGGAACATTCCGGCAGAGTGGAGCTTAGTAGGTCAAATGCCATTTGGTGAA
CCAAACGAACAACCAGCAGAAAGAACGTTCTTGCCTACTGAAGATGTAGTGAAATTTTAT
TAA

# Drug_Target_15_General_Function:
Involved in oxidoreductase activity

# Drug_Target_15_General_References:
12721630	Ivanova N, Sorokin A, Anderson I, Galleron N, Candelon B, Kapatral V, Bhattacharyya A, Reznik G, Mikhailova N, Lapidus A, Chu L, Mazur M, Goltsman E, Larsen N, D'Souza M, Walunas T, Grechkin Y, Pusch G, Haselkorn R, Fonstein M, Ehrlich SD, Overbeek R, Kyrpides N: Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis. Nature. 2003 May 1;423(6935):87-91.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
5202

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
22823

# Drug_Target_15_Name:
Nitroreductase family protein

# Drug_Target_15_Number_of_Residues:
200

# Drug_Target_15_PDB_ID:
1YWQ

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_15_Protein_Sequence:
>Nitroreductase family protein
MSATTTNLKEAIVNRRSIRKVTKNDAITKERIEEVLKTALHAPTSFNMQSGRMVVLMDGE
HEKFWDIVKETLRARVPAENFEATVERLKGFHAGVGTVLFFEDQATVEKMQENAPLYKDQ
FPFWSHQGNAMLQHTVWMLLSAEGIGASLQHYNPIVDAEVKETWNIPAEWSLVGQMPFGE
PNEQPAERTFLPTEDVVKFY

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Not Available

# Drug_Target_15_SwissProt_ID:
Q81EW9

# Drug_Target_15_SwissProt_Name:
Q81EW9_BACCR

# Drug_Target_15_Synonyms:
Not Available

# Drug_Target_15_Theoretical_pI:
5.34

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
POR

# Drug_Target_16_GenBank_ID_Gene:
S90469

# Drug_Target_16_GenBank_ID_Protein:
247307

# Drug_Target_16_GeneCard_ID:
POR

# Drug_Target_16_Gene_Name:
POR

# Drug_Target_16_Gene_Sequence:
>2031 bp
GGAGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAAGAAGTATCT
CTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTAACCTACTGG
TTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATTCAGACATTGACC
TCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGGAACATCATC
GTGTTCTACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGCCTGTCCAAGGAC
GCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGAC
CTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCCACCTACGGT
GAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAGGAGACAGACGTG
GATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAACAAGACCTACGAGCACTTC
AATGCCATGGGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCCCAGCGCATCTTT
GAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAG
CAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGGAGTCCAGC
ATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGTGTACATGGGG
GAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCCTTTGATGCCAAGAATCCG
TTCCTGGCTGCAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAGCGCCACCTCATG
CACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCT
GTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGCCGAC
CTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAGCACCCATTC
CCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACATCACCAACCCGCCG
CGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCTCGGAGCCCTCGGAGCAGGAGCTG
CTGCGCAAGATGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTG
GAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCCATC
GACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATCGCCTCATCC
TCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAGTACGAGACCAAG
GCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGCGGGCCAAGGAGCCTGTCGGG
GAGAACGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTACGCCTGCCC
TTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGTGGCACCCTTTCATA
GGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGGGGAGACGCTG
CTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGAGGAGCTGGCGCAG
TTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGGGAGCAGTCCCAC
AAGGTCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAAGTTGATCGAA
GGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCAGAAC
ACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGCGGTGGACTAC
ATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGCTAG

# Drug_Target_16_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_16_General_References:
10048323	Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, Driessen HP: Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci. 1999 Feb;8(2):298-306.
1550342	Shephard EA, Palmer CN, Segall HJ, Phillips IR: Quantification of cytochrome P450 reductase gene expression in human tissues. Arch Biochem Biophys. 1992 Apr;294(1):168-72.
2513880	Haniu M, McManus ME, Birkett DJ, Lee TD, Shively JE: Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochemistry. 1989 Oct 17;28(21):8639-45.

# Drug_Target_16_HGNC_ID:
HGNC:9208

# Drug_Target_16_HPRD_ID:
00485

# Drug_Target_16_ID:
4120

# Drug_Target_16_Locus:
7q11.2

# Drug_Target_16_Molecular_Weight:
76691

# Drug_Target_16_Name:
NADPH--cytochrome P450 reductase

# Drug_Target_16_Number_of_Residues:
677

# Drug_Target_16_PDB_ID:
1AMO

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1

# Drug_Target_16_Protein_Sequence:
>NADPH--cytochrome P450 reductase
MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWV
VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPF
IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
YIKKLMTKGRYSLDVWS

# Drug_Target_16_Reaction:
NADPH + H+ + n oxidized hemoprotein = NADP+ + n reduced hemoprotein ALL_REAC (other) R00106

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5

# Drug_Target_16_SwissProt_ID:
P16435

# Drug_Target_16_SwissProt_Name:
NCPR_HUMAN

# Drug_Target_16_Synonyms:
CPR
EC 1.6.2.4
P450R

# Drug_Target_16_Theoretical_pI:
5.28

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
PPCDC

# Drug_Target_17_GenBank_ID_Gene:
AY358848

# Drug_Target_17_GenBank_ID_Protein:
Not Available

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
PPCDC

# Drug_Target_17_Gene_Sequence:
>615 bp
ATGGAACCAAAGGCCTCCTGTCCAGCTGCTGCACCCTTGATGGAGAGAAAATTCCATGTT
CTTGTGGGTGTCACGGGGAGTGTCGCAGCCCTGAAGTTGCCTCTTCTGGTGTCAAAGCTT
TTGGACATTCCTGGGCTGGAAGTAGCAGTGGTCACAACTGAGAGAGCCAAACATTTCTAC
AGCCCCCAGGACATTCCTGTCACCCTCTACAGCGACGCTGATGAATGGGAGATGTGGAAG
AGCCGCTCTGACCCAGTTCTGCACATTGACCTGCGGAGGTGGGCAGACCTCCTGCTGGTG
GCTCCTCTTGATGCCAACACTCTGGGGAAGGTGGCCAGTGGCATCTGTGACAACTTGCTT
ACCTGCGTCATGCGGGCCTGGGACCGCAGCAAGCCCCTGCTCTTCTGCCCGGCCATGAAC
ACCGCCATGTGGGAGCACCCGATCACAGCGCAGCAGGTAGACCAGCTCAAGGCCTTTGGC
TATGTCGAGATCCCCTGTGTGGCCAAGAAGCTGGTGTGCGGAGATGAAGGTCTCGGGGCC
ATGGCTGAAGTGGGGACCATCGTGGACAAAGTGAAAGAAGTCCTCTTCCAGCACAGTGGC
TTCCAGCAGAGTTGA

# Drug_Target_17_General_Function:
Involved in catalytic activity

# Drug_Target_17_General_References:
11923312	Daugherty M, Polanuyer B, Farrell M, Scholle M, Lykidis A, de Crecy-Lagard V, Osterman A: Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. J Biol Chem. 2002 Jun 14;277(24):21431-9. Epub 2002 Mar 28.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_17_HGNC_ID:
HGNC:28107

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
5206

# Drug_Target_17_Locus:
15q24.2

# Drug_Target_17_Molecular_Weight:
22413

# Drug_Target_17_Name:
Phosphopantothenoylcysteine decarboxylase

# Drug_Target_17_Number_of_Residues:
204

# Drug_Target_17_PDB_ID:
1QZU

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF02441	Flavoprotein

# Drug_Target_17_Protein_Sequence:
>Phosphopantothenoylcysteine decarboxylase
MEPKASCPAAAPLMERKFHVLVGVTGSVAALKLPLLVSKLLDIPGLEVAVVTTERAKHFY
SPQDIPVTLYSDADEWEMWKSRSDPVLHIDLRRWADLLLVAPLDANTLGKVASGICDNLL
TCVMRAWDRSKPLLFCPAMNTAMWEHPITAQQVDQLKAFGYVEIPCVAKKLVCGDEGLGA
MAEVGTIVDKVKEVLFQHSGFQQS

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Necessary for the biosynthesis of coenzyme A. Catalyzes the decarboxylation of 4-phosphopantothenoylcysteine to form 4'- phosphopantotheine

# Drug_Target_17_SwissProt_ID:
Q96CD2

# Drug_Target_17_SwissProt_Name:
COAC_HUMAN

# Drug_Target_17_Synonyms:
CoaC
EC 4.1.1.36
PPC-DC

# Drug_Target_17_Theoretical_pI:
6.01

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
Not Available

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
AF005404

# Drug_Target_18_GenBank_ID_Protein:
Not Available

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
phzG

# Drug_Target_18_Gene_Sequence:
>645 bp
ATGGGCGTCAACGCGAACATTTCCGAGTCCCTCACCGGGACCATCGAAGCCCCTTTCCCG
GAGTTCGAGGCGCCGCCGGCGAACCCCATGGAGGTGCTGCGCAACTGGCTGGAACGCGCC
CGCCGCTACGGCGTGCGCGAGCCGCGGGCACTGGCCCTGGCCACGGTCGACGGGCAGGGC
CGGCCGTCGACGCGGATCGTGGTGATCGCCGAGCTGGGCGAGCGCGGGGTGGTGTTCGCC
ACCCACGCCGATAGCCAGAAGGGCCGCGAACTGGCGCAGAACCCCTGGGCCTCGGGGGTG
CTGTACTGGCGCGAGAGCAGCCAGCAGATCATCCTCAACGGCCGCGCCGAACGCCTGCCC
GACGAGCGCGCCGACGCCCAGTGGCTGAGCCGCCCGTACCAGACCCACCCGATGTCGATC
GCCTCGCGGCAGAGCGAAACCCTCGCCGACATCCACGCCCTGCGCGCCGAAGCCCGGCGC
CTGGCGGAAACCGACGGCCCGCTGCCGCGCCCGCCGGGCTACTGCCTGTTCGAACTGTGC
CTGGAGTCGGTGGAGTTCTGGGGCAACGGCACCGAGCGGCTGCACGAGCGCCTGCGCTAC
GACCGCGACGAAGGAGGCTGGAAGCACCGCTACCTGCAACCGTGA

# Drug_Target_18_General_Function:
Involved in FMN binding

# Drug_Target_18_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
11591691	Mavrodi DV, Bonsall RF, Delaney SM, Soule MJ, Phillips G, Thomashow LS: Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from Pseudomonas aeruginosa PAO1. J Bacteriol. 2001 Nov;183(21):6454-65.

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
5131

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
24269

# Drug_Target_18_Name:
PhzG

# Drug_Target_18_Number_of_Residues:
214

# Drug_Target_18_PDB_ID:
1T9M

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_18_Protein_Sequence:
>PhzG
MGVNANISESLTGTIEAPFPEFEAPPANPMEVLRNWLERARRYGVREPRALALATVDGQG
RPSTRIVVIAELGERGVVFATHADSQKGRELAQNPWASGVLYWRESSQQIILNGRAERLP
DERADAQWLSRPYQTHPMSIASRQSETLADIHALRAEARRLAETDGPLPRPPGYCLFELC
LESVEFWGNGTERLHERLRYDRDEGGWKHRYLQP

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Not Available

# Drug_Target_18_SwissProt_ID:
O69755

# Drug_Target_18_SwissProt_Name:
O69755_PSEAE

# Drug_Target_18_Synonyms:
Probable pyridoxamine 5'-phosphate oxidase

# Drug_Target_18_Theoretical_pI:
6.37

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
Not Available

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
X92480

# Drug_Target_19_GenBank_ID_Protein:
Not Available

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
gltS

# Drug_Target_19_Gene_Sequence:
>4674 bp
ATGTCCTTCCAATATCCGTTGCTAGCTCCTATGACAAACTCCTCTGTTGCCACCAATTCT
AACCAACCATTCCTTGGTCAACCTTGGTTAGTGGAAGAACGAGATGCCTGTGGTGTGGGT
TTTATTGCCAATCTCCGGGGTAAGCCGGACCATACCCTGGTGGAGCAGGCCCTAAAGGCT
CTGGGGTGTATGGAACATCGGGGGGGATGCAGTGCCGATAACGATTCAGGGGACGGGGCC
GGGGTGATGACCGCCATTCCTCGGGAACTACTGGCCCAGTGGTTTAACACCCGCAATTTG
CCCATGCCCGATGGCGATCGACTGGGGGTGGGAATGGTATTTTTACCCCAGGAACCCTCC
GCTAGGGAAGTGGCCCGGGCCTACGTAGAAGAAGTGGTACGGCTGGAAAAATTAACAGTG
TTAGGGTGGCGGGAAGTGCCCGTTAATTCTGATGTGCTGGGCATTCAAGCCAAAAATAAT
CAGCCCCACATTGAACAAATTTTAGTTACTTGTCCCGAAGGTTGTGCCGGAGATGAATTA
GATCGGCGATTGTACATTGCCCGCTCCATCATTGGTAAAAAATTAGCGGAAGATTTCTAC
GTTTGTTCCTTTTCCTGTCGCACCATTGTCTATAAAGGCATGGTCCGGAGCATTATTCTG
GGGGAATTTTATTTAGATTTAAAAAATCCTGGATATACCAGTAATTTCGCCGTTTACCAC
CGTCGTTTCAGCACCAATACCATGCCCAAATGGCCCCTGGCTCAACCCATGCGGCTATTG
GGTCATAACGGGGAAATTAATACCCTTTTAGGCAATATTAATTGGATGGCGGCCAGGGAA
AAAGAATTGGAAGTGTCGGGCTGGACAAAGGCGGAGTTAGAAGCATTAACTCCTATTGTT
AACCAAGCCAACAGTGATTCCTATAACCTTGATAGTGCCCTGGAATTGTTGGTGCGTACT
GGCCGCAGTCCCCTAGAAGCGGCGATGATTTTAGTGCCGGAAGCTTATAAAAATCAGCCA
GCTTTAAAAGATTACCCGGAAATTAGTGATTTCCATGACTACTACAGCGGTTTACAGGAA
CCCTGGGATGGCCCCGCTTTATTAGTATTTAGTGACGGCAAAATTGTTGGCGCTGGGCTA
GACCGGAATGGTTTACGGCCCGCCCGTTATTGCATTACCAAAGATGACTATATTGTCTTG
GGTTCCGAAGCGGGAGTCGTGGATTTACCGGAAGTAGATATTGTTGAAAAAGGTCGCCTA
GCACCGGGGCAAATGATTGCGGTGGATTTGGCTGAGCAAAAAATTCTCAAAAACTATCAA
ATTAAACAGCAGGCGGCCCAAAAATATCCCTATGGGGAATGGATAAAAATCCAGCGTCAA
ACGGTAGCTTCTGATAGCTTTGCTGAAAAAACTTTATTCAATGACGCTCAAACTGTACTG
CAACAACAGGCAGCTTTTGGCTACACCGCTCAAGATGTGGAAATGGTAGTGGTACCCATG
GCCAGCCAAGGTAAGGAACCAACTTTTTGCATGGGGGACGATACGCCCTTAGCTGTACTA
TCCCATAAACCCCGCTTACTGTACGACTATTTCAAACAGCGCTTTGCCCAGGTGACCAAT
CCCCCCATTGATCCTCTGCGGGAAAATTTGGTCATGTCCCTAGCTATGTTTTTAGGCAAA
CGGGGCAATTTGTTAGAGCCTAAAGCGAATCCGCGCCGGACGATTAAACTCCGATCGCCA
TTGGTCAATGAAGTAGAGTTACAGGCCATTAAAACTGGACAGTTGCAGGTGGCAGAAGTT
TCTACCCTTTACGATCTAGATGGGGTGAATAGTCTGGAAACCGCCTTAGATAATTTAGTT
AAAACGGCGATCGCCACTGTGCAAGCCGGGGCAGAAATCTTGGTTTTAACTGATCGTCCT
AACCGGCGCAATATTGGACTGAGAATCAAAGTTTTTATTCCCCCCTTGTTGGCAGTGGAA
GCAGTACATCACCATCTAATTCGGGCCGGGCTAAGGCTAAAAGCGTCCCTAATTGTGGAC
ACCGCCCAGTGTTGGAGTACCCATCATTTTGCCTGCTTGGTAGGCTATGGTGCTTCGGCC
ATTTGTCCCTACCTAGCGTTGGAATCCGTGCGGCAATGGTGGTTAGATGAAAAGACCCAA
AAGCTGATGGAAAATGGGCGCTTGGATCGGATTGACTTACCCACGGCGCTGAAGAATTAT
CGCCAATCCGTGGAAGCAGGATTATTTAAAATTCTCTCCAAAATGGGCATTTCCCTGCTG
GCTTCCTACCACGGTGCCCAAATCTTCGAGGCGATCGGTTTAGGGGCGGAATTGGTGGAA
TATGCCTTTGCTGGAACTACCAGTCGGGTGGGCGGTTTGACCATCGCTGATGTGGCCGGG
GAAGTAATGGTTTTCCATGGCATGGCCTTCCCGGAAATGGCTAAGAAGTTAGAGAACTTT
GGCTTTGTCAACTACCGTCCCGGCGGAGAATATCACATGAACTCGCCGGAGATGTCCAAG
TCTCTCCATAAGGCAGTGGCAGCCTACAAAGTGGGCGGTAATGGTAACAATGGGGAAGCC
TATGACCATTACGAGTTGTACCGTCAATATCTCAAAGACCGTCCTGTCACTGCCCTGCGG
GATTTGCTCGATTTCAATGCAGACCAACCGGCCATTTCCTTAGAAGAAGTGGAATCGGTG
GAAAGTATTGTCAAGCGCTTCTGTACTGGCGGTATGTCCCTCGGTGCGTTGTCCCGGGAA
GCCCATGAAACCTTGGCGATCGCCATGAATCGTTTAGGAGCTAAATCCAATTCCGGGGAA
CCCCCAGAAGATGTAGTACGTTACCTCACTCTAGATGATGTGGATAGCGAAGGAAATTCC
CCCACCTTGCCCCATCTCCACGGCCTGCAAAATGGAGACACGGCCAACTCCGCCATTAAG
CAAATTGCCTCCGGTCGTTTTGGGGTTACCCCGGAATATTTGATGAGTGGCAAACAGTTG
GAAATTAAAATGGCCCAGGGTGCTAAACCTGGGGAAGGGGGGCAGTTACCAGGCAAAAAA
GTCAGTGAATATATTGCCATGTTGCGCCGTTCTAAACCCGGTGTAACCCTCATTTCTCCG
CCGCCCCACCATGACATTTACTCCATCGAAGATTTAGCCCAATTAATTTACGATCTCCTA
CAAATCAATCCCGAAGCCCAGGTATCGGTGAAATTGGTGGCGGAAATTGGTATTGGTACG
ATCGCCGCTGGGGTTGCTAAGGCCAATGCGGATATTATCCAAATTTCTGGCCATGACGGT
GGTACAGGGGCATCACCTTTAAGCTCCATTAAACACGCTGGTTCTCCCTGGGAGCTTGGT
GTTACGGAAGTGCATCGGGTGTTAATGGAAAACCAACTGCGCGATCGGGTTTTGCTGCGG
GCTGATGGTGGTCTGAAAACCGGTTGGGACGTAGTGATGGCCGCCCTTATGGGAGCGGAG
GAGTATGGCTTTGGCTCCATTGCCATGATTGCCGAAGGTTGCATTATGGCCCGGGTTTGC
CACACTAATAATTGTCCCGTCGGGGTTGCCACCCAGCAAGAACGGTTACGGCAACGCTTT
AAAGGAGTGCCGGGGCAGGTGGTTAATTTCTTCTATTTCATTGCCGAGGAAGTGCGCTCC
CTGTTGGCCCATTTAGGTTATCGCAGTTTGGACGACATCATTGGCCGCACTGATCTACTC
AAAGTTCGCTCCGATGTCCAGTTGAGCAAAACCCAGAATCTGACCTTAGATTGTCTGTTA
AATTTGCCCGACACGAAGCAAAACCGGCAATGGTTAAATCACGAACCAGTCCACAGCAAC
GGCCCAGTGTTGGACGACGACATTTTGGCCGACCCTGACATCCAAAGGAAAGCCATTAAC
CATCAAACCACTGCGACCAAAACCTATCGGCTGGACAATACCGACCGCACTGTGGGCACC
CGTCTCTCCGGGTCGATCGCGAAAAAGTATGGCAACAATGGTTTTGAAGGTAACATTACC
CTCAACTTCCAAGGCGCCGCTGGTCAGAGTTTTGGTGCCTTTAACCTGGATGGCATGACC
CTACATCTGCAAGGGGAAGCCAACGACTATGTGGGCAAAGGCATGAATGGGGGTGAAATT
GTCATCGTGCCCCATCCCCAGGCGAGCTTTGCACCGGAAGACAATGTAATTATTGGTAAC
ACCTGTCTCTATGGAGCGACGGGGGGCAACCTTTATGCCAACGGCCGGGCGGGGGAACGC
TTTGCAGTGCGTAACTCCGTGGGTAAAGCCGTGATTGAAGGAGCTGGCGATCACTGTTGT
GAATATATGACCGGTGGCGTGATTGTCGTCCTTGGCCCTGTGGGTCGGAACGTTGGTGCT
GGCATGACTGGTGGTTTGGCTTACTTCCTCGATGAAGTAGGGGATTTACCAGAAAAAATC
AACCCGGAAATCATCACCTTGCAAAGGATCACAGCTTCTAAAGGGGAGGAACAATTGAAA
TCCTTGATTACTGCCCACGTTGAACACACAGGTAGCCCAAAAGGCAAGGCAATTCTGGCT
AACTGGTCCGATTATCTCGGCAAATTCTGGCAGGCCCCTCCTTCCGAAAAAGACTCTCCT
GAAGCCAATGGGGATGTCAGCTTAACCGGGGAGAAGACACTGACCTCTGTCTAG

# Drug_Target_19_General_Function:
Involved in catalytic activity

# Drug_Target_19_General_References:
7727752	Navarro F, Chavez S, Candau P, Florencio FJ: Existence of two ferredoxin-glutamate synthases in the cyanobacterium Synechocystis sp. PCC 6803. Isolation and insertional inactivation of gltB and gltS genes. Plant Mol Biol. 1995 Feb;27(4):753-67.
8905231	Kaneko T, Sato S, Kotani H, Tanaka A, Asamizu E, Nakamura Y, Miyajima N, Hirosawa M, Sugiura M, Sasamoto S, Kimura T, Hosouchi T, Matsuno A, Muraki A, Nakazaki N, Naruo K, Okumura S, Shimpo S, Takeuchi C, Wada T, Watanabe A, Yamada M, Yasuda M, Tabata S: Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. DNA Res. 1996 Jun 30;3(3):109-36.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
4836

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
169501

# Drug_Target_19_Name:
Ferredoxin-dependent glutamate synthase 2

# Drug_Target_19_Number_of_Residues:
1556

# Drug_Target_19_PDB_ID:
1OFE

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00310	GATase_2
PF01493	GXGXG
PF01645	Glu_synthase
PF04898	Glu_syn_central

# Drug_Target_19_Protein_Sequence:
>Ferredoxin-dependent glutamate synthase 2
MSFQYPLLAPMTNSSVATNSNQPFLGQPWLVEERDACGVGFIANLRGKPDHTLVEQALKA
LGCMEHRGGCSADNDSGDGAGVMTAIPRELLAQWFNTRNLPMPDGDRLGVGMVFLPQEPS
AREVARAYVEEVVRLEKLTVLGWREVPVNSDVLGIQAKNNQPHIEQILVTCPEGCAGDEL
DRRLYIARSIIGKKLAEDFYVCSFSCRTIVYKGMVRSIILGEFYLDLKNPGYTSNFAVYH
RRFSTNTMPKWPLAQPMRLLGHNGEINTLLGNINWMAAREKELEVSGWTKAELEALTPIV
NQANSDSYNLDSALELLVRTGRSPLEAAMILVPEAYKNQPALKDYPEISDFHDYYSGLQE
PWDGPALLVFSDGKIVGAGLDRNGLRPARYCITKDDYIVLGSEAGVVDLPEVDIVEKGRL
APGQMIAVDLAEQKILKNYQIKQQAAQKYPYGEWIKIQRQTVASDSFAEKTLFNDAQTVL
QQQAAFGYTAEDVEMVVVPMASQGKEPTFCMGDDTPLAVLSHKPRLLYDYFKQRFAQVTN
PPIDPLRENLVMSLAMFLGKRGNLLEPKAESARTIKLRSPLVNEVELQAIKTGQLQVAEV
STLYDLDGVNSLETALDNLVKTAIATVQAGAEILVLTDRPNGAILTENQSFIPPLLAVGA
VHHHLIRAGLRLKASLIVDTAQCWSTHHFACLVGYGASAICPYLALESVRQWWLDEKTQK
LMENGRLDRIDLPTALKNYRQSVEAGLFKILSKMGISLLASYHGAQIFEAIGLGAELVEY
AFAGTTSRVGGLTIADVAGEVMVFHGMAFPEMAKKLENFGFVNYRPGGEYHMNSPEMSKS
LHKAVAAYKVGGNGNNGEAYDHYELYRQYLKDRPVTALRDLLDFNADQPAISLEEVESVE
SIVKRFCTGGMSLGALSREAHETLAIAMNRLGAKSNSGEGGEDVVRYLTLDDVDSEGNSP
TLPHLHGLQNGDTANSAIKQIASGRFGVTPEYLMSGKQLEIKMAQGAKPGEGGQLPGKKV
SEYIAMLRRSKPGVTLISPPPHHDIYSIEDLAQLIYDLHQINPEAQVSVKLVAEIGIGTI
AAGVAKANADIIQISGHDGGTGASPLSSIKHAGSPWELGVTEVHRVLMENQLRDRVLLRA
DGGLKTGWDVVMAALMGAEEYGFGSIAMIAEGCIMARVCHTNNCPVGVATQQERLRQRFK
GVPGQVVNFFYFIAEEVRSLLAHLGYRSLDDIIGRTDLLKVRSDVQLSKTQNLTLDCLLN
LPDTKQNRQWLNHEPVHSNGPVLDDDILADPDIQEAINHQTTATKTYRLVNTDRTVGTRL
SGAIAKKYGNNGFEGNITLNFQGAAGQSFGAFNLDGMTLHLQGEANDYVGKGMNGGEIVI
VPHPQASFAPEDNVIIGNTCLYGATGGNLYANGRAGERFAVRNSVGKAVIEGAGDHCCEY
MTGGVIVVLGPVGRNVGAGMTGGLAYFLDEVGDLPEKINPEIITLQRITASKGEEQLKSL
ITAHVEHTGSPKGKAILANWSDYLGKFWQAVPPSEKDSPEANGDVSLTGEKTLTSV

# Drug_Target_19_Reaction:
Not Available

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
2 L-glutamate + 2 oxidized ferredoxin = L- glutamine + 2-oxoglutarate + 2 reduced ferredoxin

# Drug_Target_19_SwissProt_ID:
P55038

# Drug_Target_19_SwissProt_Name:
GLTS_SYNY3

# Drug_Target_19_Synonyms:
EC 1.4.7.1
FD-GOGAT

# Drug_Target_19_Theoretical_pI:
5.53

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X68079

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
tmd

# Drug_Target_1_Gene_Sequence:
>2193 bp
ATGGCACGAGATCCGAAGCATGATATTTTGTTTGAGCCAATACAAATTGGCCCCAAAACA
TTACGCAATCGCTTTTACCAGGTACCGCATTGTATCGGTGCTGGATCCGATAAGCCTGGC
TTTCAATCTGCACACCGTTCGGTTAAAGCTGAAGGCGGTTGGGCGGCTTTAAACACTGAA
TATTGCTCCATTAACCCTGAGTCAGATGATACACATCGTTTGTCCGCACGTATCTGGGAC
GAAGGTGATGTGCGTAACTTGAAAGCCATGACCGACGAAGTTCATAAGTACGGTGCATTA
GCCGGGGTCGAGTTATGGTACGGCGGTGCACACGCACCTAACATGGAGTCACGCGCGACC
CCACGTGGTCCAAGCCAATATGCGTCAGAGTTTGAGACGCTGTCCTACTGTAAAGAAATG
GATCTAAGCGATATCGCTCAGGTACAGCAGTTCTATGTTGATGCAGCGAAGCGCTCTCGT
GACGCTGGTTTTGACATTGTCTACGTATACGGTGCGCACTCTTATTTGCCGCTGCAATTC
CTGAATCCATACTACAACAAGCGTACAGACAAATACGGTGGCTCATTGGAGAACCGTGCG
CGCTTCTGGCTGGAAACACTAGAAAAAGTGAAGCATGCCGTGGGTTCAGATTGTGCGATT
GCGACACGTTTCGGCGTGGATACTGTGTATGGTCCAGGTCAAATCGAAGCAGAAGTGGAT
GGTCAGAAGTTTGTTGAAATGGCTGACTCACTGGTCGATATGTGGGATATCACAATTGGT
GATATTGCCGAGTGGGGCGAAGATGCGGGGCCGTCACGTTTCTACCAGCAAGGTCACACC
ATCCCTTGGGTTAAATTGGTCAAACAGGTTTCCAAAAAACCAGTATTAGGCGTTGGCCGT
TATACCGACCCTGAGAAAATGATCGAAATCGTCACCAAAGGCTATGCCGACATTATTGGT
TGTGCACGCCCTTCTATTGCTGATCCGTTCTTGCCACAAAAGGTTGAGCAGGGTCGCTAC
GACGATATCCGTGTATGTATTGGTTGTAACGTGTGTATTTCCCGCTGGGAAATCGGTGGT
CCTCCAATGATTTGTACCCAGAATGCGACAGCAGGTGAAGAGTACCGTCGTGGTTGGCAT
CCAGAGAAATTCCGTCAAACCAAGAACAAGGATTCTGTATTGATCGTTGGTGCAGGCCCA
TCCGGTTCTGAAGCAGCCCGCGTATTGATGGAAAGCGGTTATACCGTGCACTTGACCGAT
ACCGCAGAGAAAATCGGTGGTCACTTGAACCAGGTGGCAGCGTTGCCTGGCTTGGGTGAG
TGGAGCTATCACCGCGATTATCGTGAAACACAAATCACCAAGTTGCTGAAGAAGAACAAA
GAAAGCCAATTGGCATTGGGTCAAAAACCAATGACGGCTGACGACGTGCTGCAATATGGT
GCTGACAAAGTCATCATCGCTACCGGTGCGCGCTGGAATACCGATGGTACCAACTGCCTG
ACGCATGACCCAATTCCAGGGGCAGATGCTTCCTTGCCAGATCAACTGACACCAGAGCAA
GTCATGGATGGTAAGAAGAAGATTGGTAAGCGCGTGGTGATTCTGAATGCGGATACTTAT
TTCATGGCGCCTAGCCTGGCTGAGAAGCTTGCGACGGCTGGTCACGAAGTAACCATCGTT
TCTGGCGTGCACCTGGCTAACTACATGCACTTCACGCTGGAATATCCAAACATGATGCGT
CGTTTGCACGAACTGCATGTTGAAGAGTTGGGCGATCACTTCTGCTCACGTATCGAACCA
GGCCGTATGGAAATCTACAACATCTGGGGCGATGGTTCCAAACGTACTTACCGTGGCCCA
GGCGTTTCTCCGCGTGATGCCAATACCTCGCATCGTTGGATTGAGTTTGACTCCCTGGTG
CTGGTGACAGGCCGTCATTCAGAGTGCACGCTGTGGAATGAGTTAAAAGCCCGTGAATCT
GAGTGGGCTGAGAACGACATTAAAGGTATCTACCTGATTGGTGATGCTGAGGCGCCTCGT
TTGATTGCTGATGCCACATTTACGGGTCACCGTGTGGCCCGTGAAATTGAAGAAGCAAAC
CCACAAATTGCCATCCCATACAAGCGTGAAACCATCGCATGGGGCACGCCGCATATGCCA
GGTGGTAATTTCAAAATTGAGTACAAAGTTTAA

# Drug_Target_1_General_Function:
Involved in catalytic activity

# Drug_Target_1_General_References:
12567183	Leys D, Basran J, Talfournier F, Sutcliffe MJ, Scrutton NS: Extensive conformational sampling in a ternary electron transfer complex. Nat Struct Biol. 2003 Mar;10(3):219-25.
1505666	Boyd G, Mathews FS, Packman LC, Scrutton NS: Trimethylamine dehydrogenase of bacterium W3A1. Molecular cloning, sequence determination and over-expression of the gene. FEBS Lett. 1992 Aug 24;308(3):271-6.
1551870	Barber MJ, Neame PJ, Lim LW, White S, Matthews FS: Correlation of x-ray deduced and experimental amino acid sequences of trimethylamine dehydrogenase. J Biol Chem. 1992 Apr 5;267(10):6611-9.
620783	Kenney WC, McIntire W, Steenkamp DJ: Amino acid sequence of a cofactor peptide from trimethylamine dehydrogenase. FEBS Lett. 1978 Jan 1;85(1):137-40.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5189

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
81630

# Drug_Target_1_Name:
Trimethylamine dehydrogenase

# Drug_Target_1_Number_of_Residues:
730

# Drug_Target_1_PDB_ID:
1O95

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00724	Oxidored_FMN
PF07992	Pyr_redox_2

# Drug_Target_1_Protein_Sequence:
>Trimethylamine dehydrogenase
MARDPKHDILFEPIQIGPKTLRNRFYQVPHCIGAGSDKPGFQSAHRSVKAEGGWAALNTE
YCSINPESDDTHRLSARIWDEGDVRNLKAMTDEVHKYGALAGVELWYGGAHAPNMESRAT
PRGPSQYASEFETLSYCKEMDLSDIAQVQQFYVDAAKRSRDAGFDIVYVYGAHSYLPLQF
LNPYYNKRTDKYGGSLENRARFWLETLEKVKHAVGSDCAIATRFGVDTVYGPGQIEAEVD
GQKFVEMADSLVDMWDITIGDIAEWGEDAGPSRFYQQGHTIPWVKLVKQVSKKPVLGVGR
YTDPEKMIEIVTKGYADIIGCARPSIADPFLPQKVEQGRYDDIRVCIGCNVCISRWEIGG
PPMICTQNATAGEEYRRGWHPEKFRQTKNKDSVLIVGAGPSGSEAARVLMESGYTVHLTD
TAEKIGGHLNQVAALPGLGEWSYHRDYRETQITKLLKKNKESQLALGQKPMTADDVLQYG
ADKVIIATGARWNTDGTNCLTHDPIPGADASLPDQLTPEQVMDGKKKIGKRVVILNADTY
FMAPSLAEKLATAGHEVTIVSGVHLANYMHFTLEYPNMMRRLHELHVEELGDHFCSRIEP
GRMEIYNIWGDGSKRTYRGPGVSPRDANTSHRWIEFDSLVLVTGRHSECTLWNELKARES
EWAENDIKGIYLIGDAEAPRLIADATFTGHRVAREIEEANPQIAIPYKRETIAWGTPHMP
GGNFKIEYKV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Trimethylamine + H(2)O + electron-transferring flavoprotein = dimethylamine + formaldehyde + reduced electron- transferring flavoprotein

# Drug_Target_1_SwissProt_ID:
P16099

# Drug_Target_1_SwissProt_Name:
DHTM_METME

# Drug_Target_1_Synonyms:
EC 1.5.8.2
TMADh

# Drug_Target_1_Theoretical_pI:
6.31

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
M92351

# Drug_Target_20_GenBank_ID_Protein:
Not Available

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
pdxH

# Drug_Target_20_Gene_Sequence:
Not Available

# Drug_Target_20_General_Function:
Coenzyme transport and metabolism

# Drug_Target_20_General_References:
10903950	Safo MK, Mathews I, Musayev FN, di Salvo ML, Thiel DJ, Abraham DJ, Schirch V: X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with FMN at 1.8 A resolution. Structure. 2000 Jul 15;8(7):751-62.
11453690	Safo MK, Musayev FN, di Salvo ML, Schirch V: X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with pyridoxal 5'-phosphate at 2.0 A resolution. J Mol Biol. 2001 Jul 20;310(4):817-26.
1356963	Lam HM, Winkler ME: Characterization of the complex pdxH-tyrS operon of Escherichia coli K-12 and pleiotropic phenotypes caused by pdxH insertion mutations. J Bacteriol. 1992 Oct;174(19):6033-45.
7860596	Zhao G, Winkler ME: Kinetic limitation and cellular amount of pyridoxine (pyridoxamine) 5'-phosphate oxidase of Escherichia coli K-12. J Bacteriol. 1995 Feb;177(4):883-91.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9693059	Di Salvo M, Yang E, Zhao G, Winkler ME, Schirch V: Expression, purification, and characterization of recombinant Escherichia coli pyridoxine 5'-phosphate oxidase. Protein Expr Purif. 1998 Aug;13(3):349-56.

# Drug_Target_20_HGNC_ID:
Not Available

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
3766

# Drug_Target_20_Locus:
Not Available

# Drug_Target_20_Molecular_Weight:
25545

# Drug_Target_20_Name:
Pyridoxamine 5'-phosphate oxidase

# Drug_Target_20_Number_of_Residues:
218

# Drug_Target_20_PDB_ID:
1WV4

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_20_Protein_Sequence:
>Pyridoxamine 5'-phosphate oxidase
MSDNDELQQIAHLRREYTKGGLRRRDLPADPLTLFERWLSQACEAKLADPTAMVVATVDE
HGQPYQRIVLLKHYDEKGMVFYTNLGSRKAHQIENNPRVSLLFPWHTLERQVMVIGKAER
LSTLEVMKYFHSRPRDSQIGAWVSKQSSRISARGILESKFLELKQKFQQGEVPLPSFWGG
FRVSLEQIEFWQGGEHRLHDRFLYQRENDAWKIDRLAP

# Drug_Target_20_Reaction:
pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + ammonia + H2O2

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Oxidizes PNP and PMP into pyridoxal 5'-phosphate (PLP)

# Drug_Target_20_SwissProt_ID:
P0AFI7

# Drug_Target_20_SwissProt_Name:
PDXH_ECOLI

# Drug_Target_20_Synonyms:
EC 1.4.3.5
PNP/PMP oxidase
PNPOx

# Drug_Target_20_Theoretical_pI:
9.60

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Not Available

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
Not Available

# Drug_Target_21_GenBank_ID_Gene:
Not Available

# Drug_Target_21_GenBank_ID_Protein:
Not Available

# Drug_Target_21_GeneCard_ID:
Not Available

# Drug_Target_21_Gene_Name:
Not Available

# Drug_Target_21_Gene_Sequence:
Not Available

# Drug_Target_21_General_Function:
Energy production and conversion

# Drug_Target_21_General_References:
4843141	Burnett RM, Darling GD, Kendall DS, LeQuesne ME, Mayhew SG, Smith WW, Ludwig ML: The structure of the oxidized form of clostridial flavodoxin at 1.9-A resolution. J Biol Chem. 1974 Jul 25;249(14):4383-92.
4843142	Tanka M, Haniu M, Yasunobu F, Mayhew SG: The amino acid sequence of the Clostridium MP flavodoxin. J Biol Chem. 1974 Jul 25;249(14):4393-6.
9063874	Ludwig ML, Pattridge KA, Metzger AL, Dixon MM, Eren M, Feng Y, Swenson RP: Control of oxidation-reduction potentials in flavodoxin from Clostridium beijerinckii: the role of conformation changes. Biochemistry. 1997 Feb 11;36(6):1259-80.

# Drug_Target_21_HGNC_ID:
Not Available

# Drug_Target_21_HPRD_ID:
Not Available

# Drug_Target_21_ID:
3293

# Drug_Target_21_Locus:
Not Available

# Drug_Target_21_Molecular_Weight:
15332

# Drug_Target_21_Name:
Flavodoxin

# Drug_Target_21_Number_of_Residues:
138

# Drug_Target_21_PDB_ID:
5ULL

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_21_Protein_Sequence:
>Flavodoxin
MKIVYWSGTGNTEKMAELIAKGIIESGKDVNTINVSDVNIDELLNEDILILGCSAMGDEV
LEESEFEPFIEEISTKISGKKVALFGSYGWGDGKWMRDFEERMNGYGCVVVETPLIVQNE
PDEAEQDCIEFGKKIANI

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Low-potential electron donor to a number of redox enzymes

# Drug_Target_21_SwissProt_ID:
P00322

# Drug_Target_21_SwissProt_Name:
FLAV_CLOBE

# Drug_Target_21_Synonyms:
Not Available

# Drug_Target_21_Theoretical_pI:
3.93

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Not Available

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
Not Available

# Drug_Target_22_GenBank_ID_Gene:
D25414

# Drug_Target_22_GenBank_ID_Protein:
538227

# Drug_Target_22_GeneCard_ID:
Not Available

# Drug_Target_22_Gene_Name:
nfnB

# Drug_Target_22_Gene_Sequence:
>654 bp
ATGGATATCATTTCTGTCGCCTTAAAGCGTCATTCCACTAAGGCATTTGATGCCAGCAAA
AAACTTACCCCGGAACAGGCCGAGCAGATCAAAACGCTACTGCAATACAGCCCATCCAGC
ACCAACTCCCAGCCGTGGCATTTTATTGTTGCCAGCACGGAAGAAGGTAAAGCGCGTGTT
GCCAAATCCGCTGCCGGTAATTACGTGTTCAACGAGCGTAAAATGCTTGATGCCTCGCAC
GTCGTGGTGTTCTGTGCAAAAACCGCGATGGACGATGTCTGGCTGAAGCTGGTTGTTGAC
CAGGAAGATGCCGATGGCCGCTTTGCCACGCCGGAAGCGAAAGCCGCGAACGATAAAGGT
CGCAAGTTCTTCGCTGATATGCACCGTAAAGATCTGCATGATGATGCAGAGTGGATGGCA
AAACAGGTTTATCTCAACGTCGGTAACTTCCTGCTCGGCGTGGCGGCTCTGGGTCTGGAC
GCGGTACCCATCGAAGGTTTTGACGCCGCCATCCTCGATGCAGAATTTGGTCTGAAAGAG
AAAGGCTACACCAGTCTGGTGGTTGTTCCGGTAGGTCATCACAGCGTTGAAGATTTTAAC
GCTACGCTGCCGAAATCTCGTCTGCCGCAAAACATCACCTTAACCGAAGTGTAA

# Drug_Target_22_General_Function:
Energy production and conversion

# Drug_Target_22_General_References:
11020276	Parkinson GN, Skelly JV, Neidle S: Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J Med Chem. 2000 Oct 5;43(20):3624-31.
1472094	Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ: The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol. 1992 Dec 15;44(12):2289-95.
3060113	Vasudevan SG, Shaw DC, Armarego WL: Dihydropteridine reductase from Escherichia coli. Biochem J. 1988 Oct 15;255(2):581-8.
7813889	Michael NP, Brehm JK, Anlezark GM, Minton NP: Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. FEMS Microbiol Lett. 1994 Dec 1;124(2):195-202.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_22_HGNC_ID:
Not Available

# Drug_Target_22_HPRD_ID:
Not Available

# Drug_Target_22_ID:
2936

# Drug_Target_22_Locus:
Not Available

# Drug_Target_22_Molecular_Weight:
23905

# Drug_Target_22_Name:
Oxygen-insensitive NAD(P)H nitroreductase

# Drug_Target_22_Number_of_Residues:
217

# Drug_Target_22_PDB_ID:
1YLU

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_22_Protein_Sequence:
>Oxygen-insensitive NAD(P)H nitroreductase
MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIVASTEEGKARV
AKSAAGNYVFNERKMLDASHVVVFCAKTAMDDVWLKLVVDQEDADGRFATPEAKAANDKG
RKFFADMHRKDLHDDAEWMAKQVYLNVGNFLLGVAALGLDAVPIEGFDAAILDAEFGLKE
KGYTSLVVVPVGHHSVEDFNATLPKSRLPQNITLTEV

# Drug_Target_22_Reaction:
a 5,6,7,8-tetrahydropteridine + NAD(P)+ = a 6,7-dihydropteridine + NAD(P)H + H+

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred. Capable of reducing nitrofurazone, quinones and the anti-tumor agent CB1954 (5- (aziridin-1-yl)-2,4-dinitrobenzamide). The reduction of CB1954 results in the generation of cytotoxic species

# Drug_Target_22_SwissProt_ID:
P38489

# Drug_Target_22_SwissProt_Name:
NFNB_ECOLI

# Drug_Target_22_Synonyms:
Dihydropteridine reductase
EC 1.-.-.-
EC 1.5.1.34
FMN-dependent nitroreductase

# Drug_Target_22_Theoretical_pI:
6.16

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Not Available

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
Not Available

# Drug_Target_23_GenBank_ID_Gene:
AE008495

# Drug_Target_23_GenBank_ID_Protein:
15458869

# Drug_Target_23_GeneCard_ID:
Not Available

# Drug_Target_23_Gene_Name:
aroC

# Drug_Target_23_Gene_Sequence:
>1167 bp
TTAATAGTTCTTTGTATAGTCTCGGTGTTTGGCTACCGCTTCTTTTAGTTCCTCAAGATT
ATCTGATGAGAATTTTTCGAGGATTTCTTGCGCCAGAACCGTTGCTACAACTGCTTCCAT
GACCATTCCTGCAGCTGGAAGAGCAGTCGGATCGCTTCTCTCCACGGTTGCCTTGTAAGG
TTCGTGGGTTTCGATATCCACACTCATAAGAGGTTTATAAAGAGTAGGAATAGGTTTCAT
GACCCCACGAACAACGATGGGTTGCCCATTAGTCATACCACCTTCAAAACCACCTAGATT
ATTGGTACGGCGAGTATAACCGTCTTCTTTAGACCAGAGAATTTCATCCATAACTTGGCT
GCCTTTACGATAACCAGCCTCAAAGCCAAGACCAAATTCCACCCCTTTAAAGGCATTGAT
AGAGACAACAGCTTGAGCCAATCTTGCATCCAATTTTCTATCCCATTGGACATAGGAACC
AAGACCAACTGGAACGCCTCCGACGACTGTCTCCACAACCCCACCGATGGTATCACCATC
ACGTTTGATTTGGTCAATATAGTCCTTGATTTCCTGTTCTCGTTCTTGGTTGACAATAGA
AACTTCAGACTGGGCAGCTCTTTGCTTAATTTCAGCGACTGTCAGATTTTCAGGAACATC
GATTTCCTTACCACCAAAGACCACGACATGGTTGGCAATCTCCATATCCAGCTCAGCCAA
GAGGCGTTTGGCTACTGCACCAACTGCCACCCGCATGGTGGTTTCACGAGCTGATGAACG
CTCCAAAGAATTTCGCAAATCATCAAAACGGTACTTAATCCCCCCAACCAAATCGGCATG
ACCTGGGCGAGGATGAGTAATTTTCCGCTTGCTTTTAAGGCGGTCTTCAATGTCCTCCGC
AGACATGATGTCCAGCCATTTCTGGTGGTCCTTATTGATGACATCCATAGTAATAGGCGC
CCCTGTCGTCTTCCCGTGGCGAACGCCCGAAGTAAAGACAACCTGGTCATTCTCAATCTT
CATACGACCACCACGACCGTAGCCACCCTGACGGCGTCTAAGGTCCTCATTGATATCCTC
AGCTGTCAATGGAAGTCCAGCTGGAATTCCCTCAATAATAGCTGTTAGACGGGGGCCGTG
TGATTCTCCTGCAGTTAAATATCTCAT

# Drug_Target_23_General_Function:
Amino acid transport and metabolism

# Drug_Target_23_General_References:
11544234	Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR Jr, Skatrud PL, Glass JI: Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001 Oct;183(19):5709-17.

# Drug_Target_23_HGNC_ID:
Not Available

# Drug_Target_23_HPRD_ID:
Not Available

# Drug_Target_23_ID:
3507

# Drug_Target_23_Locus:
Not Available

# Drug_Target_23_Molecular_Weight:
42872

# Drug_Target_23_Name:
Chorismate synthase

# Drug_Target_23_Number_of_Residues:
388

# Drug_Target_23_PDB_ID:
1QXO

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF01264	Chorismate_synt

# Drug_Target_23_Protein_Sequence:
>Chorismate synthase
MRYLTAGESHGPRLTAIIEGIPAGLPLTAEDINEDLRRRQGGYGRGGRMKIENDQVVFTS
GVRHGKTTGAPITMDVINKDHQKWLDIMSAEDIEDRLKSKRKITHPRPGHADLVGGIKYR
FDDLRNSLERSSARETTMRVAVGAVAKRLLAELDMEIANHVVVFGGKEIDVPENLTVAEI
KQRAAQSEVSIVNQEREQEIKDYIDQIKRDGDTIGGVVETVVGGVPVGLGSYVQWDRKLD
ARLAQAVVSINAFKGVEFGLGFEAGYRKGSQVMDEILWSKEDGYTRRTNNLGGFEGGMTN
GQPIVVRGVMKPIPTLYKPLMSVDIETHEPYKATVERSDPTALPAAGMVMEAVVATVLAQ
EILEKFSSDNLEELKEAVAKHRDYTKNY

# Drug_Target_23_Reaction:
5-O-(1-carboxyvinyl)-3-phosphoshikimate = chorismate + phosphate

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
5-O-(1-carboxyvinyl)-3-phosphoshikimate = chorismate + phosphate

# Drug_Target_23_SwissProt_ID:
P0A2Y7

# Drug_Target_23_SwissProt_Name:
AROC_STRR6

# Drug_Target_23_Synonyms:
5-enolpyruvylshikimate-3-phosphate phospholyase
EC 4.2.3.5

# Drug_Target_23_Theoretical_pI:
6.14

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Not Available

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
Not Available

# Drug_Target_24_GenBank_ID_Gene:
U93405

# Drug_Target_24_GenBank_ID_Protein:
2584857

# Drug_Target_24_GeneCard_ID:
Not Available

# Drug_Target_24_Gene_Name:
fadH

# Drug_Target_24_Gene_Sequence:
>2019 bp
ATGAGCTACCCGTCGCTGTTCGCCCCGCTGGATTTAGGTTTTACCACGTTAAAAAACCGC
GTGTTGATGGGCTCAATGCACACCGGGCTGGAGGAATACCCGGACGGTGCCGAGCGGCTG
GCAGCGTTTTATGCCGAACGCGCCCGTCACGGCGTGGCGCTGATTGTCAGCGGCGGCATT
GCACCAGATTTAACAGGCGTTGGCATGGAAGGTGGCGCAATGCTCAACGACGCCAGCCAG
ATCCCACACCATCGCACCATTACCGAAGCGGTACATCAGGAAGGCGGCAAAATAGCCCTG
CAAATTTTGCATACCGGGCGCTACAGCTACCAACCGCATCTGGTCGCCCCGTCCGCATTG
CAGGCCCCCATCAACCGTTTCGTGCCCCATGAGTTAAGCCATGAAGAGATCCTGCAACTG
ATCGACAATTTCGCCCGCTGCGCGCAACTGGCGCGGGAGGCAGGATACGACGGTGTAGAG
GTGATGGGTTCCGAAGGGTATTTGATCAACGAATTTCTGACGCTGCGCACCAATCAGCGT
AGTGACCAGTGGGGCGGCGATTACCGCAACCGGATGCGATTTGCCGTAGAAGTAGTGCGT
GCGGTGCGCGAACGCGTCGGCAACGACTTCATTATTATCTACCGACTGTCGATGCTCGAC
CTGGTCGAAGACGGCGGGACTTTTGCCGAAACGGTAGAGCTGGCGCAGGCCATTGAAGCG
GCGGGCGCGACCATTATCAACACCGGCATTGGCTGGCATGAAGCACGTATTCCGACCATT
GCCACGCCCGTGCCGCGCGGCGCATTTAGCTGGGTCACGCGCAAACTGAAAGGCCACGTC
TCGCTGCCGCTGGTAACCACCAACCGGATTAACGATCCGCAGGTTGCCGACGATATTCTC
TCGCGCGGCGATGCCGATATGGTATCGATGGCGCGACCGTTTCTTGCTGATGCGGAGCTG
CTGTCAAAAGCGCAATCGGGACGAGCCGATGAGATCAACACTTGTATTGGCTGCAATCAG
GCCTGTCTCGATCAAATCTTCGTTGGCAAAGTCACCTCGTGCCTGGTGAATCCTCGCGCC
TGCCACGAAACCAAAATGCCAATCCTTCCCGCCGTGCAGAAAAAAAATCTGGCGGTGGTC
GGTGCGGGACCTGCTGGGCTGGCGTTTGCCATTAACGCGGCGGCGCGTGGGCATCAGGTA
ACATTGTTTGACGCTCATAGCGAGATTGGCGGGCAGTTTAATATCGCCAAACAGATCCCC
GGCAAAGAGGAGTTTTACGAAACGCTGCGCTATTACCGCCGGATGATCGAAGTGACGGGC
GTGACGCTAAAACTCAATCACACCGTGACGGCGGATCAGTTACAGGCTTTCGATGAAACG
ATCCTCGCCAGTGGGATCGTGCCGCGCACTCCGCCCATCGACGGGATCGATCATCCGAAG
GTATTGAGTTATCTCGATGTACTGCGCGACAAAGCGCCGGTTGGCAACAAAGTTGCCATC
ATCGGTTGTGGCGGGATTGGTTTTGATACGGCGATGTATTTAAGTCAGCCGGGCGAATCC
ACCAGCCAGAATATCGCCGGGTTCTGTAATGAATGGGGGATCGACAGTAGCCTACAACAG
GCTGGTGGCTTAAGCCCGCAGGGAATGCAGATCCCCCGTAGCCCACGGCAGATTGTGATG
CTCCAGCGCAAAGCCAGCAAACCAGGACAGGGGTTAGGCAAAACCACCGGCTGGATCCAT
CGCACCACCCTGCTCTCGCGGGGTGTGAAAATGATCCCAGGCGTAAGTTATCAGAAGATT
GACGATGACGGGCTGCATGTGGTGATCAACGGCGAAACGCAGGTATTAGCAGTGGACAAT
GTGGTGATCTGCGCAGGGCAAGAGCCAAACCGCGCGCTGGCGCAACCGCTGATTGATAGC
GGGAAAACGGTGCATTTAATTGGCGGCTGCGATGTGGCTATGGAGCTGGACGCACGACGG
GCAATTGCCCAGGGAACACGGCTGGCGCTGGAGATTTAA

# Drug_Target_24_General_Function:
Energy production and conversion

# Drug_Target_24_General_References:
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9346310	He XY, Yang SY, Schulz H: Cloning and expression of the fadH gene and characterization of the gene product 2,4-dienoyl coenzyme A reductase from Escherichia coli. Eur J Biochem. 1997 Sep 1;248(2):516-20.

# Drug_Target_24_HGNC_ID:
Not Available

# Drug_Target_24_HPRD_ID:
Not Available

# Drug_Target_24_ID:
3573

# Drug_Target_24_Locus:
Not Available

# Drug_Target_24_Molecular_Weight:
72679

# Drug_Target_24_Name:
2,4-dienoyl-CoA reductase [NADPH]

# Drug_Target_24_Number_of_Residues:
672

# Drug_Target_24_PDB_ID:
1PS9

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF00070	Pyr_redox
PF00724	Oxidored_FMN
PF07992	Pyr_redox_2

# Drug_Target_24_Protein_Sequence:
>2,4-dienoyl-CoA reductase [NADPH]
MSYPSLFAPLDLGFTTLKNRVLMGSMHTGLEEYPDGAERLAAFYAERARHGVALIVSGGI
APDLTGVGMEGGAMLNDASQIPHHRTITEAVHQEGGKIALQILHTGRYSYQPHLVAPSAL
QAPINRFVPHELSHEEILQLIDNFARCAQLAREAGYDGVEVMGSEGYLINEFLTLRTNQR
SDQWGGDYRNRMRFAVEVVRAVRERVGNDFIIIYRLSMLDLVEDGGTFAETVELAQAIEA
AGATIINTGIGWHEARIPTIATPVPRGAFSWVTRKLKGHVSLPLVTTNRINDPQVADDIL
SRGDADMVSMARPFLADAELLSKAQSGRADEINTCIGCNQACLDQIFVGKVTSCLVNPRA
CHETKMPILPAVQKKNLAVVGAGPAGLAFAINAAARGHQVTLFDAHSEIGGQFNIAKQIP
GKEEFYETLRYYRRMIEVTGVTLKLNHTVTADQLQAFDETILASGIVPRTPPIDGIDHPK
VLSYLDVLRDKAPVGNKVAIIGCGGIGFDTAMYLSQPGESTSQNIAGFCNEWGIDSSLQQ
AGGLSPQGMQIPRSPRQIVMLQRKASKPGQGLGKTTGWIHRTTLLSRGVKMIPGVSYQKI
DDDGLHVVINGETQVLAVDNVVICAGQEPNRALAQPLIDSGKTVHLIGGCDVAMELDARR
AIAQGTRLALEI

# Drug_Target_24_Reaction:
trans-2,3-didehydroacyl-CoA + NADP+ = trans,trans-2,3,4,5-tetradehydroacyl-CoA + NADPH + H+

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
Catalyzes the NADP-dependent reduction of 2,4-dienoyl- CoA to yield trans-2- enoyl-CoA

# Drug_Target_24_SwissProt_ID:
P42593

# Drug_Target_24_SwissProt_Name:
FADH_ECOLI

# Drug_Target_24_Synonyms:
2,4-dienoyl coenzyme A reductase
EC 1.3.1.34

# Drug_Target_24_Theoretical_pI:
6.55

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Cytoplasm

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
Not Available

# Drug_Target_25_GenBank_ID_Gene:
AY323899

# Drug_Target_25_GenBank_ID_Protein:
33302311

# Drug_Target_25_GeneCard_ID:
Not Available

# Drug_Target_25_Gene_Name:
pyrDA

# Drug_Target_25_Gene_Sequence:
>936 bp
ATGCTTAATACAACTTTTGCAAATGCCAAATTCGCTAATCCATTTATGAACGCTTCAGGA
GTCCATTGTATGACGATTGAGGATTTAGAAGAATTAAAAGCCTCTCAAGCAGGGGCCTAT
ATCACCAAAAGTTCCACATTAGAAAAAAGAGAAGGTAATCCACTCCCACGTTATGTTGAC
TTAGAATTAGGGTCAATTAATTCTATGGGTCTGCCTAATTTAGGATTTGATTACTACTTA
GACTATGTTTTAAAAAATCAAAAAGAAAATGCTCAAGAAGGGCCAATCTTCTTTTCCATT
GCGGGTATGAGTGCAGCAGAAAATATCGCTATGCTCAAGAAAATTCAAGAAAGTGATTTT
TCAGGAATTACAGAGTTGAATCTTTCTTGTCCAAATGTTCCTGGTAAACCACAACTTGCT
TATGATTTTGAAGCAACTGAAAAGCTCCTAAAAGAAGTTTTTACTTTCTTTACAAAACCG
CTAGGTGTCAAACTTCCCCCTTATTTTGACCTTGTACATTTTGATATTATGGCAGAAATC
CTCAATCAGTTTCCATTGACTTATGTGAATTCAGTGAATAGTATTGGAAATGGACTTTTT
ATTGACCCAGAAGCAGAAAGCGTAGTTATTAAGCCTAAAGATGGATTTGGTGGAATTGGT
GGAGCTTACATCAAACCAACAGCGCTTGCAAATGTCCGTGCTTTCTATACTCGACTCAAA
CCTGAAATTCAAATCATTGGAACAGGTGGGATTGAAACAGGACAAGATGCCTTTGAACAC
CTCTTATGTGGAGCTACAATGCTTCAAATTGGAACAGCTTTACACAAAGAAGGACCTGCA
ATCTTTGATAGAATCATTAAAGAATTAGAAGAAATAATGAATCAAAAAGGCTATCAATCA
ATTGCTGATTTCCATGGAAAATTAAAATCATTATAA

# Drug_Target_25_General_Function:
Nucleotide transport and metabolism

# Drug_Target_25_General_References:
9032071	Rowland P, Nielsen FS, Jensen KF, Larsen S: The crystal structure of the flavin containing enzyme dihydroorotate dehydrogenase A from Lactococcus lactis. Structure. 1997 Feb 15;5(2):239-52.
9405053	Bjornberg O, Rowland P, Larsen S, Jensen KF: Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis. Biochemistry. 1997 Dec 23;36(51):16197-205.
9655329	Rowland P, Bjornberg O, Nielsen FS, Jensen KF, Larsen S: The crystal structure of Lactococcus lactis dihydroorotate dehydrogenase A complexed with the enzyme reaction product throws light on its enzymatic function. Protein Sci. 1998 Jun;7(6):1269-79.

# Drug_Target_25_HGNC_ID:
Not Available

# Drug_Target_25_HPRD_ID:
Not Available

# Drug_Target_25_ID:
3680

# Drug_Target_25_Locus:
Not Available

# Drug_Target_25_Molecular_Weight:
34211

# Drug_Target_25_Name:
Dihydroorotate dehydrogenase A

# Drug_Target_25_Number_of_Residues:
311

# Drug_Target_25_PDB_ID:
1JUE

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_25_Protein_Sequence:
>Dihydroorotate dehydrogenase A
MLNTTFANAKFANPFMNASGVHCMTIEDLEELKASQAGAYITKSSTLEKREGNPLPRYVD
LELGSINSMGLPNLGFDYYLDYVLKNQKENAQEGPIFFSIAGMSAAENIAMLKKIQESDF
SGITELNLSCPNVPGKPQLAYDFEATEKLLKEVFTFFTKPLGVKLPPYFDLVHFDIMAEI
LNQFPLTYVNSVNSIGNGLFIDPEAESVVIKPKDGFGGIGGAYIKPTALANVRAFYTRLK
PEIQIIGTGGIETGQDAFEHLLCGATMLQIGTALHKEGPAIFDRIIKELEEIMNQKGYQS
IADFHGKLKSL

# Drug_Target_25_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
(S)-dihydroorotate + O(2) = orotate + H(2)O(2)

# Drug_Target_25_SwissProt_ID:
Q53ZE5

# Drug_Target_25_SwissProt_Name:
PYRDA_LACLC

# Drug_Target_25_Synonyms:
DHOD A
DHODase A
DHOdehase A
Dihydroorotate oxidase A
EC 1.3.3.1

# Drug_Target_25_Theoretical_pI:
4.84

# Drug_Target_25_Transmembrane_Regions:
None

# Drug_Target_26_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
BLVRB

# Drug_Target_26_GenBank_ID_Gene:
D26308

# Drug_Target_26_GenBank_ID_Protein:
1384068

# Drug_Target_26_GeneCard_ID:
BLVRB

# Drug_Target_26_Gene_Name:
BLVRB

# Drug_Target_26_Gene_Sequence:
>621 bp
ATGGCCGTCAAGAAGATCGCGATCTTCGGCGCCACTGGCCAGACCGGGCTCACCACCCTG
GCGCAGGCGGTGCAAGCAGGTTACGAAGTGACAGTGCTGGTGCGGGACTCCTCCAGGCTG
CCATCAGAGGGGCCCCGGCCGGCCCACGTGGTAGTGGGAGATGTTCTGCAGGCAGCCGAT
GTGGACAAGACCGTGGCTGGGCAGGACGCTGTCATCGTGCTGCTGGGCACCCGCAATGAC
CTCAGTCCCACGACAGTGATGTCCGAGGGCGCCCGGAACATTGTGGCAGCCATGAAGGCT
CATGGTGTGGACAAGGTCGTGGCCTGCACCTCGGCTTTCCTGCTCTGGGACCCTACCAAG
GTGCCCCCACGACTGCAGGCTGTGACTGATGACCACATCCGGATGCACAAGGTGCTGCGG
GAATCAGGCCTGAAGTACGTGGCTGTGATGCCGCCACACATAGGAGACCAGCCACTAACT
GGGGCGTACACAGTGACCCTGGATGGACGAGGGCCCTCAAGGGTCATCTCCAAACATGAC
CTGGGCCATTTCATGCTGCGCTGCCTCACCACCGATGAGTACGACGGACACAGCACCTAC
CCCTCCCACCAGTACCAGTAG

# Drug_Target_26_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_26_General_References:
11224564	Pereira PJ, Macedo-Ribeiro S, Parraga A, Perez-Luque R, Cunningham O, Darcy K, Mantle TJ, Coll M: Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol. 2001 Mar;8(3):215-20.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
7929092	Yamaguchi T, Komoda Y, Nakajima H: Biliverdin-IX alpha reductase and biliverdin-IX beta reductase from human liver. Purification and characterization. J Biol Chem. 1994 Sep 30;269(39):24343-8.
8117274	Chikuba K, Yubisui T, Shirabe K, Takeshita M: Cloning and nucleotide sequence of a cDNA of the human erythrocyte NADPH-flavin reductase. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1170-6.
8280170	Yamaguchi T, Komuro A, Nakano Y, Tomita M, Nakajima H: Complete amino acid sequence of biliverdin-IX beta reductase from human liver. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1518-23.
8313871	Golaz O, Hughes GJ, Frutiger S, Paquet N, Bairoch A, Pasquali C, Sanchez JC, Tissot JD, Appel RD, Walzer C, et al.: Plasma and red blood cell protein maps: update 1993. Electrophoresis. 1993 Nov;14(11):1223-31.
8687377	Shalloe F, Elliott G, Ennis O, Mantle TJ: Evidence that biliverdin-IX beta reductase and flavin reductase are identical. Biochem J. 1996 Jun 1;316 ( Pt 2):385-7.
8799475	Komuro A, Tobe T, Hashimoto K, Nakano Y, Yamaguchi T, Nakajima H, Tomita M: Molecular cloning and expression of human liver biliverdin-IX beta reductase. Biol Pharm Bull. 1996 Jun;19(6):796-804.

# Drug_Target_26_HGNC_ID:
HGNC:1063

# Drug_Target_26_HPRD_ID:
02967

# Drug_Target_26_ID:
654

# Drug_Target_26_Locus:
19q13.1-q13.2

# Drug_Target_26_Molecular_Weight:
21988

# Drug_Target_26_Name:
Flavin reductase

# Drug_Target_26_Number_of_Residues:
205

# Drug_Target_26_PDB_ID:
1HE5

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_26_Protein_Sequence:
>Flavin reductase
AVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADV
DKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKV
PPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDL
GHFMLRCLTTDEYDGHSTYPSHQYQ

# Drug_Target_26_Reaction:
bilirubin + NAD(P)+ = biliverdin + NAD(P)H + H+

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Catalyzes electron transfer from reduced pyridine nucleotides to flavins as well as methylene blue, pyrroloquinoline quinone, riboflavin, or methemoglobin. Possible role in protecting cells from oxidative damage or in regulating iron metabolism. In the liver, converts biliverdin to bilirubin

# Drug_Target_26_SwissProt_ID:
P30043

# Drug_Target_26_SwissProt_Name:
BLVRB_HUMAN

# Drug_Target_26_Synonyms:
BVR-B
Biliverdin reductase B
Biliverdin-IX beta-reductase
EC 1.3.1.24
EC 1.5.1.30
FLR
FR
GHBP
Green heme-binding protein
NADPH-dependent diaphorase
NADPH-flavin reductase

# Drug_Target_26_Theoretical_pI:
7.76

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Peroxisome

# Drug_Target_27_Chromosome_Location:
2

# Drug_Target_27_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
AF244134

# Drug_Target_27_GenBank_ID_Protein:
7530485

# Drug_Target_27_GeneCard_ID:
HAO1

# Drug_Target_27_Gene_Name:
HAO1

# Drug_Target_27_Gene_Sequence:
Not Available

# Drug_Target_27_General_Function:
Energy production and conversion

# Drug_Target_27_General_References:
10777549	Jones JM, Morrell JC, Gould SJ: Identification and characterization of HAOX1, HAOX2, and HAOX3, three human peroxisomal 2-hydroxy acid oxidases. J Biol Chem. 2000 Apr 28;275(17):12590-7.
10978532	Williams E, Cregeen D, Rumsby G: Identification and expression of a cDNA for human glycolate oxidase. Biochim Biophys Acta. 2000 Sep 7;1493(1-2):246-8.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.

# Drug_Target_27_HGNC_ID:
GNC:4809

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
6268

# Drug_Target_27_Locus:
20p12

# Drug_Target_27_Molecular_Weight:
40923.9

# Drug_Target_27_Name:
Hydroxyacid oxidase 1

# Drug_Target_27_Number_of_Residues:
370

# Drug_Target_27_PDB_ID:
Not Available

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF01070	FMN_dh

# Drug_Target_27_Protein_Sequence:
>Hydroxyacid oxidase 1
MLPRLICINDYEQHAKSVLPKSIYDYYRSGANDEETLADNIAAFSRWKLYPRMLRNVAET
DLSTSVLGQRVSMPICVGATAMQRMAHVDGELATVRACQSLGTGMMLSSWATSSIEEVAE
AGPEALRWLQLYIYKDREVTKKLVRQAEKMGYKAIFVTVDTPYLGNRLDDVRNRFKLPPQ
LRMKNFETSTLSFSPEENFGDDSGLAAYVAKAIDPSISWEDIKWLRRLTSLPIVAKGILR
GDDAREAVKHGLNGILVSNHGARQLDGVPATIDVLPEIVEAVEGKVEVFLDGGVRKGTDV
LKALALGAKAVFVGRPIVWGLAFQGEKGVQDVLEILKEEFRLAMALSGCQNVKVIDKTLV
RKNPLAVSKI

# Drug_Target_27_Reaction:
Not Available

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Has 2-hydroxyacid oxidase activity. Most active on the 2-carbon substrate glycolate, but is also active on 2-hydroxy fatty acids

# Drug_Target_27_SwissProt_ID:
Q9UJM8

# Drug_Target_27_SwissProt_Name:
HAOX1_HUMAN

# Drug_Target_27_Synonyms:
GOX
Glycolate oxidase
HAOX1

# Drug_Target_27_Theoretical_pI:
8.29

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Not Available

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
PNPO

# Drug_Target_28_GenBank_ID_Gene:
AF468030

# Drug_Target_28_GenBank_ID_Protein:
21728336

# Drug_Target_28_GeneCard_ID:
PNPO

# Drug_Target_28_Gene_Name:
PNPO

# Drug_Target_28_Gene_Sequence:
>786 bp
ATGACGTGCTGGCTGCGGGGCGTCACGGCGACGTTCGGGCGACCTGCCGAGTGGCCAGGC
TACCTCAGTCACCTGTGTGGTCGCAGTGCTGCCATGGACCTGGGACCCATGCGCAAGAGT
TACCGCGGGGACCGAGAGGCATTTGAGGAGACTCATCTGACCTCCCTTGACCCAGTGAAA
CAGTTTGCTGCCTGGTTTGAGGAGGCTGTTCAGTGTCCTGACATAGGGGAAGCCAATGCC
ATGTGTCTGGCTACCTGCACCAGAGATGGAAAACCCTCTGCTCGCATGTTGCTGCTGAAG
GGCTTCGGGAAAGATGGCTTCCGCTTCTTCACTAACTTCGAGAGTCGAAAAGGAAAAGAG
CTGGACTCTAATCCCTTTGCTTCCCTTGTCTTCTACTGGGAGCCACTTAACCGTCAGGTG
CGTGTGGAAGGCCCTGTGAAGAAACTGCCTGAGGAGGAGGCTGAGTGCTACTTCCACTCC
CGCCCCAAGAGCAGCCAGATTGGGGCTGTGGTCAGCCACCAGAGTTCTGTGATCCCTGAT
CGGGAGTATCTGAGAAAGAAAAATGAGGAACTGGAACAGCTCTACCAGGATCAAGAGGTG
CCCAAGCCAAAATCCTGGGGTGGCTATGTCCTGTACCCTCAGGTGATGGAGTTCTGGCAA
GGTCAAACCAACCGCCTGCATGACCGGATAGTCTTTCGGCGGGGCCTACCCACAGGAGAT
TCCCCTTTGGGGCCCATGACCCACCGCGGGGAGGAAGACTGGCTCTATGAGAGACTTGCA
CCTTAA

# Drug_Target_28_General_Function:
Coenzyme transport and metabolism

# Drug_Target_28_General_References:
12824491	Musayev FN, Di Salvo ML, Ko TP, Schirch V, Safo MK: Structure and properties of recombinant human pyridoxine 5'-phosphate oxidase. Protein Sci. 2003 Jul;12(7):1455-63.

# Drug_Target_28_HGNC_ID:
HGNC:30260

# Drug_Target_28_HPRD_ID:
04476

# Drug_Target_28_ID:
203

# Drug_Target_28_Locus:
17q21.32

# Drug_Target_28_Molecular_Weight:
29988

# Drug_Target_28_Name:
Pyridoxine-5'-phosphate oxidase

# Drug_Target_28_Number_of_Residues:
261

# Drug_Target_28_PDB_ID:
1NRG

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_28_Protein_Sequence:
>Pyridoxine-5'-phosphate oxidase
MTCWLRGVTATFGRPAEWPGYLSHLCGRSAAMDLGPMRKSYRGDREAFEETHLTSLDPVK
QFAAWFEEAVQCPDIGEANAMCLATCTRDGKPSARMLLLKGFGKDGFRFFTNFESRKGKE
LDSNPFASLVFYWEPLNRQVRVEGPVKKLPEEEAECYFHSRPKSSQIGAVVSHQSSVIPD
REYLRKKNEELEQLYQDQEVPKPKSWGGYVLYPQVMEFWQGQTNRLHDRIVFRRGLPTGD
SPLGPMTHRGEEDWLYERLAP

# Drug_Target_28_Reaction:
(1) pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + NH3 + H2O2

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Oxidizes PNP and PMP into pyridoxal 5'-phosphate (PLP)

# Drug_Target_28_SwissProt_ID:
Q9NVS9

# Drug_Target_28_SwissProt_Name:
PNPO_HUMAN

# Drug_Target_28_Synonyms:
EC 1.4.3.5
Pyridoxamine-phosphate oxidase

# Drug_Target_28_Theoretical_pI:
7.09

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Not Available

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
Not Available

# Drug_Target_29_GenBank_ID_Gene:
D17743

# Drug_Target_29_GenBank_ID_Protein:
6539550

# Drug_Target_29_GeneCard_ID:
Not Available

# Drug_Target_29_Gene_Name:
Not Available

# Drug_Target_29_Gene_Sequence:
>657 bp
ATGACGCATCCAATTATTCATGATCTTGAAAATCGTTATACATCAAAAAAATATGACCCA
TCAAAGAAAGTATCTCAAGAAGATTTAGCGGTTTTGCTTGAGGCTCTGCGTTTATCTGCT
TCTTCAATTAATTCACAGCCTTGGAAATTCATTGTTATTGAATCCGATGCAGCGAAGCAA
CGTATGCATGATTCGTTTGCAAATATGCATCAGTTTAATCAACCTCACATCAAAGCGTGT
TCTCATGTGATTTTATTTGCAAATAAGCTTTCGTATACACGAGATGATTATGATGTGGTT
TTATCTAAAGCGGTTGCTGACAAGCGTATTACTGAAGAGCAAAAAGAAGCTGCTTTTGCT
TCGTTTAAGTTTGTAGAATTGAACTGTGATGAAAATGGTGAGCATAAAGCATGGACTAAG
CCTCAAGCTTATTTAGCTCTTGGTAATGCTCTGCATACATTAGCTAGACTGAACATTGAC
TCAACAACAATGGAAGGCATTGATCCTGAATTATTGAGTGAAATTTTTGCTGATGAATTA
AAAGGGTATGAATGTCATGTTGCTTTAGCCATTGGTTATCATCATCCAAGCGAAGATTAT
AATGCCTCTTTGCCTAAGTCTCGTAAGGCATTTGAAGACGTAATTACCATCCTTTAG

# Drug_Target_29_General_Function:
Energy production and conversion

# Drug_Target_29_General_References:
8033996	Inouye S: NAD(P)H-flavin oxidoreductase from the bioluminescent bacterium, Vibrio fischeri ATCC 7744, is a flavoprotein. FEBS Lett. 1994 Jun 27;347(2-3):163-8.
8206830	Zenno S, Saigo K, Kanoh H, Inouye S: Identification of the gene encoding the major NAD(P)H-flavin oxidoreductase of the bioluminescent bacterium Vibrio fischeri ATCC 7744. J Bacteriol. 1994 Jun;176(12):3536-43.
9654450	Koike H, Sasaki H, Kobori T, Zenno S, Saigo K, Murphy ME, Adman ET, Tanokura M: 1.8 A crystal structure of the major NAD(P)H:FMN oxidoreductase of a bioluminescent bacterium, Vibrio fischeri: overall structure, cofactor and substrate-analog binding, and comparison with related flavoproteins. J Mol Biol. 1998 Jul 10;280(2):259-73.

# Drug_Target_29_HGNC_ID:
Not Available

# Drug_Target_29_HPRD_ID:
Not Available

# Drug_Target_29_ID:
2261

# Drug_Target_29_Locus:
Not Available

# Drug_Target_29_Molecular_Weight:
24721

# Drug_Target_29_Name:
Major NAD(P)H-flavin oxidoreductase

# Drug_Target_29_Number_of_Residues:
218

# Drug_Target_29_PDB_ID:
1VFR

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_29_Protein_Sequence:
>Major NAD(P)H-flavin oxidoreductase
MTHPIIHDLENRYTSKKYDPSKKVSQEDLAVLLEALRLSASSINSQPWKFIVIESDAAKQ
RMHDSFANMHQFNQPHIKACSHVILFANKLSYTRDDYDVVLSKAVADKRITEEQKEAAFA
SFKFVELNCDENGEHKAWTKPQAYLALGNALHTLARLNIDSTTMEGIDPELLSEIFADEL
KGYECHVALAIGYHHPSEDYNASLPKSRKAFEDVITIL

# Drug_Target_29_Reaction:
Not Available

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Involved in bioluminescence. It is a good supplier of reduced flavin mononucleotide (FMNH2) to the bioluminescence reaction. Major FMN reductase. It is capable of using both NADH and NADPH as electron donors. As electron acceptor, FMN is the most effective, FAD is considerably effective, and riboflavin is the least effective

# Drug_Target_29_SwissProt_ID:
P46072

# Drug_Target_29_SwissProt_Name:
FRA1_VIBFI

# Drug_Target_29_Synonyms:
EC 1.6.99.-
FRASE I

# Drug_Target_29_Theoretical_pI:
6.12

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AF218053

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
roo

# Drug_Target_2_Gene_Sequence:
>1209 bp
ATGCAAGCGACTAAGATTATTGACGGCTTCCACCTCGTGGGCGCCATTGACTGGAACAGC
CGCGACTTCCACGGCTATACGCTTTCGCCCATGGGCACCACGTACAACGCCTATCTGGTG
GAAGACGAAAAGACCACGCTCTTCGACACGGTGAAGGCCGAGTACAAAGGCGAGCTGCTC
TGCGGCATCGCCAGCGTCATCGATCCCAAAAAGATCGACTATCTGGTGATCCAGCACCTG
GAGCTGGACCATGCCGGCGCCCTGCCCGCCCTCATCGAAGCCTGCCAGCCCGAGAAGATC
TTCACCTCCTCCCTGGGCCAGAAGGCCATGGAATCCCACTTCCATTACAAGGACTGGCCC
GTGCAGGTGGTCAAGCACGGGGAAACGCTCTCCCTGGGCAAGCGCACGGTCACGTTCTAC
GAAACCCGCATGCTGCACTGGCCGGACAGCATGGTCTCCTGGTTCGCCGACGAAAAGGTG
CTCATCAGCAACGACATCTTCGGCCAGAACATCGCCGCCAGCGAGCGCTTCAGCGACCAG
ATCCCGGTCCACACCCTGGAACGGGCCATGCGCGAATACTACGCCAACATCGTCAACCCC
TACGCCCCGCAGACCCTCAAGGCCATTGAGACCCTGGTGGGCGCAGGCGTGGCGCCGGAA
TTCATCTGCCCGGACCACGGCGTGATCTTCCGCGGCGCGGACCAGTGCACCTTCGCCGTG
CAGAAGTATGTGGAATACGCCGAACAGAAGCCCACCAACAAGGTGGTGATCTTCTACGAC
TCCATGTGGCATTCCACAGAAAAGATGGCCCGTGTGCTGGCCGAATCCTTCCGCGATGAA
GGCTGCACCGTGAAGCTCATGTGGTGCAAGGCCTGCCATCATTCGCAGATCATGAGCGAA
ATCAGCGATGCCGGCGCGGTGATCGTCGGTTCTCCCACCCACAACAACGGCATCCTGCCG
TATGTGGCCGGTACGCTGCAGTACATCAAGGGCCTGCGGCCGCAGAACAAGATCGGCGGC
GCATTCGGCTCCTTCGGCTGGAGCGGGGAATCCACCAAGGTCCTGGCCGAATGGCTCACC
GGCATGGGCTTCGACATGCCGGCCACCCCGGTCAAGGTCAAGAACGTCCCCACCCATGCG
GACTACGAACAGCTCAAGACCATGGCGCAGACCATCGCCAGGGCCCTGAAGGCCAAGCTG
GCCGCCTAG

# Drug_Target_2_General_Function:
Involved in hydrolase activity

# Drug_Target_2_General_References:
11062560	Frazao C, Silva G, Gomes CM, Matias P, Coelho R, Sieker L, Macedo S, Liu MY, Oliveira S, Teixeira M, Xavier AV, Rodrigues-Pousada C, Carrondo MA, Le Gall J: Structure of a dioxygen reduction enzyme from Desulfovibrio gigas. Nat Struct Biol. 2000 Nov;7(11):1041-5.
8503894	Chen L, Liu MY, LeGall J, Fareleira P, Santos H, Xavier AV: Rubredoxin oxidase, a new flavo-hemo-protein, is the site of oxygen reduction to water by the "strict anaerobe" Desulfovibrio gigas. Biochem Biophys Res Commun. 1993 May 28;193(1):100-5.
9278402	Gomes CM, Silva G, Oliveira S, LeGall J, Liu MY, Xavier AV, Rodrigues-Pousada C, Teixeira M: Studies on the redox centers of the terminal oxidase from Desulfovibrio gigas and evidence for its interaction with rubredoxin. J Biol Chem. 1997 Sep 5;272(36):22502-8.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
5190

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
44797

# Drug_Target_2_Name:
Rubredoxin-oxygen oxidoreductase

# Drug_Target_2_Number_of_Residues:
402

# Drug_Target_2_PDB_ID:
1E5D

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00258	Flavodoxin_1
PF00753	Lactamase_B

# Drug_Target_2_Protein_Sequence:
>Rubredoxin-oxygen oxidoreductase
MQATKIIDGFHLVGAIDWNSRDFHGYTLSPMGTTYNAYLVEDEKTTLFDTVKAEYKGELL
CGIASVIDPKKIDYLVIQHLELDHAGALPALIEACQPEKIFTSSLGQKAMESHFHYKDWP
VQVVKHGETLSLGKRTVTFYETRMLHWPDSMVSWFADEKVLISNDIFGQNIAASERFSDQ
IPVHTLERAMREYYANIVNPYAPQTLKAIETLVGAGVAPEFICPDHGVIFRGADQCTFAV
QKYVEYAEQKPTNKVVIFYDSMWHSTEKMARVLAESFRDEGCTVKLMWCKACHHSQIMSE
ISDAGAVIVGSPTHNNGILPYVAGTLQYIKGLRPQNKIGGAFGSFGWSGESTKVLAEWLT
GMGFDMPATPVKVKNVPTHADYEQLKTMAQTIARALKAKLAA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the four-electron reduction of one oxygen molecule to two water molecules

# Drug_Target_2_SwissProt_ID:
Q9F0J6

# Drug_Target_2_SwissProt_Name:
ROO_DESGI

# Drug_Target_2_Synonyms:
EC 1.-.-.-
ROO
Rubredoxin oxidase

# Drug_Target_2_Theoretical_pI:
6.56

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_30_Cellular_Location:
Cytoplasm

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
RFK

# Drug_Target_30_GenBank_ID_Gene:
AK002011

# Drug_Target_30_GenBank_ID_Protein:
7023634

# Drug_Target_30_GeneCard_ID:
RFK

# Drug_Target_30_Gene_Name:
RFK

# Drug_Target_30_Gene_Sequence:
>489 bp
ATGCCCCGAGCGGACTGCATTATGAGGCACCTGCCTTACTTCTGCCGGGGTCAAGTGGTG
CGGGGCTTCGGCCGCGGCTCCAAGCAGCTGGGCATCCCCACAGCTAATTTTCCTGAGCAA
GTGGTAGATAATCTTCCAGCTGATATATCCACTGGTATTTACTATGGTTGGGCCAGTGTT
GGAAGTGGAGATGTCCATAAGATGGTGGTGAGCATAGGATGGAACCCATATTACAAGAAT
ACGAAGAAGTCTATGGAAACACATATCATGCATACCTTCAAAGAGGACTTCTATGGGGAA
ATCCTCAGTGTGGCCATTGTTGGCTACCTGAGACCAGAAAAGAACTTTGATTCTTTAGAG
TCACTTATTTCAGCAATTCAAGGTGATATTGAAGAAGCTAAGAAACGACTAGAGTTACCA
GAACATTTGAAAATCAAAGAAGACAATTTCTTCCAGGTTTCTAAAAGCAAAATAATGAAT
GGCCACTGA

# Drug_Target_30_General_Function:
Coenzyme transport and metabolism

# Drug_Target_30_General_References:
12623014	Karthikeyan S, Zhou Q, Mseeh F, Grishin NV, Osterman AL, Zhang H: Crystal structure of human riboflavin kinase reveals a beta barrel fold and a novel active site arch. Structure. 2003 Mar;11(3):265-73.

# Drug_Target_30_HGNC_ID:
HGNC:30324

# Drug_Target_30_HPRD_ID:
17969

# Drug_Target_30_ID:
408

# Drug_Target_30_Locus:
9q21.13

# Drug_Target_30_Molecular_Weight:
18410

# Drug_Target_30_Name:
Riboflavin kinase

# Drug_Target_30_Number_of_Residues:
162

# Drug_Target_30_PDB_ID:
1Q9S

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF01687	Flavokinase

# Drug_Target_30_Protein_Sequence:
>Riboflavin kinase
MPRADCIMRHLPYFCRGQVVRGFGRGSKQLGIPTANFPEQVVDNLPADISTGIYYGWASV
GSGDVHKMVVSIGWNPYYKNTKKSMETHIMHTFKEDFYGEILNVAIVGYLRPEKNFDSLE
SLISAIQGDIEEAKKRLELPEHLKIKEDNFFQVSKSKIMNGH

# Drug_Target_30_Reaction:
ATP + riboflavin = ADP + FMN

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Catalyzes the phosphorylation of riboflavin (vitamin B2) to form flavin-mononucleotide (FMN)

# Drug_Target_30_SwissProt_ID:
Q969G6

# Drug_Target_30_SwissProt_Name:
RIFK_HUMAN

# Drug_Target_30_Synonyms:
ATP:riboflavin 5'-phosphotransferase
EC 2.7.1.26
Flavokinase

# Drug_Target_30_Theoretical_pI:
8.22

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Not Available

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
Not Available

# Drug_Target_31_GenBank_ID_Gene:
U18655

# Drug_Target_31_GenBank_ID_Protein:
609324

# Drug_Target_31_GeneCard_ID:
Not Available

# Drug_Target_31_Gene_Name:
nfsA

# Drug_Target_31_Gene_Sequence:
>723 bp
ATGACGCCAACCATTGAACTTATTTGTGGCCATCGCTCCATTCGCCATTTCACTGATGAA
CCCATTTCCGAAGCGCAGCGTGAGGCGATTATTAACAGCGCCCGTGCGACGTCCAGTTCC
AGTTTTTTGCAGTGCAGTAGCATTATTCGCATTACCGACAAAGCGTTACGTGAAGAACTG
GTGACGCTGACCGGCGGGCAAAAACACGTAGCGCAAGCGGCGGAGTTCTGGGTGTTCTGT
GCCGACTTTAACCGCCATTTACAGATCTGTCCGGATGCTCAGCTCGGCCTGGCGGAACAA
CTGTTGCTCGGTGTCGTTGATACGGCAATGATGGCGCAGAATGCATTAATCGCAGCGGAA
TCGCTGGGATTGGGCGGGGTATATATCGGCGGCCTGCGCAATAATATTGAAGCGGTGACG
AAACTGCTTAAATTACCGCAGCATGTTCTGCCGCTGTTTGGGCTGTGCCTTGGCTGGCCT
GCGGATAATCCGGATCTTAAGCCGCGTTTACCGGCCTCCATTTTGGTGCATGAAAACAGC
TATCAACCGCTGGATAAAGGCGCACTGGCGCAGTATGACGAGCAACTGGCGGAATATTAC
CTCACCCGTGGCAGCAATAATCGCCGGGATACCTGGAGCGATCATATCCGCCGAACAATC
ATTAAAGAAAGCCGCCCATTTATTCTGGATTATTTGCACAAACAGGGTTGGGCGACGCGC
TAA

# Drug_Target_31_General_Function:
Energy production and conversion

# Drug_Target_31_General_References:
11034992	Kobori T, Sasaki H, Lee WC, Zenno S, Saigo K, Murphy ME, Tanokura M: Structure and site-directed mutagenesis of a flavoprotein from Escherichia coli that reduces nitrocompounds: alteration of pyridine nucleotide binding by a single amino acid substitution. J Biol Chem. 2001 Jan 26;276(4):2816-23. Epub 2000 Oct 16.
2570347	Kang WK, Icho T, Isono S, Kitakawa M, Isono K: Characterization of the gene rimK responsible for the addition of glutamic acid residues to the C-terminus of ribosomal protein S6 in Escherichia coli K12. Mol Gen Genet. 1989 Jun;217(2-3):281-8.
7568050	Chatterjee PK, Sternberg NL: A general genetic approach in Escherichia coli for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8950-4.
8755878	Zenno S, Koike H, Kumar AN, Jayaraman R, Tanokura M, Saigo K: Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9440535	Zenno S, Kobori T, Tanokura M, Saigo K: Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.

# Drug_Target_31_HGNC_ID:
Not Available

# Drug_Target_31_HPRD_ID:
Not Available

# Drug_Target_31_ID:
685

# Drug_Target_31_Locus:
Not Available

# Drug_Target_31_Molecular_Weight:
26801

# Drug_Target_31_Name:
Oxygen-insensitive NADPH nitroreductase

# Drug_Target_31_Number_of_Residues:
240

# Drug_Target_31_PDB_ID:
1F5V

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_31_Protein_Sequence:
>Oxygen-insensitive NADPH nitroreductase
MTPTIELICGHRSIRHFTDEPISEAQREAIINSARATSSSSFLQCSSIIRITDKALREEL
VTLTGGQKHVAQAAEFWVFCADFNRHLQICPDAQLGLAEQLLLGVVDTAMMAQNALIAAE
SLGLGGVYIGGLRNNIEAVTKLLKLPQHVLPLFGLCLGWPADNPDLKPRLPASILVHENS
YQPLDKGALAQYDEQLAEYYLTRGSNNRRDTWSDHIRRTIIKESRPFILDYLHKQGWATR

# Drug_Target_31_Reaction:
Not Available

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Reduction of nitroaromatic compounds using NADH. Reduces nitrofurazone by a ping-pong bi-bi mechanism possibly to generate a two-electron transfer product. Major component of the oxygen- insensitive nitroreductase activity in E.coli

# Drug_Target_31_SwissProt_ID:
P17117

# Drug_Target_31_SwissProt_Name:
NFSA_ECOLI

# Drug_Target_31_Synonyms:
EC 1.-.-.-
Modulator of drug activity A

# Drug_Target_31_Theoretical_pI:
6.94

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Sarcolemma
peripheral membrane protein. In skeletal muscle, it is localized b
sarcolemmal membrane

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
NOS1

# Drug_Target_32_GenBank_ID_Gene:
U17327

# Drug_Target_32_GenBank_ID_Protein:
642526

# Drug_Target_32_GeneCard_ID:
NOS1

# Drug_Target_32_Gene_Name:
NOS1

# Drug_Target_32_Gene_Sequence:
>4305 bp
ATGGAGGATCACATGTTCGGTGTTCAGCAAATCCAGCCCAATGTCATTTCTGTTCGTCTC
TTCAAGCGCAAAGTTGGGGGCCTGGGATTTCTGGTGAAGGAGCGGGTCAGTAAGCCGCCC
GTGATCATCTCTGACCTGATTCGTGGGGGCGCCGCAGAGCAGAGTGGCCTCATCCAGGCC
GGAGACATCATTCTTGCGGTCAACGGCCGGCCCTTGGTGGACCTGAGCTATGACAGCGCC
CTGGAGGTACTCAGAGGCATTGCCTCTGAGACCCACGTGGTCCTCATTCTGAGGGGCCCT
GAAGGTTTCACCACGCACCTGGAGACCACCTTTACAGGTGATGGGACCCCCAAGACCATC
CGGGTGACACAGCCCCTGGGTCCCCCCACCAAAGCCGTGGATCTGTCCCACCAGCCACCG
GCCGGCAAAGAACAGCCCCTGGCAGTGGATGGGGCCTCGGGTCCCGGGAATGGGCCTCAG
CATGCCTACGATGATGGGCAGGAGGCTGGCTCACTCCCCCATGCCAACGGCCTGGCCCCC
AGGCCCCCAGGCCAGGACCCCGCGAAGAAAGCAACCAGAGTCAGCCTCCAAGGCAGAGGG
GAGAACAATGAACTGCTCAAGGAGATAGAGCCTGTGCTGAGCCTTCTCACCAGTGGGAGC
AGAGGGGTCAAGGGAGGGGCACCTGCCAAGGCAGAGATGAAAGATATGGGAATCCAGGTG
GACAGAGATTTGGACGGCAAGTCACACAAACCTCTGCCCCTCGGCGTGGAGAACGACCGA
GTCTTCAATGACCTATGGGGGAAGGGCAATGTGCCTGTCGTCCTCAACAACCCATATTCA
GAGAAGGAGCAGCCCCCCACCTCAGGAAAACAGTCCCCCACAAAGAATGGCAGCCCCTCC
AAGTGTCCACGCTTCCTCAAGGTCAAGAACTGGGAGACTGAGGTGGTTCTCACTGACACC
CTCCACCTTAAGAGCACATTGGAAACGGGATGCACTGAGTACATCTGCATGGGCTCCATC
ATGCATCCTTCTCAGCATGCAAGGAGGCCTGAAGACGTCCGCACAAAAGGACAGCTCTTC
CCTCTCGCCAAAGAGTTTATTGATCAATACTATTCATCAATTAAAAGATTTGGCTCCAAA
GCCCACATGGAAAGGCTGGAAGAGGTGAACAAAGAGATCGACACCACTAGCACTTACCAG
CTCAAGGACACAGAGCTCATCTATGGGGCCAAGCACGCCTGGCGGAATGCCTCGCGCTGT
GTGGGCAGGATCCAGTGGTCCAAGCTGCAGGTATTCGATGCCCGTGACTGCACCACGGCC
CACGGGATGTTCAACTACATCTGTAACCATGTCAAGTATGCCACCAACAAAGGGAACCTC
AGGTCTGCCATCACCATATTCCCCCAGAGGACAGACGGCAAGCACGACTTCCGAGTCTGG
AACTCCCAGCTCATCCGCTACGCTGGCTACAAGCAGCCTGACGGCTCCACCCTGGGGGAC
CCAGCCAATGTGCAGTTCACAGAGATATGCATACAGCAGGGCTGGAAACCGCCTAGAGGC
CGCTTCGATGTCCTGCCGCTCCTGCTTCAGGCCAACGGCAATGACCCTGAGCTCTTCCAG
ATTCCTCCAGAGCTGGTGTTGGAAGTTCCCATCAGGCACCCCAAGTTTGAGTGGTTCAAG
GACCTGGGGCTGAAGTGGTACGGCCTCCCCGCCGTGTCCAACATGCTCCTAGAGATTGGC
GGCCTGGAGTTCAGCGCCTGTCCCTTCAGTGGCTGGTACATGGGCACAGAGATTGGTGTC
CGCGACTACTGTGACAACTCCCGCTACAATATCCTGGAGGAAGTGGCCAAGAAGATGAAC
TTAGACATGAGGAAGACGTCCTCCCTGTGGAAGGACCAGGCGCTGGTGGAGATCAATATC
GCGGTTCTCTATAGCTTCCAGAGTGACAAAGTGACCATTGTTGACCATCACTCCGCCACC
GAGTCCTTCATTAAGCACATGGAGAATGAGTACCGCTGCCGGGGGGGCTGCCCTGCCGAC
TGGGTGTGGATCGTGCCCCCCATGTCCGGAAGCATCACCCCTGTGTTCCACCAGGAGATG
CTCAACTACCGGCTCACCCCCTCCTTCGAATACCAGCCTGATCCCTGGAACACGCATGTC
TGGAAAGGCACCAACGGGACCCCCACAAAGCGGCGAGCCATCGGCTTCAAGAAGCTAGCA
GAAGCTGTCAAGTTCTCGGCCAAGCTGATGGGGCAGGCTATGGCCAAGAGGGTGAAAGCG
ACCATCCTCTATGCCACAGAGACAGGCAAATCGCAAGCTTATGCCAAGACCTTGTGTGAG
ATCTTCAAACACGCCTTTGATGCCAAGGTGATGTCCATGGAAGAATATGACATTGTGCAC
CTGGAACATGAAACTCTGGTCCTTGTGGTCACCAGCACCTTTGGCAATGGAGATCCCCCT
GAGAATGGGGAGAAATTCGGCTGTGCTTTGATGGAAATGAGGCACCCCAACTCTGTGCAG
GAAGAAAGGAAGAGCTACAAGGTCCGATTCAACAGCGTCTCCTCCTACTCTGACTCCCAA
AAATCATCAGGCGATGGGCCCGACCTCAGAGACAACTTTGAGAGTGCTGGACCCCTGGCC
AATGTGAGGTTCTCAGTTTTTGGCCTCGGCTCACGAGCATACCCTCACTTTTGCGCCTTC
GGACACGCTGTGGACACCCTCCTGGAAGAACTGGGAGGGGAGAGGATCCTGAAGATGAGG
GAAGGGGATGAGCTCTGTGGGCAGGAAGAGGCTTTCAGGACCTGGGCCAAGAAGGTCTTC
AAGGCAGCCTGTGATGTCTTCTGTGTGGGAGATGATGTCAACATTGAAAAGGCCAACAAT
TCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGCCTCACCTTTGTGGCC
GAAGCTCCAGAACTCACACAAGGTCTATCCAATGTCCACAAAAAGCGAGTCTCAGCTGCC
CGGCTCCTTAGCCGTCAAAACCTCCAGAGCCCTAAATCCAGTCGGTCAACTATCTTCGTG
CGTCTCCACACCAACGGGAGCCAGGAGCTGCAGTACCAGCCTGGGGACCACCTGGGTGTC
TTCCCTGGCAACCACGAGGACCTCGTGAATGCCCTGATCGAGCGGCTGGAGGACGCGCCG
CCTGTCAACCAGATGGTGAAAGTGGAACTGCTGGAGGAGCGGAACACGGCTTTAGGTGTC
ATCAGTAACTGGACAGACGAGCTCCGCCTCCCGCCCTGCACCATCTTCCAGGCCTTCAAG
TACTACCTGGACATCACCACGCCACCAACGCCTCTGCAGCTGCAGCAGTTTGCCTCCCTA
GCTACCAGCGAGAAGGAGAAGCAGCGTCTGCTGGTCCTCAGCAAGGGTTTGCAGGAGTAC
GAGGAATGGAAATGGGGCAAGAACCCCACCATCGTGGAGGTGCTGGAGGAGTTCCCATCT
ATCCAGATGCCGGCCACCCTGCTCCTGACCCAGCTGTCCCTGCTGCAGCCCCGCTACTAT
TCCATCAGCTCCTCCCCAGACATGTACCCTGATGAAGTGCACCTCACTGTGGCCATCGTT
TCCTACCGCACTCGAGATGGAGAAGGACCAATTCACCACGGCGTATGCTCCTCCTGGCTC
AACCGGATACAGGCTGACGAACTGGTCCCCTGTTTCGTGAGAGGAGCACCCAGCTTCCAC
CTGCCCCGGAACCCCCAAGTCCCCTGCATCCTCGTTGGACCAGGCACCGGCATTGCCCCT
TTCCGAAGCTTCTGGCAACAGCGGCAATTTGATATCCAACACAAAGGAATGAACCCCTGC
CCCATGGTCCTGGTCTTCGGGTGCCGGCAATCCAAGATAGATCATATCTACAGGGAAGAG
ACCCTGCAGGCCAAGAACAAGGGGGTCTTCAGAGAGCTGTACACGGCTTACTCCCGGGAG
CCAGACAAACCAAAGAAGTACGTGCAGGACATCCTGCAGGAGCAGCTGGCGGAGTCTGTG
TACCGAGCCCTGAAGGAGCAAGGGGGCCACATATACGTCTGTGGGGACGTCACCATGGCT
GCTGATGTCCTCAAAGCCATCCAGCGCATCATGACCCAGCAGGGGAAGCTCTCGGCAGAG
GACGCCGGCGTATTCATCAGCCGGATGAGGGATGACAACCGATACCATGAGGATATTTTT
GGAGTCACCCTGCGAACGTACGAAGTGACCAACCGCCTTAGATCTGAGTCCATTGCCTTC
ATTGAAGAGAGCAAAAAAGACACCGATGAGGTTTTCAGCTCCTAA

# Drug_Target_32_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_32_General_References:
7515942	Fujisawa H, Ogura T, Kurashima Y, Yokoyama T, Yamashita J, Esumi H: Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines. J Neurochem. 1994 Jul;63(1):140-5.
7528745	Hall AV, Antoniou H, Wang Y, Cheung AH, Arbus AM, Olson SL, Lu WC, Kau CL, Marsden PA: Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J Biol Chem. 1994 Dec 30;269(52):33082-90.
7678401	Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F: Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett. 1993 Jan 25;316(2):175-80.
8879752	Park CS, Gianotti C, Park R, Krishna G: Neuronal isoform of nitric oxide synthase is expressed at low levels in human retina. Cell Mol Neurobiol. 1996 Aug;16(4):499-515.
9111048	Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA: A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem. 1997 Apr 25;272(17):11392-401.

# Drug_Target_32_HGNC_ID:
HGNC:7872

# Drug_Target_32_HPRD_ID:
01226

# Drug_Target_32_ID:
76

# Drug_Target_32_Locus:
12q24.2-q24.31

# Drug_Target_32_Molecular_Weight:
160972

# Drug_Target_32_Name:
Nitric-oxide synthase, brain

# Drug_Target_32_Number_of_Residues:
1434

# Drug_Target_32_PDB_ID:
1TLL

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00595	PDZ
PF00667	FAD_binding_1
PF02898	NO_synthase

# Drug_Target_32_Protein_Sequence:
>Nitric-oxide synthase, brain
MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA
GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI
RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP
RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV
DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS
KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF
PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC
VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW
NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ
IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV
RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT
ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV
WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE
IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ
EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF
GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN
SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV
RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV
ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY
EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV
SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP
FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE
PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE
DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS

# Drug_Target_32_Reaction:
L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter

# Drug_Target_32_SwissProt_ID:
P29475

# Drug_Target_32_SwissProt_Name:
NOS1_HUMAN

# Drug_Target_32_Synonyms:
Constitutive NOS
EC 1.14.13.39
N-NOS
NC-NOS
NOS type I
Neuronal NOS
bNOS
nNOS

# Drug_Target_32_Theoretical_pI:
7.44

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Cell membrane
peripheral membrane protein

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
Not Available

# Drug_Target_33_GenBank_ID_Gene:
X02826

# Drug_Target_33_GenBank_ID_Protein:
42609

# Drug_Target_33_GeneCard_ID:
Not Available

# Drug_Target_33_Gene_Name:
pyrD

# Drug_Target_33_Gene_Sequence:
>1011 bp
ATGTACTACCCCTTCGTTCGTAAAGCCCTTTTCCAGCTCGATCCAGAGCGCGCTCATGAG
TTTACTTTTCAGCAATTACGCCGTATTACAGGAACGCCGTTTGAAGCACTGGTGCGGCAG
AAAGTGCCTGCGAAACCTGTTAACTGCATGGGCCTGACGTTTAAAAATCCGCTTGGTCTG
GCAGCCGGTCTTGATAAAGACGGGGAGTGCATTGACGCGTTAGGCGCGATGGGATTTGGA
TCGATCGAGATCGGTACCGTCACGCCACGTCCACAGCCAGGTAATGACAAGCCGCGTCTC
TTTCGTCTGGTAGATGCCGAAGGTTTGATCAACCGTATGGGCTTTAATAATCTTGGCGTT
GATAACCTCGTAGAGAACGTAAAAAAGGCCCATTATGACGGCGTCCTGGGTATTAACATC
GGCAAAAATAAAGATACGCCAGTGGAGCAGGGCAAAGATGACTATCTGATTTGTATGGAA
AAAATCTATGCCTATGCGGGATATATCGCCATCAATATTTCATCGCCGAATACCCCAGGA
TTACGCACGCTGCAATATGGTGAAGCGCTGGATGATCTCTTAACCGCGATTAAAAATAAG
CAAAATGATTTGCAAGCGATGCACCATAAATATGTGCCGATCGCAGTGAAGATCGCGCCG
GATCTTTCTGAAGAAGAATTGATCCAGGTTGCCGATAGTTTAGTTCGCCATAATATTGAT
GGCGTTATTGCAACCAATACCACACTCGATCGTTCTCTTGTTCAGGGAATGAAAAATTGC
GATCAAACCGGTGGCTTAAGTGGTCGTCCGCTTCAGTTAAAAAGCACCGAAATTATTCGC
CGCTTGTCACTGGAATTAAACGGTCGCTTACCGATCATCGGTGTTGGCGGCATCGACTCG
GTTATCGCTGCGCGTGAAAAGATTGCTGCGGGTGCCTCACTGGTGCAAATTTATTCTGGT
TTTATTTTTAAAGGTCCGCCGCTGATTAAAGAAATCGTTACCCATATCTAA

# Drug_Target_33_General_Function:
Nucleotide transport and metabolism

# Drug_Target_33_General_References:
12220493	Norager S, Jensen KF, Bjornberg O, Larsen S: E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure. 2002 Sep;10(9):1211-23.
2992959	Larsen JN, Jensen KF: Nucleotide sequence of the pyrD gene of Escherichia coli and characterization of the flavoprotein dihydroorotate dehydrogenase. Eur J Biochem. 1985 Aug 15;151(1):59-65.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_33_HGNC_ID:
Not Available

# Drug_Target_33_HPRD_ID:
Not Available

# Drug_Target_33_ID:
2775

# Drug_Target_33_Locus:
Not Available

# Drug_Target_33_Molecular_Weight:
36775

# Drug_Target_33_Name:
Dihydroorotate dehydrogenase

# Drug_Target_33_Number_of_Residues:
336

# Drug_Target_33_PDB_ID:
1F76

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_33_Protein_Sequence:
>Dihydroorotate dehydrogenase
MYYPFVRKALFQLDPERAHEFTFQQLRRITGTPFEALVRQKVPAKPVNCMGLTFKNPLGL
AAGLDKDGECIDALGAMGFGSIEIGTVTPRPQPGNDKPRLFRLVDAEGLINRMGFNNLGV
DNLVENVKKAHYDGVLGINIGKNKDTPVEQGKDDYLICMEKIYAYAGYIAINISSPNTPG
LRTLQYGEALDDLLTAIKNKQNDLQAMHHKYVPIAVKIAPDLSEEELIQVADSLVRHNID
GVIATNTTLDRSLVQGMKNCDQTGGLSGRPLQLKSTEIIRRLSLELNGRLPIIGVGGIDS
VIAAREKIAAGASLVQIYSGFIFKGPPLIKEIVTHI

# Drug_Target_33_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_33_Signals:
None

# Drug_Target_33_Specific_Function:
(S)-dihydroorotate + O(2) = orotate + H(2)O(2)

# Drug_Target_33_SwissProt_ID:
P0A7E1

# Drug_Target_33_SwissProt_Name:
PYRD_ECOLI

# Drug_Target_33_Synonyms:
DHOD
DHODase
DHOdehase
Dihydroorotate oxidase
EC 1.3.3.1

# Drug_Target_33_Theoretical_pI:
7.97

# Drug_Target_33_Transmembrane_Regions:
None

# Drug_Target_34_Cellular_Location:
Cytoplasm

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
DPYD

# Drug_Target_34_GenBank_ID_Gene:
U09178

# Drug_Target_34_GenBank_ID_Protein:
558305

# Drug_Target_34_GeneCard_ID:
DPYD

# Drug_Target_34_Gene_Name:
DPYD

# Drug_Target_34_Gene_Sequence:
>3078 bp
ATGGCCCCTGTGCTCAGTAAGGACTCGGCGGACATCGAGAGTATCCTGGCTTTAAATCCT
CGAACACAAACTCATGCAACTCTGTGTTCCACTTCGGCCAAGAAATTAGACAAGAAACAT
TGGAAAAGAAATCCTGATAAGAACTGCTTTAATTGTGAGAAGCTGGAGAATAATTTTGAT
GACATCAAGCACACGACTCTTGGTGAGCGAGGAGCTCTCCGAGAAGCAATGAGATGCCTG
AAATGTGCAGATGCCCCGTGTCAGAAGAGCTGTCCAACTAATCTTGATATTAAATCATTC
ATCACAAGTATTGCAAACAAGAACTATTATGGAGCTGCTAAGATGATATTTTCTGACAAC
CCACTTGGTCTGACTTGTGGAATGGTATGTCCAACCTCTGATCTATGTGTAGGTGGATGC
AATTTATATGCCACTGAAGAGGGACCCATTAATATTGGTGGATTGCAGCAATTTGCTACT
GAGGTATTCAAAGCAATGAGTATCCCACAGATCAGAAATCCTTCGCTGCCTCCCCCAGAA
AAAATGTCTGAAGCCTATTCTGCAAAGATTGCTCTTTTTGGTGCTGGGCCTGCAAGTATA
AGTTGTGCTTCCTTTTTGGCTCGATTGGGGTACTCTGACATCACTATATTTGAAAAACAA
GAATATGTTGGTGGTTTAAGTACTTCTGAAATTCCTCAGTTCCGGCTGCCGTATGATGTA
GTGAATTTTGAGATTGAGCTAATGAAGGACCTTGGTGTAAAGATAATTTGCGGTAAAAGC
CTTTCAGTGAATGAAATGACTCTTAGCACTTTGAAAGAAAAAGGCTACAAAGCTGCTTTC
ATTGGAATAGGTTTGCCAGAACCCAATAAAGATGCCATCTTCCAAGGCCTGACGCAGGAC
CAGGGGTTTTATACATCCAAAGACTTTTTGCCACTTGTAGCCAAAGGCAGTAAAGCAGGA
ATGTGCGCCTGTCACTCTCCATTGCCATCGATACGGGGAGTCGTGATTGTACTTGGAGCT
GGAGACACTGCCTTCGACTGTGCAACATCTGCTCTACGTTGTGGAGCTCGCCGAGTGTTC
ATCGTCTTCAGAAAAGGCTTTGTTAATATAAGAGCTGTCCCTGAGGAGATGGAGCTTGCT
AAGGAAGAAAAGTGTGAATTTCTGCCATTCCTGTCCCCACGGAAGGTTATAGTAAAAGGT
GGGAGAATTGTTGCTATGCAGTTTGTTCGGACAGAGCAAGATGAAACTGGAAAATGGAAT
GAAGATGAAGATCAGATGGTCCATCTGAAAGCCGATGTGGTCATCAGTGCCTTTGGTTCA
GTTCTGAGTGATCCTAAAGTAAAAGAAGCCTTGAGCCCTATAAAATTTAACAGATGGGGT
CTCCCAGAAGTAGATCCAGAAACTATGCAAACTAGTGAAGCATGGGTATTTGCAGGTGGT
GATGTCGTTGGTTTGGCTAACACTACAGTGGAATCGGTGAATGATGGAAAGCAAGCTTCT
TGGTACATTCACAAATACGTACAGTCACAATATGGAGCTTCCGTTTCTGCCAAGCCTGAA
CTACCCCTCTTTTACACTCCTATTGATCTGGTGGACATTAGTGTAGAAATGGCCGGATTG
AAGTTTATAAATCCTTTTGGTCTTGCTAGCGCAACTCCAGCCACCAGCACATCAATGATT
CGAAGAGCTTTTGAAGCTGGATGGGGTTTTGCCCTCACCAAAACTTTCTCTCTTGATAAG
GACATTGTGACAAATGTTTCCCCCAGAATCATCCGGGGAACCACCTCTGGCCCCATGTAT
GGCCCTGGACAAAGCTCCTTTCTGAATATTGAGCTCATCAGTGAGAAAACGGCTGCATAT
TGGTGTCAAAGTGTCACTGAACTAAAGGCTGACTTCCCAGACAACATTGTGATTGCTAGC
ATTATGTGCAGTTACAATAAAAATGACTGGACGGAACTTGCCAAGAAGTCTGAGGATTCT
GGAGCAGATGCCCTGGAGTTAAATTTATCATGTCCACATGGCATGGGAGAAAGAGGAATG
GGCCTGGCCTGTGGGCAGGATCCAGAGCTGGTGCGGAACATCTGCCGCTGGGTTAGGCAA
GCTGTTCAGATTCCTTTTTTTGCCAAGCTGACCCCAAATGTCACTGATATTGTGAGCATC
GCAAGAGCTGCAAAGGAAGGTGGTGCCAATGGCGTTACAGCCACCAACACTGTCTCAGGT
CTGATGGGATTAAAATCTGATGGCACACCTTGGCCAGCAGTGGGGATTGCAAAGCGAACT
ACATATGGAGGAGTGTCTGGGACAGCAATCAGACCTATTGCTTTGAGAGCTGTGACCTCC
ATTGCTCGTGCTCTGCCTGGATTTCCCATTTTGGCTACTGGTGGAATTGACTCTGCTGAA
AGTGGTCTTCAGTTTCTCCATAGTGGTGCTTCCGTCCTCCAGGTATGCAGTGCCATTCAG
AATCAGGATTTCACTGTGATCGAAGACTACTGCACTGGCCTCAAAGCCCTGCTTTATCTG
AAAAGCATTGAAGAACTACAAGACTGGGATGGACAGAGTCCAGCTACTGTGAGTCACCAG
AAAGGGAAACCAGTTCCACGTATAGCTGAACTCATGGACAAGAAACTGCCAAGTTTTGGA
CCTTATCTGGAACAGCGCAAGAAAATCATAGCAGAAAACAAGATTAGACTGAAAGAACAA
AATGTAGCTTTTTCACCACTTAAGAGAAGCTGTTTTATCCCCAAAAGGCCTATTCCTACC
ATCAAGGATGTAATAGGAAAAGCACTGCAGTACCTTGGAACATTTGGTGAATTGAGCAAC
GTAGAGCAAGTTGTGGCTATGATTGATGAAGAAATGTGTATCAACTGTGGTAAATGCTAC
ATGACCTGTAATGATTCTGGCTACCAGGCTATACAGTTTGATCCAGAAACCCACCTGCCC
ACCATAACCGACACTTGTACAGGCTGTACTCTGTGTCTCAGTGTTTGCCCTATTGTCGAC
TGCATCAAAATGGTTTCCAGGACAACACCTTATGAACCAAAGAGAGGCGTACCCTTATCT
GTGAATCCGGTGTGTTAA

# Drug_Target_34_General_Function:
Amino acid transport and metabolism

# Drug_Target_34_General_References:
1512248	Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem. 1992 Aug 25;267(24):17102-9.
8083224	Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem. 1994 Sep 16;269(37):23192-6.
8892022	Vreken P, Van Kuilenburg AB, Meinsma R, Smit GP, Bakker HD, De Abreu RA, van Gennip AH: A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(5):645-54.
9135003	Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 1997 May 1;57(9):1660-3.
9170156	Fernandez-Salguero PM, Sapone A, Wei X, Holt JR, Jones S, Idle JR, Gonzalez FJ: Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. Pharmacogenetics. 1997 Apr;7(2):161-3.
9266349	Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH: Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherit Metab Dis. 1997 Jul;20(3):335-8.
9439663	Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH: Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet. 1997 Dec;101(3):333-8.
9464498	Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y, Watabe T: Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett. 1998 Jan 9;122(1-2):107-13.

# Drug_Target_34_HGNC_ID:
HGNC:3012

# Drug_Target_34_HPRD_ID:
02036

# Drug_Target_34_ID:
1302

# Drug_Target_34_Locus:
1p22

# Drug_Target_34_Molecular_Weight:
111375

# Drug_Target_34_Name:
Dihydropyrimidine dehydrogenase [NADP+]

# Drug_Target_34_Number_of_Residues:
1025

# Drug_Target_34_PDB_ID:
1GTE

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF00037	Fer4
PF01180	DHO_dh
PF07992	Pyr_redox_2

# Drug_Target_34_Protein_Sequence:
>Dihydropyrimidine dehydrogenase [NADP+] precursor
MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFD
DIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDN
PLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPE
KMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDV
VNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQD
QGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVF
IVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWN
EDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGG
DVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGL
KFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMY
GPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDS
GADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSI
ARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTS
IARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYL
KSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQ
NVAFSPLKRSCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCY
MTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLS
VNPVC

# Drug_Target_34_Reaction:
5,6-dihydrouracil + NADP+ = uracil + NADPH + H+

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil

# Drug_Target_34_SwissProt_ID:
Q12882

# Drug_Target_34_SwissProt_Name:
DPYD_HUMAN

# Drug_Target_34_Synonyms:
DHPDHase
DPD
Dihydropyrimidine dehydrogenase precursor
Dihydrothymine dehydrogenase
Dihydrouracil dehydrogenase
EC 1.3.1.2

# Drug_Target_34_Theoretical_pI:
7.05

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
DHODH

# Drug_Target_35_GenBank_ID_Gene:
M94065

# Drug_Target_35_GenBank_ID_Protein:
555594

# Drug_Target_35_GeneCard_ID:
DHODH

# Drug_Target_35_Gene_Name:
DHODH

# Drug_Target_35_Gene_Sequence:
>1191 bp
AAATTACCGTGGAGACACCTGCAAAAGCGGGCCCAGGATGCTGTGATCATCCTGGGGGGA
GGAGGACTTCTCTTCGCCTCCTACCTGATGGCCACGGGAGATGAGCGTTTCTATGCTGAA
CACCTGATGCCGACTCTGCAGGGGCTGCTGGACCCGGAGTCAGCCCACAGACTGGCTGTT
CGCTTCACCTCCCTGGGGCTCCTTCCACGGGCCAGATTTCAAGACTCTGACATGCTGGAA
GTGAGAGTTCTGGGCCATAAATTCCGAAATCCAGTAGGAATTGCTGCAGGATTTGACAAG
CATGGGGAAGCCGTGGACGGACTTTATAAGATGGGCTTTGGTTTTGTTGAGATAGGAAGT
GTGACTCCAAAACCTCAGGAAGGAAACCCTAGACCCAGAGTCTTCCGCCTCCCTGAGGAC
CAAGCTGTCATTAACAGGTATGGATTTAACAGTCACGGGCTTTCAGTGGTGGAACACAGG
TTACGGGCCAGACAGCAGAAGCAGGCCAAGCTCACAGAAGATGGACTGCCTCTGGGGGTC
AACTTGGGGAAGAACAAGACCTCAGTGGACGCCGCGGAGGACTACGCAGAAGGGGTGCGC
GTACTGGGCCCCCTGGCCGACTACCTGGTGGTGAATGTGTCCAGCCCCAACACTGCCGGG
CTGCGGAGCCTTCAGGGAAAGGCCGAGCTGCGCCGCCTGCTGACCAAGGTGCTGCAGGAG
AGGGATGGCTTGCGGAGAGTGCACAGGCCGGCAGTCCTGGTGAAGATCGCTCCTGACCTC
ACCAGCCAGGATAAGGAGGACATTGCCAGTGTGGTCAAAGAGTTGGGCATCGATGGGCTG
ATTGTTACGAACACCACCGTGAGTCGCCCTGCGGGCCTCCAGGGTGCCCTGCGCTCTGAA
ACAGGAGGGCTGAGTGGGAAGCCCCTCCGGGATTTATCAACTCAAACCATTCGGGAGATG
TATGCACTCACCCAAGGCCGAGTTCCCATAATTGGGGTTGGTGGTGTGAGCAGCGGGCAG
GACGCGCTGGAGAAGATCCGGGCAGGGGCCTCCCTGGTGCAGCTGTACACGGCCCTCACC
TTCTGGGGGCCACCCGTTGTGGGCAAAGTCAAGCGGGAACTGGAGGCCCTTCTGAAAGAG
CAGGGCTTTGGCGGAGTCACAGATGCCATTGGAGCAGATCATCGGAGGTGA

# Drug_Target_35_General_Function:
Nucleotide transport and metabolism

# Drug_Target_35_General_References:
1446837	Minet M, Dufour ME, Lacroute F: Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant. Gene. 1992 Nov 16;121(2):393-6.

# Drug_Target_35_HGNC_ID:
HGNC:2867

# Drug_Target_35_HPRD_ID:
00521

# Drug_Target_35_ID:
424

# Drug_Target_35_Locus:
16q22

# Drug_Target_35_Molecular_Weight:
42868

# Drug_Target_35_Name:
Dihydroorotate dehydrogenase, mitochondrial

# Drug_Target_35_Number_of_Residues:
395

# Drug_Target_35_PDB_ID:
1D3H

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_35_Protein_Sequence:
>Dihydroorotate dehydrogenase, mitochondrial precursor
MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVR
FTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSV
TPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVN
LGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQER
DGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSET
GGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTF
WGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR

# Drug_Target_35_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Not Available

# Drug_Target_35_SwissProt_ID:
Q02127

# Drug_Target_35_SwissProt_Name:
PYRD_HUMAN

# Drug_Target_35_Synonyms:
DHOdehase
Dihydroorotate dehydrogenase, mitochondrial precursor
Dihydroorotate oxidase
EC 1.3.3.1

# Drug_Target_35_Theoretical_pI:
10.23

# Drug_Target_35_Transmembrane_Regions:
13-32

# Drug_Target_36_Cellular_Location:
Not Available

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
Not Available

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
Not Available

# Drug_Target_36_GenBank_ID_Gene:
U68759

# Drug_Target_36_GenBank_ID_Protein:
Not Available

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
onr

# Drug_Target_36_Gene_Sequence:
>1098 bp
ATGTCCGCTGAAAAGCTGTTTACCCCACTGAAAGTGGGTGCCGTTACTGCCCCAAACCGC
GTGTTTATGGCCCCACTTACCCGTCTGCGCAGCATCGAGCCGGGCGATATCCCAACGCCA
TTGATGGGTGAGTATTACCGCCAGCGCGCCAGCGCGGGCCTGATTATCTCCGAAGCCACG
CAGATTTCTGCTCAGGCAAAAGGCTACGCCGGTGCACCGGGTCTGCACAGCCCGGAACAG
ATCGCCGCGTGGAAAAAAATCACCGCAGGCGTGCATGCTGAAGATGGCCGTATTGCGGTT
CAGCTGTGGCACACCGGTCGTATCTCACACAGCAGCATCCAGCCTGGCGGTCAGGCGCCG
GTTTCTGCCTCTGCCCTGAACGCCAATACCCGCACTTCCCTGCGCGATGAAAACGGTAAT
GCGATCCGCGTCGACACCACCACGCCACGCGCGCTGGAGCTGGACGAGATCCCGGGTATC
GTGAATGATTTCCGTCAGGCCGTCGCCAACGCCCGGGAAGCGGGCTTCGACCTGGTTGAG
CTTCACTCTGCGCACGGTTACCTGCTGCATCAGTTCCTGTCCCCGTCTTCCAACCAGCGT
ACCGACCAGTACGGCGGCAGCGTTGAAAACCGCGCGCGTCTGGTGCTTGAAGTGGTGGAT
GCTGTCTGTAATGAGTGGAGCGCAGACCGCATTGGTATTCGTGTCTCCCCGATCGGTACT
TTCCAGAACGTCGACAACGGTCCGAACGAAGAAGCAGACGCGCTGTATCTGATTGAAGAG
CTGGCGAAACGCGGTATCGCCTATCTGCACATGTCCGAGACGGACTTGGCAGGCGGCAAG
CCTTACAGTGAAGCCTTCCGTCAGAAAGTGCGCGAGCGCTTCCACGGCGTGATTATCGGG
GCGGGTGCGTATACGGCAGAAAAAGCCGAGGATTTGATCGGTAAAGGCCTGATCGACGCC
GTGGCCTTTGGCCGTGACTACATTGCTAACCCGGATCTGGTTGCCCGTTTGCAGAAAAAA
GCCGAACTGAACCCGCAGCGTCCTGAAAGCTTCTATGGCGGCGGCGCGGAAGGTTATACC
GACTACCCTTCACTGTAA

# Drug_Target_36_General_Function:
Involved in FMN binding

# Drug_Target_36_General_References:
8919782	Binks PR, French CE, Nicklin S, Bruce NC: Degradation of pentaerythritol tetranitrate by Enterobacter cloacae PB2. Appl Environ Microbiol. 1996 Apr;62(4):1214-9.
8932320	French CE, Nicklin S, Bruce NC: Sequence and properties of pentaerythritol tetranitrate reductase from Enterobacter cloacae PB2. J Bacteriol. 1996 Nov;178(22):6623-7.

# Drug_Target_36_HGNC_ID:
Not Available

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
4284

# Drug_Target_36_Locus:
Not Available

# Drug_Target_36_Molecular_Weight:
39490

# Drug_Target_36_Name:
Pentaerythritol tetranitrate reductase

# Drug_Target_36_Number_of_Residues:
365

# Drug_Target_36_PDB_ID:
1VYR

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00724	Oxidored_FMN

# Drug_Target_36_Protein_Sequence:
>Pentaerythritol tetranitrate reductase
MSAEKLFTPLKVGAVTAPNRVFMAPLTRLRSIEPGDIPTPLMGEYYRQRASAGLIISEAT
QISAQAKGYAGAPGLHSPEQIAAWKKITAGVHAEDGRIAVQLWHTGRISHSSIQPGGQAP
VSASALNANTRTSLRDENGNAIRVDTTTPRALELDEIPGIVNDFRQAVANAREAGFDLVE
LHSAHGYLLHQFLSPSSNQRTDQYGGSVENRARLVLEVVDAVCNEWSADRIGIRVSPIGT
FQNVDNGPNEEADALYLIEELAKRGIAYLHMSETDLAGGKPYSEAFRQKVRERFHGVIIG
AGAYTAEKAEDLIGKGLIDAVAFGRDYIANPDLVARLQKKAELNPQRPESFYGGGAEGYT
DYPSL

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Not Available

# Drug_Target_36_SwissProt_ID:
P71278

# Drug_Target_36_SwissProt_Name:
P71278_ENTCL

# Drug_Target_36_Synonyms:
Not Available

# Drug_Target_36_Theoretical_pI:
6.06

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Not Available

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
Not Available

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
AE008772

# Drug_Target_37_GenBank_ID_Protein:
Not Available

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
azoR

# Drug_Target_37_Gene_Sequence:
>606 bp
ATGAGCAAGGTATTAGTTCTTAAATCCAGTATTCTGGCAGGGTACTCTCAGTCTGGTCAG
TTGACTGACTATTTTATTGAACAATGGCGCGAAAAACACGTCGCAGATGAAATTACTGTC
CGCGATCTGGCGGCCAACCCTGTTCCGGTGCTGGATGGCGAGCTGGTGGGCGCGATGCGT
CCGGGCGATGCGCCTTTAACGCCACGTCAGCAGGACGCTCTGGCGCTGTCTGATGAACTC
ATTGCTGAACTGAAAGCCCACGACGTCATCGTTATTGCGGCGCCGATGTACAATTTCAAT
ATCCCGACGCAGCTGAAAAACTACTTTGATCTGATTGCCCGCGCCGGTATCACTTTCCGC
TATACCGAAAAAGGCCCGGAAGGTCTGGTAACCGGTAAACGCGCGGTGGTTCTCTCCAGC
CGCGGCGGTATCCATAAAGACACCCCGACGGATTTGATTGCGCCTTACCTGAAAGTGTTC
CTTGGTTTTATCGGTATCACCGACGTGAATTTTGTCTTTGCCGAAGGCATCGCCTACGGG
CCGGAAGTGGCAGCTAAAGCCCAGGCCGATGCAAAAGCCGCGATTGACAGCGTCGTGGCC
GCTTAA

# Drug_Target_37_General_Function:
Involved in oxidoreductase activity

# Drug_Target_37_General_References:
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
5169

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
21628

# Drug_Target_37_Name:
FMN-dependent NADH-azoreductase

# Drug_Target_37_Number_of_Residues:
201

# Drug_Target_37_PDB_ID:
1T5B

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF02525	Flavodoxin_2

# Drug_Target_37_Protein_Sequence:
>FMN-dependent NADH-azoreductase
MSKVLVLKSSILAGYSQSGQLTDYFIEQWREKHVADEITVRDLAANPVPVLDGELVGAMR
PGDAPLTPRQQDALALSDELIAELKAHDVIVIAAPMYNFNIPTQLKNYFDLIARAGITFR
YTEKGPEGLVTGKRAVVLSSRGGIHKDTPTDLIAPYLKVFLGFIGITDVNFVFAEGIAYG
PEVAAKAQADAKAAIDSVVAA

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
None

# Drug_Target_37_Specific_Function:
Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADH, but not NADPH, as an electron donor for its activity (By similarity)

# Drug_Target_37_SwissProt_ID:
P63462

# Drug_Target_37_SwissProt_Name:
AZOR_SALTY

# Drug_Target_37_Synonyms:
Azo-dye reductase
EC 1.7.-.-
FMN-dependent NADH-azo compound oxidoreductase

# Drug_Target_37_Theoretical_pI:
5.02

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Not Available

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
Not Available

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
Not Available

# Drug_Target_38_GenBank_ID_Gene:
X62386

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
epiD

# Drug_Target_38_Gene_Sequence:
>546 bp
ATGTATGGAAAATTATTGATATGCGCTACAGCATCGATAAATGTAATTAATATTAATCAC
TACATAGTTGAGTTAAAGCAACATTTTGATGAAGTTAATATATTATTTAGTCCTAGTAGT
AAAAATTTTATAAATACTGATGTTCTCAAGTTATTTTGTGATAACTTGTACGATGAAATT
AAAGATCCTCTTTTAAATCATATCAATATTGTAGAAAATCATGAATATATTTTAGTATTA
CCTGCATCAGCAAATACTATTAATAAAATAGCTAATGGTATATGTGATAATCTTTTAACT
ACTGTATGTTTAACCGGATATCAAAAATTATTTATATTTCCAAATATGAACATAAGAATG
TGGGGAAATCCATTTTTACAAAAAAATATTGATTTACTTAAAAATAATGATGTGAAAGTG
TATTCCCCTGATATGAATAAATCATTCGAAATATCTAGTGGCCGTTACAAAAACAATATC
ACAATGCCTAATATTGAAAATGTACTAAATTTTGTATTAAATAACGAAAAAAGACCTTTG
GATTAA

# Drug_Target_38_General_Function:
Involved in catalytic activity

# Drug_Target_38_General_References:
11101502	Blaesse M, Kupke T, Huber R, Steinbacher S: Crystal structure of the peptidyl-cysteine decarboxylase EpiD complexed with a pentapeptide substrate. EMBO J. 2000 Dec 1;19(23):6299-310.
1644762	Kupke T, Stevanovic S, Sahl HG, Gotz F: Purification and characterization of EpiD, a flavoprotein involved in the biosynthesis of the lantibiotic epidermin. J Bacteriol. 1992 Aug;174(16):5354-61.
1740156	Schnell N, Engelke G, Augustin J, Rosenstein R, Ungermann V, Gotz F, Entian KD: Analysis of genes involved in the biosynthesis of lantibiotic epidermin. Eur J Biochem. 1992 Feb 15;204(1):57-68.

# Drug_Target_38_HGNC_ID:
Not Available

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
5170

# Drug_Target_38_Locus:
Not Available

# Drug_Target_38_Molecular_Weight:
20825

# Drug_Target_38_Name:
Epidermin decarboxylase

# Drug_Target_38_Number_of_Residues:
181

# Drug_Target_38_PDB_ID:
1G63

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF02441	Flavoprotein

# Drug_Target_38_Protein_Sequence:
>Epidermin decarboxylase
MYGKLLICATASINVININHYIVELKQHFDEVNILFSPSSKNFINTDVLKLFCDNLYDEI
KDPLLNHINIVENHEYILVLPASANTINKIANGICDNLLTTVCLTGYQKLFIFPNMNIRM
WGNPFLQKNIDLLKNNDVKVYSPDMNKSFEISSGRYKNNITMPNIENVLNFVLNNEKRPL
D

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
Catalyzes the removal of two reducing equivalents (oxidative decarboxylation) from the cysteine residue of the C- terminal meso-lanthionine of epidermin to form a --C==C-- double bond

# Drug_Target_38_SwissProt_ID:
P30197

# Drug_Target_38_SwissProt_Name:
EPID_STAEP

# Drug_Target_38_Synonyms:
EC 4.1.1.-
Epidermin-modifying enzyme epiD

# Drug_Target_38_Theoretical_pI:
6.50

# Drug_Target_38_Transmembrane_Regions:
None

# Drug_Target_39_Cellular_Location:
Not Available

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
Not Available

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
Not Available

# Drug_Target_39_GenBank_ID_Gene:
D85081

# Drug_Target_39_GenBank_ID_Protein:
Not Available

# Drug_Target_39_GeneCard_ID:
Not Available

# Drug_Target_39_Gene_Name:
azoR

# Drug_Target_39_Gene_Sequence:
>606 bp
TTATGCAGAAACAATGCTGTCGATGGCTGCTTTTGCGTCAGACTGTGCTTTCGCTGCCAT
TTCCGGACCGTATGCGATCCCTTCGGCGAAGACAAATTTCACATCGGTAATGCCGATAAA
GCCGAGGAACGTGGACAGATACGGCGTCACCAGGTCCGTTGGTCCATCTTTGTGGATCCC
GCCGCGGCTGGTAATAACGATGGCTTTTTTACCCGTTACCAGACCTTCCGGACCGTTCTC
GGTATAGCGGAAAGTAACGCCTGCGCGGGCAACCAGGTCAAAATAGTTTTTCAACTGAGT
CGAGATGTTGAAGTTATACATCGGTGCCGCAATAACGATAACGTCGTGGGCTTTCAGCTC
GGCAATCAACTCATCGGAAAGTGCCAGAGCTTCCTGCTGACGCGGAGTCAGCGGCGCATC
GCTCGGACGCAGAGCGCCAACCAGTTCGCCATCCAGTACCGGAATCGGATTTGCAGCCAG
GTCGCGAACGGTGATTTCATCACGCGGAGTGCTTTTCGCGCCATTGTTCAACAAAATAAT
CGACAACTGATTAGACTGAGAGTACCCTGCCAGGATGCTGGATTTAAGAACTAATACCTT
GCTCAT

# Drug_Target_39_General_Function:
Involved in oxidoreductase activity

# Drug_Target_39_General_References:
2168383	Fischl AS, Kennedy EP: Isolation and properties of acyl carrier protein phosphodiesterase of Escherichia coli. J Bacteriol. 1990 Sep;172(9):5445-9.
7899078	Moriya H, Kasai H, Isono K: Cloning and characterization of the hrpA gene in the terC region of Escherichia coli that is highly similar to the DEAH family RNA helicase genes of Saccharomyces cerevisiae. Nucleic Acids Res. 1995 Feb 25;23(4):595-8.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_39_HGNC_ID:
Not Available

# Drug_Target_39_HPRD_ID:
Not Available

# Drug_Target_39_ID:
4407

# Drug_Target_39_Locus:
Not Available

# Drug_Target_39_Molecular_Weight:
21658

# Drug_Target_39_Name:
FMN-dependent NADH-azoreductase

# Drug_Target_39_Number_of_Residues:
201

# Drug_Target_39_PDB_ID:
1V4B

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF02525	Flavodoxin_2

# Drug_Target_39_Protein_Sequence:
>FMN-dependent NADH-azoreductase
MSKVLVLKSSILAGYSQSNQLSDYFVEQWREKHSADEITVRDLAANPIPVLDGELVGALR
PSDAPLTPRQQEALALSDELIAELKAHDVIVIAAPMYNFNISTQLKNYFDLVARAGVTFR
YTENGPEGLVTGKKAIVITSRGGIHKDGPTDLVTPYLSTFLGFIGITDVKFVFAEGIAYG
PEMAAKAQSDAKAAIDSIVSA

# Drug_Target_39_Reaction:
Not Available

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
Catalyzes the reductive cleavage of azo bond in aromatic azo compounds to the corresponding amines. Requires NADH, but not NADPH, as an electron donor for its activity. The enzyme can reduce ethyl red and methyl red, but is not able to convert sulfonated azo dyes

# Drug_Target_39_SwissProt_ID:
P41407

# Drug_Target_39_SwissProt_Name:
AZOR_ECOLI

# Drug_Target_39_Synonyms:
Azo-dye reductase
EC 1.7.-.-
FMN-dependent NADH-azo compound oxidoreductase

# Drug_Target_39_Theoretical_pI:
4.84

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE000512

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
TM_0857

# Drug_Target_3_Gene_Sequence:
>882 bp
ATGGTTGTCAGCATCGGAGTTTTCGATGGAGTTCACATCGGGCATCAGAAGGTCTTGAGG
ACCATGAAGGAAATAGCATTTTTCAGGAAGGACGATAGCCTTATCTACACCATATCTTAT
CCCCCCGAATATTTCTTACCGGATTTTCCCGGTCTTCTCATGACGGTAGAAAGCAGGGTG
GAGATGCTTTCTCGTTACGCCAGAACCGTTGTTCTGGATTTTTTCAGAATAAAAGATCTC
ACCCCAGAAGGGTTCGTCGAGAGGTATCTATCTGGAGTATCGGCTGTTGTTGTTGGAAGG
GATTTCAGATTTGGCAAGAACGCGAGCGGAAACGCGTCTTTTCTCAGAAAGAAAGGTGTG
GAAGTCTATGAAATTGAAGATGTCGTTGTTCAGGGAAAAAGAGTGAGCAGTTCTCTGATC
AGAAACCTCGTTCAGGAGGGAAGAGTGGAGGAAATTCCTGCATATCTCGGCAGATATTTC
GAAATCGAAGGAATCGTCCACAAAGATAGGGAATTTGGAAGAAAACTGGGATTTCCAACT
GCCAACATCGATAGAGGAAATGAAAAACTCGTAGATCTGAAAAGAGGAGTTTATCTGGTG
AGAGTTCATCTGCCGGATGGAAAGAAAAAATTCGGTGTTATGAACGTGGGTTTCAGGCCC
ACCGTGGGTGATGCGAGAAACGTGAAGTACGAGGTGTACATCCTGGATTTCGAAGGGGAT
CTTTACGGGCAGAGACTGAAACTGGAAGTATTGAAATTCATGAGGGATGAGAAGAAATTT
GATTCAATCGAGGAGCTGAAGGCTGCTATTGACCAGGATGTAAAGAGCGCCAGAAACATG
ATAGATGATATAATCAATTCGAAGTTCGAAAAAGAGGGGTGA

# Drug_Target_3_General_Function:
Involved in FMN adenylyltransferase activity

# Drug_Target_3_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
12910462	Wang W, Kim R, Jancarik J, Yokota H, Kim SH: Crystal structure of a flavin-binding protein from Thermotoga maritima. Proteins. 2003 Sep 1;52(4):633-5.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4366

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
33614

# Drug_Target_3_Name:
Riboflavin kinase/FMN adenylyltransferase

# Drug_Target_3_Number_of_Residues:
293

# Drug_Target_3_PDB_ID:
1T6Z

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01687	Flavokinase
PF06574	FAD_syn

# Drug_Target_3_Protein_Sequence:
>Riboflavin kinase/FMN adenylyltransferase
MVVSIGVFDGVHIGHQKVLRTMKEIAFFRKDDSLIYTISYPPEYFLPDFPGLLMTVESRV
EMLSRYARTVVLDFFRIKDLTPEGFVERYLSGVSAVVVGRDFRFGKNASGNASFLRKKGV
EVYEIEDVVVQGKRVSSSLIRNLVQEGRVEEIPAYLGRYFEIEGIVHKDREFGRKLGFPT
ANIDRGNEKLVDLKRGVYLVRVHLPDGKKKFGVMNVGFRPTVGDARNVKYEVYILDFEGD
LYGQRLKLEVLKFMRDEKKFDSIEELKAAIDQDVKSARNMIDDIINSKFEKEG

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q9WZW1

# Drug_Target_3_SwissProt_Name:
Q9WZW1_THEMA

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
9.26

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
Not Available

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
Not Available

# Drug_Target_40_GenBank_ID_Gene:
AE000511

# Drug_Target_40_GenBank_ID_Protein:
Not Available

# Drug_Target_40_GeneCard_ID:
Not Available

# Drug_Target_40_Gene_Name:
aroC

# Drug_Target_40_Gene_Sequence:
>1098 bp
ATGAACACTTTGGGGCGTTTTTTAAGGCTCACGACTTTTGGGGAATCGCATGGGGATGTG
ATAGGGGGGGTATTAGACGGCATGCCTAGCGGGATTAAAATAGACTATGCGCTATTAGAA
AATGAAATGAAGCGCCGCCAAGGGGGGAGGAACGTTTTCATTACGCCACGAAAAGAAGAC
GATAAAGTGGAAATAACAAGCGGGGTTTTTGAAGATTTTAGCACAGGGACTCCTATAGGG
TTTTTAATCCACAACCAAAGGGCTAGGAGCAAGGATTACGATAACATTAAAAACCTTTTT
AGGCCTAGCCATGCGGATTTCACTTATTTTCATAAATACGGCATTAGGGATTTTAGGGGT
GGGGGGAGGAGTTCGGCCAGAGAGAGTGCTATAAGAGTGGCTGCTGGGGCGTTTGCTAAA
ATGCTTTTAAGAGAAATCGGTATTGTTTGTGAAAGCGGGATTATAGAAATTGGGGGTATT
AAAGCCAAAAATTATGATTTTAATCACGCCTTAAAAAGCGAGATTTTTGCCCTAGATGAA
GAACAAGAAGAAGCGCAAAAAACAGCCATTCAAAACGCTATCAAAAACCACGATAGCATA
GGGGGTGTGGCTTTGATTAGAGCGAGGAGCATAAAAACCAATCAAAAGCTCCCCATTGGC
TTAGGTCAAGGGCTATACGCTAAATTAGACGCTAAAATCGCTGAAGCGATGATGGGGCTT
AATGGGGTGAAAGCGGTTGAAATAGGCAAGGGGGTAGAAAGCTCTTTATTAAAAGGCTCA
GAGTATAATGATTTAATGGATCAAAAGGGGTTTTTGAGCAATCGTAGCGGAGGGGTTTTA
GGGGGCATGAGCAATGGGGAAGAAATCATTGTTAGAGTGCATTTCAAACCCACGCCAAGC
ATTTTCCAACCTCAACGAACCATAGACATTAATGGCAATGAGTGCGAATGCTTGTTAAAG
GGCAGGCATGATCCTTGCATTGCGATTAGAGGGAGCGTGGTGTGCGAGAGTTTGTTAGCG
TTGGTGTTGGCTGATATGGTATTACTCAATTTGACTTCAAAAATAGAGTATTTAAAAACG
ATTTATAATGAGAATTAA

# Drug_Target_40_General_Function:
Involved in chorismate synthase activity

# Drug_Target_40_General_References:
9252185	Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997 Aug 7;388(6642):539-47.

# Drug_Target_40_HGNC_ID:
Not Available

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
5171

# Drug_Target_40_Locus:
Not Available

# Drug_Target_40_Molecular_Weight:
40101

# Drug_Target_40_Name:
Chorismate synthase

# Drug_Target_40_Number_of_Residues:
365

# Drug_Target_40_PDB_ID:
1UMF

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF01264	Chorismate_synt

# Drug_Target_40_Protein_Sequence:
>Chorismate synthase
MNTLGRFLRLTTFGESHGDVIGGVLDGMPSGIKIDYALLENEMKRRQGGRNVFITPRKED
DKVEITSGVFEDFSTGTPIGFLIHNQRARSKDYDNIKNLFRPSHADFTYFHKYGIRDFRG
GGRSSARESAIRVAAGAFAKMLLREIGIVCESGIIEIGGIKAKNYDFNHALKSEIFALDE
EQEEAQKTAIQNAIKNHDSIGGVALIRARSIKTNQKLPIGLGQGLYAKLDAKIAEAMMGL
NGVKAVEIGKGVESSLLKGSEYNDLMDQKGFLSNRSGGVLGGMSNGEEIIVRVHFKPTPS
IFQPQRTIDINGNECECLLKGRHDPCIAIRGSVVCESLLALVLADMVLLNLTSKIEYLKT
IYNEN

# Drug_Target_40_Reaction:
Not Available

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
5-O-(1-carboxyvinyl)-3-phosphoshikimate = chorismate + phosphate

# Drug_Target_40_SwissProt_ID:
P56122

# Drug_Target_40_SwissProt_Name:
AROC_HELPY

# Drug_Target_40_Synonyms:
5-enolpyruvylshikimate-3-phosphate phospholyase
EC 4.2.3.5

# Drug_Target_40_Theoretical_pI:
8.21

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
Not Available

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
X14577

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
isiB

# Drug_Target_41_Gene_Sequence:
>513 bp
ATGTCAAAGAAAATTGGTTTATTCTACGGTACTCAAACTGGTAAAACTGAATCAGTAGCA
GAAATCATTCGAGACGAGTTTGGTAATGATGTGGTGACATTACACGATGTTTCCCAGGCA
GAAGTAACTGACTTGAATGATTATCAATATTTGATTATTGGCTGTCCTACTTGGAATATT
GGCGAACTGCAAAGCGATTGGGAAGGACTCTATTCAGAACTGGATGATGTAGATTTTAAT
GGTAAATTGGTTGCCTACTTTGGGACTGGTGACCAAATAGGTTACGCAGATAATTTTCAG
GATGCGATCGGTATTTTGGAAGAAAAAATTTCTCAACGTGGTGGTAAAACTGTCGGCTAT
TGGTCAACTGATGGATATGATTTTAATGATTCCAAGGCACTAAGAAATGGCAAGTTTGTA
GGACTAGCTCTTGATGAAGATAATCAATCTGACTTAACAGACGATCGCATCAAAAGTTGG
GTTGCTCAATTAAAGTCTGAATTTGGTTTGTAA

# Drug_Target_41_General_Function:
Involved in FMN binding

# Drug_Target_41_General_References:
11759840	Kaneko T, Nakamura Y, Wolk CP, Kuritz T, Sasamoto S, Watanabe A, Iriguchi M, Ishikawa A, Kawashima K, Kimura T, Kishida Y, Kohara M, Matsumoto M, Matsuno A, Muraki A, Nakazaki N, Shimpo S, Sugimoto M, Takazawa M, Yamada M, Yasuda M, Tabata S: Complete genomic sequence of the filamentous nitrogen-fixing cyanobacterium Anabaena sp. strain PCC 7120. DNA Res. 2001 Oct 31;8(5):205-13; 227-53.
1303762	Rao ST, Shaffie F, Yu C, Satyshur KA, Stockman BJ, Markley JL, Sundarlingam M: Structure of the oxidized long-chain flavodoxin from Anabaena 7120 at 2 A resolution. Protein Sci. 1992 Nov;1(11):1413-27.
2125478	Stockman BJ, Krezel AM, Markley JL, Leonhardt KG, Straus NA: Hydrogen-1, carbon-13, and nitrogen-15 NMR spectroscopy of Anabaena 7120 flavodoxin: assignment of beta-sheet and flavin binding site resonances and analysis of protein-flavin interactions. Biochemistry. 1990 Oct 16;29(41):9600-9.
2500643	Leonhardt KG, Straus NA: Sequence of the flavodoxin gene from Anabaena variabilis 7120. Nucleic Acids Res. 1989 Jun 12;17(11):4384.

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
5172

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
18964

# Drug_Target_41_Name:
Flavodoxin

# Drug_Target_41_Number_of_Residues:
170

# Drug_Target_41_PDB_ID:
1RCF

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_41_Protein_Sequence:
>Flavodoxin
MSKKIGLFYGTQTGKTESVAEIIRDEFGNDVVTLHDVSQAEVTDLNDYQYLIIGCPTWNI
GELQSDWEGLYSELDDVDFNGKLVAYFGTGDQIGYADNFQDAIGILEEKISQRGGKTVGY
WSTDGYDFNDSKALRNGKFVGLALDEDNQSDLTDDRIKSWVAQLKSEFGL

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Low-potential electron donor to a number of redox enzymes

# Drug_Target_41_SwissProt_ID:
P0A3D9

# Drug_Target_41_SwissProt_Name:
FLAV_NOSS1

# Drug_Target_41_Synonyms:
Not Available

# Drug_Target_41_Theoretical_pI:
3.96

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Not Available

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
Not Available

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
Not Available

# Drug_Target_42_GenBank_ID_Gene:
J04033

# Drug_Target_42_GenBank_ID_Protein:
Not Available

# Drug_Target_42_GeneCard_ID:
Not Available

# Drug_Target_42_Gene_Name:
DVU_2680

# Drug_Target_42_Gene_Sequence:
>447 bp
ATGCCCAAAGCCCTCATCGTCTACGGTTCCACCACAGGCAACACGGAATACACCGCCGAA
ACCATCGCACGTGAACTTGCCGATGCAGGGTACGAAGTCGATAGCCGGGACGCGGCCTCT
GTCGAGGCTGGCGGTCTCTTCGAAGGCTTCGACCTCGTCCTTCTCGGATGCTCGACGTGG
GGTGACGACTCCATCGAACTGCAGGACGACTTCATTCCCCTTTTCGACTCCCTCGAAGAG
ACGGGGGCGCAGGGCCGCAAGGTGGCCTGCTTCGGCTGCGGCGACAGTTCCTACGAGTAC
TTCTGCGGGGCTGTCGACGCCATCGAAGAGAAGCTCAAGAACCTCGGTGCCGAAATCGTT
CAGGACGGTCTTCGCATCGATGGCGACCCCCGCGCCGCCCGGGACGACATCGTCGGCTGG
GCGCATGACGTGAGGGGCGCCATCTAG

# Drug_Target_42_General_Function:
Involved in FMN binding

# Drug_Target_42_General_References:
2002503	Watt W, Tulinsky A, Swenson RP, Watenpaugh KD: Comparison of the crystal structures of a flavodoxin in its three oxidation states at cryogenic temperatures. J Mol Biol. 1991 Mar 5;218(1):195-208.
3170590	Krey GD, Vanin EF, Swenson RP: Cloning, nucleotide sequence, and expression of the flavodoxin gene from Desulfovibrio vulgaris (Hildenborough). J Biol Chem. 1988 Oct 25;263(30):15436-43.
402366	Dubourdieu M, Fox JL: Amino acid sequence of Desulfovibrio vulgaris flavodoxin. J Biol Chem. 1977 Feb 25;252(4):1453-63.
4508313	Watenpaugh KD, Sieker LC, Jensen LH, Legall J, Dubourdieu M: Structure of the oxidized form of a flavodoxin at 2.5-Angstrom resolution: resolution of the phase ambiguity by anomalous scattering. Proc Natl Acad Sci U S A. 1972 Nov;69(11):3185-8.
4521211	Watenpaugh KD, Sieker LC, Jensen LH: The binding of riboflavin-5'-phosphate in a flavoprotein: flavodoxin at 2.0-Angstrom resolution. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3857-60.
8477691	Knauf MA, Lohr F, Curley GP, O'Farrell P, Mayhew SG, Muller F, Ruterjans H: Homonuclear and heteronuclear NMR studies of oxidized Desulfovibrio vulgaris flavodoxin. Sequential assignments and identification of secondary structure elements. Eur J Biochem. 1993 Apr 1;213(1):167-84.
8681954	Knauf MA, Lohr F, Blumel M, Mayhew SG, Ruterjans H: NMR investigation of the solution conformation of oxidized flavodoxin from Desulfovibrio vulgaris. Determination of the tertiary structure and detection of protein-bound water molecules. Eur J Biochem. 1996 Jun 1;238(2):423-34.
9874201	Walsh MA, McCarthy A, O'Farrell PA, McArdle P, Cunningham PD, Mayhew SG, Higgins TM: X-ray crystal structure of the Desulfovibrio vulgaris (Hildenborough) apoflavodoxin-riboflavin complex. Eur J Biochem. 1998 Dec 1;258(2):362-71.

# Drug_Target_42_HGNC_ID:
Not Available

# Drug_Target_42_HPRD_ID:
Not Available

# Drug_Target_42_ID:
4614

# Drug_Target_42_Locus:
Not Available

# Drug_Target_42_Molecular_Weight:
15823

# Drug_Target_42_Name:
Flavodoxin

# Drug_Target_42_Number_of_Residues:
148

# Drug_Target_42_PDB_ID:
1BU5

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_42_Protein_Sequence:
>Flavodoxin
MPKALIVYGSTTGNTEYTAETIARELADAGYEVDSRDAASVEAGGLFEGFDLVLLGCSTW
GDDSIELQDDFIPLFDSLEETGAQGRKVACFGCGDSSYEYFCGAVDAIEEKLKNLGAEIV
QDGLRIDGDPRAARDDIVGWAHDVRGAI

# Drug_Target_42_Reaction:
Not Available

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
Low-potential electron donor to a number of redox enzymes

# Drug_Target_42_SwissProt_ID:
P00323

# Drug_Target_42_SwissProt_Name:
FLAV_DESVH

# Drug_Target_42_Synonyms:
Not Available

# Drug_Target_42_Theoretical_pI:
3.83

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Not Available

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
Not Available

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
Not Available

# Drug_Target_43_GenBank_ID_Gene:
M19116

# Drug_Target_43_GenBank_ID_Protein:
Not Available

# Drug_Target_43_GeneCard_ID:
Not Available

# Drug_Target_43_Gene_Name:
isiB

# Drug_Target_43_Gene_Sequence:
>513 bp
ATGGCCAAAATTGGCTTATTCTACGGAACTCAAACAGGCGTTACCCAAACTATTGCTGAA
TCGATTCAACAAGAGTTTGGCGGTGAAAGTATTGTTGACCTCAATGATATTGCGAATGCT
GATGCCAGTGATTTAAATGCCTATGATTATTTAATTATCGGTTGTCCTACTTGGAATGTT
GGTGAACTGCAAAGTGACTGGGAAGGAATCTATGATGATTTAGACTCAGTCAACTTTCAA
GGGAAGAAAGTTGCCTACTTTGGAGCGGGTGATCAAGTAGGCTATTCCGATAACTTTCAG
GATGCTATGGGCATTCTAGAAGAAAAAATTAGCTCTTTAGGTAGTCAAACAGTTGGCTAT
TGGCCTATTGAAGGCTATGACTTCAATGAGTCAAAAGCTGTACGCAATAATCAGTTTGTT
GGTTTAGCAATTGATGAAGACAATCAACCTGATCTCACAAAGAATCGAATTAAGACTTGG
GTCAGCCAGCTAAAGTCAGAGTTCGGTCTTTAA

# Drug_Target_43_General_Function:
Involved in FMN binding

# Drug_Target_43_General_References:
10610791	Drennan CL, Pattridge KA, Weber CH, Metzger AL, Hoover DM, Ludwig ML: Refined structures of oxidized flavodoxin from Anacystis nidulans. J Mol Biol. 1999 Dec 3;294(3):711-24.
10610792	Hoover DM, Drennan CL, Metzger AL, Osborne C, Weber CH, Pattridge KA, Ludwig ML: Comparisons of wild-type and mutant flavodoxins from Anacystis nidulans. Structural determinants of the redox potentials. J Mol Biol. 1999 Dec 3;294(3):725-43.
1907844	Clubb RT, Thanabal V, Osborne C, Wagner G: 1H and 15N resonance assignments of oxidized flavodoxin from Anacystis nidulans with 3D NMR. Biochemistry. 1991 Aug 6;30(31):7718-30.
3121586	Laudenbach DE, Reith ME, Straus NA: Isolation, sequence analysis, and transcriptional studies of the flavodoxin gene from Anacystis nidulans R2. J Bacteriol. 1988 Jan;170(1):258-65.
6406674	Smith WW, Pattridge KA, Ludwig ML, Petsko GA, Tsernoglou D, Tanaka M, Yasunobu KT: Structure of oxidized flavodoxin from Anacystis nidulans. J Mol Biol. 1983 Apr 25;165(4):737-53.

# Drug_Target_43_HGNC_ID:
Not Available

# Drug_Target_43_HPRD_ID:
Not Available

# Drug_Target_43_ID:
5173

# Drug_Target_43_Locus:
Not Available

# Drug_Target_43_Molecular_Weight:
18778

# Drug_Target_43_Name:
Flavodoxin

# Drug_Target_43_Number_of_Residues:
170

# Drug_Target_43_PDB_ID:
1OFV

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_43_Protein_Sequence:
>Flavodoxin
MAKIGLFYGTQTGVTQTIAESIQQEFGGESIVDLNDIANADASDLNAYDYLIIGCPTWNV
GELQSDWEGIYDDLDSVNFQGKKVAYFGAGDQVGYSDNFQDAMGILEEKISSLGSQTVGY
WPIEGYDFNESKAVRNNQFVGLAIDEDNQPDLTKNRIKTWVSQLKSEFGL

# Drug_Target_43_Reaction:
Not Available

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Low-potential electron donor to a number of redox enzymes

# Drug_Target_43_SwissProt_ID:
P10340

# Drug_Target_43_SwissProt_Name:
FLAV_SYNE7

# Drug_Target_43_Synonyms:
Not Available

# Drug_Target_43_Theoretical_pI:
3.78

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Not Available

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
Not Available

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
Not Available

# Drug_Target_44_GenBank_ID_Gene:
AE014875

# Drug_Target_44_GenBank_ID_Protein:
Not Available

# Drug_Target_44_GeneCard_ID:
Not Available

# Drug_Target_44_Gene_Name:
SMU_260

# Drug_Target_44_Gene_Sequence:
>603 bp
ATGTCAAATTTTTTAGATTTACAAAAACAACGTCGCAGTATCTATGCCTTAGGCAAAACT
GTTGATTTATCAAAGGCTGAATTAGTTGCATTAATTCAAAATGCCATTAAGCAGGCGCCG
TCAGCTTTTAATTCGCAAACCAGCCGTGCTCTCGTTCTTTTCGGGCAAGACTCTCAAGAT
TTTTGGAATAAAATTGCTTACAGTGAATTAGAAAAAGTCACACCAGCAGAAGCCTTTGCA
GGGACAAAAGCGAAGTTGGAAAGTTTTGCTGCTGGAGTTGGAACCATTCTGCTATTTGAA
GATCAAGCTGTTGTCAGAAATTTAGAAGAAAACTTTCCGCTTTATGCAGAGAATTTCCAG
CCTTGGTCTGAACAAGCACACGGTATTGCTCTTTATGCTATTTGGTTAGCACTAGCTGAA
CAAAATATTGGTATGAGTGTTCAGCACTACAATCCGCTTGTTGATGCTCAAGTTGCTGAA
AAATATGATTTACCAACTAACTGGAAAATGCGTGCACAAATACCTTTTGGTTCAATTGAA
GCACCTGCTGGTGAGAAAGAATTCATGGCAGACCAAGAACGTTTCAAAGTATTTGGTGAC
TAG

# Drug_Target_44_General_Function:
Involved in oxidoreductase activity

# Drug_Target_44_General_References:
12397186	Ajdic D, McShan WM, McLaughlin RE, Savic G, Chang J, Carson MB, Primeaux C, Tian R, Kenton S, Jia H, Lin S, Qian Y, Li S, Zhu H, Najar F, Lai H, White J, Roe BA, Ferretti JJ: Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14434-9. Epub 2002 Oct 23.

# Drug_Target_44_HGNC_ID:
Not Available

# Drug_Target_44_HPRD_ID:
Not Available

# Drug_Target_44_ID:
5175

# Drug_Target_44_Locus:
Not Available

# Drug_Target_44_Molecular_Weight:
22385

# Drug_Target_44_Name:
Hypothetical protein SMU.260

# Drug_Target_44_Number_of_Residues:
200

# Drug_Target_44_PDB_ID:
1YW3

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_44_Protein_Sequence:
>Hypothetical protein SMU.260
MSNFLDLQKQRRSIYALGKTVDLSKAELVALIQNAIKQAPSAFNSQTSRALVLFGQDSQD
FWNKIAYSELEKVTPAEAFAGTKAKLESFAAGVGTILLFEDQAVVRNLEENFPLYAENFQ
PWSEQAHGIALYAIWLALAEQNIGMSVQHYNPLVDAQVAEKYDLPTNWKMRAQIPFGSIE
APAGEKEFMADQERFKVFGD

# Drug_Target_44_Reaction:
Not Available

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Not Available

# Drug_Target_44_SwissProt_ID:
Q8DW21

# Drug_Target_44_SwissProt_Name:
Q8DW21_STRMU

# Drug_Target_44_Synonyms:
Not Available

# Drug_Target_44_Theoretical_pI:
4.64

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Not Available

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
Not Available

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
Not Available

# Drug_Target_45_GenBank_ID_Gene:
AF008220

# Drug_Target_45_GenBank_ID_Protein:
Not Available

# Drug_Target_45_GeneCard_ID:
Not Available

# Drug_Target_45_Gene_Name:
moxC

# Drug_Target_45_Gene_Sequence:
>1329 bp
ATGACACGTGCAGATTTTATTCAGTTTGGAGCCATGATTCACGGTGTCGGGGGAACAACT
GACGGCTGGCGTCATCCCGATGTTGATCCCTCGGCCAGCACGAATATTGAATTTTACATG
AAAAAGGCGCAAACAGCTGAAAAAGGTTTGTTTAGTTTTATTTTCATTGCAGACGGCTTA
TTTATTTCTGAAAAATCGATTCCTCATTTTTTAAACCGTTTTGAACCGATCACCATTTTA
TCTGCGCTGGCATCGGTTACCAAAAATATTGGTTTAGTAGGGACGTTCTCTACATCTTTT
ACTGAGCCATTCACTATCTCCAGACAATTGATGTCGCTGGACCATATCAGCGGGGGCAGG
GCCGGCTGGAATCTGGTTACTTCGCCGCAGGAAGGAGCGGCGCGCAACCATAGTAAGTCT
AATTTGCCAGAACACACTGAACGTTACGAGATCGCACAAGAGCATTTGGATGTTGTGCGC
GGGCTGTGGAATTCCTGGGAGCATGACGCATTTATACACAATAAGAAAACAGGGCAGTTT
TTCGATCAGGCGAAGCTTCATCGCCTGAATCATAAAGGGAAGTATTTTCAAGTAGAGGGG
CCCTTGAATATCGGGCGCTCTAAGCAGGGAGAGCCTGTAGTGTTTCAAGCGGGTTCATCA
GAAACAGGCCGGCAGTTTGCTGCTAAAAATGCGGATGCGATTTTTACCCATTCCAATTCA
TTAGAAGAGACAAAAGCGTTTTATGCGGATGTGAAAAGCCGAGCTGCTGATGAAGGGCGT
GATCCTTCAAGTGTGCGGATTTTTCCAGGGATCAGCCCGATTGTGGCAGATACGGAAGAA
GAGGCGGAAAAGAAGTATCGTGAATTTGCAGAATTGATACCGATTGAAAATGCTGTTACT
TATTTGGCCCGTTTTTTTGATGATTATGATCTGAGTGTTTACCCGTTGGATGAGCCATTT
CCCGATATTGGCGATGTGGGAAAGAATGCGTTTCAAAGCACAACAGACCGGATTAAGAGA
GAAGCAAAAGCCAGAAATCTGACATTGCGGGAGGTAGCACAGGAAATGGCTTTTCCACGG
ACTCTATTCATCGGAACACCAGAGCGTGTCGCATCCTTAATTGAAACTTGGTTCAACGCT
GAGGCGGCGGATGGGTTTATCGTTGGGTCGGATATACCGGGAACACTTGATGCTTTTGTA
GAAAAGGTGATTCCGATTCTTCAAGAAAGAGGGCTTTATCGTCAAGATTATCGCGGCGGG
ACATTGCGGGAAAATCTCGGTCTTGGCATTCCGCAGCATCAATCCGTTTTACATTCATCA
CATCATTAG

# Drug_Target_45_General_Function:
Energy production and conversion

# Drug_Target_45_General_References:
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9387221	Lapidus A, Galleron N, Sorokin A, Ehrlich SD: Sequencing and functional annotation of the Bacillus subtilis genes in the 200 kb rrnB-dnaB region. Microbiology. 1997 Nov;143 ( Pt 11):3431-41.

# Drug_Target_45_HGNC_ID:
Not Available

# Drug_Target_45_HPRD_ID:
Not Available

# Drug_Target_45_ID:
5176

# Drug_Target_45_Locus:
Not Available

# Drug_Target_45_Molecular_Weight:
49412

# Drug_Target_45_Name:
YtnJ

# Drug_Target_45_Number_of_Residues:
442

# Drug_Target_45_PDB_ID:
1TVL

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
Not Available

# Drug_Target_45_Protein_Sequence:
>YtnJ
MTRADFIQFGAMIHGVGGTTDGWRHPDVDPSASTNIEFYMKKAQTAEKGLFSFIFIADGL
FISEKSIPHFLNRFEPITILSALASVTKNIGLVGTFSTSFTEPFTISRQLMSLDHISGGR
AGWNLVTSPQEGAARNHSKSNLPEHTERYEIAQEHLDVVRGLWNSWEHDAFIHNKKTGQF
FDQAKLHRLNHKGKYFQVEGPLNIGRSKQGEPVVFQAGSSETGRQFAAKNADAIFTHSNS
LEETKAFYADVKSRAADEGRDPSSVRIFPGISPIVADTEEEAEKKYREFAELIPIENAVT
YLARFFDDYDLSVYPLDEPFPDIGDVGKNAFQSTTDRIKREAKARNLTLREVAQEMAFPR
TLFIGTPERVASLIETWFNAEAADGFIVGSDIPGTLDAFVEKVIPILQERGLYRQDYRGG
TLRENLGLGIPQHQSVLHSSHH

# Drug_Target_45_Reaction:
Not Available

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Not Available

# Drug_Target_45_SwissProt_ID:
O34974

# Drug_Target_45_SwissProt_Name:
MOXC_BACSU

# Drug_Target_45_Synonyms:
Not Available

# Drug_Target_45_Theoretical_pI:
6.09

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Not Available

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
Not Available

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
Not Available

# Drug_Target_46_GenBank_ID_Gene:
AE000512

# Drug_Target_46_GenBank_ID_Protein:
Not Available

# Drug_Target_46_GeneCard_ID:
Not Available

# Drug_Target_46_Gene_Name:
TM_0096

# Drug_Target_46_Gene_Sequence:
>921 bp
TCACACCTCCTTGATGAAATTATAAAACATCTCTTTTAAAATTTGAACTTCTTCTATTTT
CATAACTTTCTCTCTGAATCTCCTTGCGCCTTTCAGATCCTTTGTATAACCTGCCAGAAA
CTTTCTCATTTCCACAACCGCTTTTCTTTCACCCTTCGTCTTTATCAACAGCTCGAGATG
TCTTTCGAACGTTCTAAGAATCTCTTCCCGGGACGGTTCAGAGTACTTTCCGCTTCGGAG
GAAATCCTTTATCTGTTTGAAAATCCAAGGTCTTCCTATAGCACCTCTCGCTACCAGAAG
ACCATCACATCCGCTTTCTTCCAGAGCCCTCTTGGCGTCTTCTGGAGTGAAGATATCACC
ACTCACAAAGGTAGGAATTCTCTTTTCCAGAACACTCAACGCCTTCCATTCAGCCCTCCC
AGTGAAACTCTGAACCACCGTTCTCGTGTGAATGAATACCTCATCCACCCCTTCCTCAAC
GAGTATTCGATATATCTCCTCGACTTCATTTTTCTCCCATCCAAGGCGAGTTTTCACAGA
AAATTTGCCAGAAACACTCTTTCTGAGCTCCCTCACAATGTATCGAAAATGTCTCAAATC
TTTCAACAAAGCTCCGCCTGCTCCTTTTTTTACAACTTTTCTCACAGGGCAACCAGCGTT
CAAATCTATCCACTTGTACTTTTCAGAGAGAATCCTCGCTGCCTCAGAAAGTTCGTTCGG
TTCGCTTCCAAAGATCTGGACCGCCACGTTTCTTTCATGTGGTTGTGGTAAGAGTTCTTC
TGTTTTTTGAGAGTTCATGAGAAAACCCTTTGCACTCACCATTTCAGAGAAAGCAAAATC
CGCACCCCATTCGAAAGCCAGAGTGCGGAATGCTGAATCAGTGTATCCAGCCATCGGCGC
AAGACCGACTTTAACCTCCAT

# Drug_Target_46_General_Function:
Involved in tRNA dihydrouridine synthase activity

# Drug_Target_46_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_46_HGNC_ID:
Not Available

# Drug_Target_46_HPRD_ID:
Not Available

# Drug_Target_46_ID:
5177

# Drug_Target_46_Locus:
Not Available

# Drug_Target_46_Molecular_Weight:
35150

# Drug_Target_46_Name:
Hypothetical protein

# Drug_Target_46_Number_of_Residues:
306

# Drug_Target_46_PDB_ID:
1VHN

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF01207	Dus

# Drug_Target_46_Protein_Sequence:
>Hypothetical protein
MEVKVGLAPMAGYTDSAFRTLAFEWGADFAFSEMVSAKGFLMNSQKTEELLPQPHERNVA
VQIFGSEPNELSEAARILSEKYKWIDLNAGCPVRKVVKKGAGGALLKDLRHFRYIVRELR
KSVSGKFSVKTRLGWEKNEVEEIYRILVEEGVDEVFIHTRTVVQSFTGRAEWKALSVLEK
RIPTFVSGDIFTPEDAKRALEESGCDGLLVARGAIGRPWIFKQIKDFLRSGKYSEPSREE
ILRTFERHLELLIKTKGERKAVVEMRKFLAGYTKDLKGARRFREKVMKIEEVQILKEMFY
NFIKEV

# Drug_Target_46_Reaction:
Not Available

# Drug_Target_46_Signals:
None

# Drug_Target_46_Specific_Function:
Not Available

# Drug_Target_46_SwissProt_ID:
Q9WXV1

# Drug_Target_46_SwissProt_Name:
Q9WXV1_THEMA

# Drug_Target_46_Synonyms:
Not Available

# Drug_Target_46_Theoretical_pI:
9.91

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Not Available

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
Not Available

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
Not Available

# Drug_Target_47_GenBank_ID_Gene:
Z68500

# Drug_Target_47_GenBank_ID_Protein:
Not Available

# Drug_Target_47_GeneCard_ID:
Not Available

# Drug_Target_47_Gene_Name:
nrdI

# Drug_Target_47_Gene_Sequence:
>393 bp
GTGGTACAAATCATATTTGATTCGAAAACAGGGAATGTTCAGCGGTTTGTGAATAAAACA
GGCTTTCAGCAGATACGCAAGGTGGACGAAATGGACCACGTGGACACTCCGTTTGTTTTG
GTCACCTACACGACAAACTTCGGCCAGGTACCGGCATCAACACAATCATTTCTCGAAAAA
TACGCCCATCTCTTATTGGGAGTCGCTGCGAGCGGCAACAAAGTATGGGGCGATAACTTT
GCAAAAAGCGCCGATACCATTTCAAGACAATATCAGGTGCCGATCTTGCACAAATTTGAA
CTCAGCGGCACATCTAAAGACGTTGAATTGTTTACTCAGGAGGTAGAAAGAGTTGTCACA
AAATCAAGTGCCAAAATGGATCCAGTTAAATAA

# Drug_Target_47_General_Function:
Nucleotide transport and metabolism

# Drug_Target_47_General_References:
8969495	Scotti C, Valbuzzi A, Perego M, Galizzi A, Albertini AM: The Bacillus subtilis genes for ribonucleotide reductase are similar to the genes for the second class I NrdE/NrdF enzymes of Enterobacteriaceae. Microbiology. 1996 Nov;142 ( Pt 11):2995-3004.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_47_HGNC_ID:
Not Available

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
5178

# Drug_Target_47_Locus:
Not Available

# Drug_Target_47_Molecular_Weight:
14603

# Drug_Target_47_Name:
Protein nrdI

# Drug_Target_47_Number_of_Residues:
130

# Drug_Target_47_PDB_ID:
1RLJ

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF07972	Flavodoxin_NdrI

# Drug_Target_47_Protein_Sequence:
>Protein nrdI
MVQIIFDSKTGNVQRFVNKTGFQQIRKVDEMDHVDTPFVLVTYTTNFGQVPASTQSFLEK
YAHLLLGVAASGNKVWGDNFAKSADTISRQYQVPILHKFELSGTSKDVELFTQEVERVVT
KSSAKMDPVK

# Drug_Target_47_Reaction:
Not Available

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
Not known; probably involved in ribonucleotide reductase function

# Drug_Target_47_SwissProt_ID:
P50618

# Drug_Target_47_SwissProt_Name:
NRDI_BACSU

# Drug_Target_47_Synonyms:
Not Available

# Drug_Target_47_Theoretical_pI:
8.92

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Not Available

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
Not Available

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
Not Available

# Drug_Target_48_GenBank_ID_Gene:
AJ006210

# Drug_Target_48_GenBank_ID_Protein:
Not Available

# Drug_Target_48_GeneCard_ID:
Not Available

# Drug_Target_48_Gene_Name:
pad1

# Drug_Target_48_Gene_Sequence:
>594 bp
TTATTCATTCTCCTGAGAAAAATTCCGGGCCTGCGGCAATCCTTGCCAGCGCCTGGCGTA
GGGATGTTCAAGGCCAAATTGATCCAGCACGCGGGCTACCACGTGGTGGACAATGTCATC
TACCGTTTCGGGATGGTTATAAAAGGCAGGCATCGGCGGCACCATCGCCACGCCCATGCG
TGAAAGTGCGAGCATATTTTCGAGATGGATGGTGCTAAGCGGCATTTCACGCGGCACCAG
CACCAGTTTGCGGCCTTCTTTAAGCACGACGTCCGCCGCGCGCCCTACCAGGCCATCAGC
GTAACCAGCGCGGATACCGGCGAGCGTTTTCATACTGCACGGAATAACGATCATGCCGTC
TGTACGAAAGGAACCTGAGGAGATGGTCGCCGCCTGATCCGCCGGGTTATGGCTGAAGTC
AGCGAGGGCAGCAACATCGCGGGCGCTGTAAGGCGTTTCCAGTTCAATGGTGGTTTTCGC
CCACTTCGACATCACCAGATGAGTCTCGACATTCGGCATCTCCCGCAGCGCTTGCAGTAA
TGCCACACCAAGAGGCGCACCGGTAGCCCCTGTCATCCCGACGATCAGTTTCAT

# Drug_Target_48_General_Function:
Involved in catalytic activity

# Drug_Target_48_General_References:
11206551	Perna NT, Plunkett G 3rd, Burland V, Mau B, Glasner JD, Rose DJ, Mayhew GF, Evans PS, Gregor J, Kirkpatrick HA, Posfai G, Hackett J, Klink S, Boutin A, Shao Y, Miller L, Grotbeck EJ, Davis NW, Lim A, Dimalanta ET, Potamousis KD, Apodaca J, Anantharaman TS, Lin J, Yen G, Schwartz DC, Welch RA, Blattner FR: Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature. 2001 Jan 25;409(6819):529-33.
11258796	Hayashi T, Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, Han CG, Ohtsubo E, Nakayama K, Murata T, Tanaka M, Tobe T, Iida T, Takami H, Honda T, Sasakawa C, Ogasawara N, Yasunaga T, Kuhara S, Shiba T, Hattori M, Shinagawa H: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res. 2001 Feb 28;8(1):11-22.

# Drug_Target_48_HGNC_ID:
Not Available

# Drug_Target_48_HPRD_ID:
Not Available

# Drug_Target_48_ID:
5179

# Drug_Target_48_Locus:
Not Available

# Drug_Target_48_Molecular_Weight:
21470

# Drug_Target_48_Name:
Probable aromatic acid decarboxylase

# Drug_Target_48_Number_of_Residues:
197

# Drug_Target_48_PDB_ID:
Not Available

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF02441	Flavoprotein

# Drug_Target_48_Protein_Sequence:
>Probable aromatic acid decarboxylase
MKLIVGMTGATGAPLGVALLQALREMPNVETHLVMSKWAKTTIELETPYSARDVAALADF
SHNPADQAATISSGSFRTDGMIVIPCSMKTLAGIRAGYADGLVGRAADVVLKEGRKLVLV
PREMPLSTIHLENMLALSRMGVAMVPPMPAFYNHPETVDDIVHHVVARVLDQFGLEHPYA
RRWQGLPQARNFSQENE

# Drug_Target_48_Reaction:
Not Available

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
Not Available

# Drug_Target_48_SwissProt_ID:
P69772

# Drug_Target_48_SwissProt_Name:
PAD1_ECO57

# Drug_Target_48_Synonyms:
EC 4.1.1.-

# Drug_Target_48_Theoretical_pI:
6.89

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Not Available

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
Not Available

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
Not Available

# Drug_Target_49_GenBank_ID_Gene:
AY143338

# Drug_Target_49_GenBank_ID_Protein:
Not Available

# Drug_Target_49_GeneCard_ID:
Not Available

# Drug_Target_49_Gene_Name:
mdlB

# Drug_Target_49_Gene_Sequence:
>1182 bp
TCATGCGTGTGTTCCTTTACCAATGAGGTGATCGACTGGAGCGGTGTTAGTCACTCCCTC
GTTTTGGAGGTAATCAGGAGAAAGGGAGGTGATGTCAGGGCATCCAATCTGGGCAAGGGT
GCGGTCGATATCCGCTTTTAGGAGGGTTAGCACCTCGTCAACACCCGTTTCACCTCGTGC
TGCAAGGCCATACAAAGTTGCACGACCCAGGAGTACAGCCTCAGCACCTAGCGCAAGTGC
TTTAACGATGTCCGAACCCCGTCGGAAGCCGCTATCGATAAGCACTGGTTTTCCAGTTTT
CGCTACCGATTGAGCCAAAACTTCCATTGGCGATATCGCGCAATCGAGTTGGCGACCGCC
GTGGTTTGATAGGATTACGCCGTCTGCACCTTCAGCGATGCACCGATCGGCGTCCTCAGC
ACTGAGCAACCCCTTTACGAGGAGTTTGTGCGGCCAGAGGTCACGCAGCCATCTCAATGC
CTCCCAGTTGAAACTGGCATCCATTTGGCGGCTCATCAATGCTGCCTGCATTTCTAAGCT
AGACGTTTGACTGCTGACGAAATTGGCCAGTTGCGGCATGCCGTGTCGCACGAAGTCGAG
CGACCAGCGCGGATGCAGGCATCCGTCCAGCACCACCTTTGCGGAGTAGCTCATTGGTAT
CTTGAATCGGTTATGCAGGTCGCGCTCGCGATAGCCGTTAACCGCCACATCCGTAGTAAG
CACCAGTGTCGTGTAACCAGTGTGCAGGGCTTTGAGCACCATCCCCTGCGCAATCTCTCG
GTGGATCACATAGAGCTGGAACCACAGATCGCCATCACACTGACGTGCGAGGTCTTCAAT
GGACATGTTGGAGGCGGTCGACAGCACGAACGGGATTCCGGCCTTGGTTGCTGCTCGAGC
TAAAGCGAGATCCCCCTTAGGCCACAGCGCACCGTTCAGCCCAGTAGGCCCAATCAAGAG
AGGCATCGACTGCCTCTTTCCAAGTACTTCCGCTTGGAGGCTGCGGCGGCTGACGTCTAC
TAGCCGCTTCGGTTTGAATCGCCATTGCTGGAAGACGTCGCGGTTGTGTTTCACCCCGTA
TTCGTCTTCAGCCCCACCTTCCAGATAGTCGTAGACCATCTTCGGCAAGCGCTTTTGCCG
AAGCTTGCGATAGTCCTCAACGTTAAAGAGATTCTGGCTCAT

# Drug_Target_49_General_Function:
Involved in catalytic activity

# Drug_Target_49_General_References:
2271624	Tsou AY, Ransom SC, Gerlt JA, Buechter DD, Babbitt PC, Kenyon GL: Mandelate pathway of Pseudomonas putida: sequence relationships involving mandelate racemase, (S)-mandelate dehydrogenase, and benzoylformate decarboxylase and expression of benzoylformate decarboxylase in Escherichia coli. Biochemistry. 1990 Oct 23;29(42):9856-62.

# Drug_Target_49_HGNC_ID:
Not Available

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
5180

# Drug_Target_49_Locus:
Not Available

# Drug_Target_49_Molecular_Weight:
43438

# Drug_Target_49_Name:
L(+)-mandelate dehydrogenase

# Drug_Target_49_Number_of_Residues:
393

# Drug_Target_49_PDB_ID:
Not Available

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF01070	FMN_dh

# Drug_Target_49_Protein_Sequence:
>L(+)-mandelate dehydrogenase
MSQNLFNVEDYRKLRQKRLPKMVYDYLEGGAEDEYGVKHNRDVFQQWRFKPKRLVDVSRR
SLQAEVLGKRQSMPLLIGPTGLNGALWPKGDLALARAATKAGIPFVLSTASNMSIEDLAR
QCDGDLWFQLYVIHREIAQGMVLKALHTGYTTLVLTTDVAVNGYRERDLHNRFKIPMSYS
AKVVLDGCLHPRWSLDFVRHGMPQLANFVSSQTSSLEMQAALMSRQMDASFNWEALRWLR
DLWPHKLLVKGLLSAEDADRCIAEGADGVILSNHGGRQLDCAISPMEVLAQSVAKTGKPV
LIDSGFRRGSDIVKALALGAEAVLLGRATLYGLAARGETGVDEVLTLLKADIDRTLAQIG
CPDITSLSPDYLQNEGVTNTAPVDHLIGKGTHA

# Drug_Target_49_Reaction:
Not Available

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Reduction of L(+)-mandelate to benzoylformate

# Drug_Target_49_SwissProt_ID:
P20932

# Drug_Target_49_SwissProt_Name:
MDLB_PSEPU

# Drug_Target_49_Synonyms:
EC 1.-.-.-
MDH
S-mandelate dehydrogenase

# Drug_Target_49_Theoretical_pI:
8.22

# Drug_Target_49_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
U37350

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
morB

# Drug_Target_4_Gene_Sequence:
>1134 bp
ATGCCGGATACATCCTTCTCCAACCCCGGGCTCTTCACCCCGCTGCAGCTGGGCAGCCTC
AGCCTGCCCAACCGCGTGATCATGGCGCCGCTGACCCGCTCGCGCACGCCGGACAGCGTT
CCCGGCAGGTTGCAGCAGATCTACTATGGCCAGCGCGCCAGCGCCGGGCTGATCATCAGC
GAGGCCACCAATATCTCGCCCACCGCCCGCGGCTACGTCTACACGCCGGGGATCTGGACC
GACGCGCAGGAAGCCGGCTGGAAGGGCGTCGTCGAGGCGGTGCATGCCAAGGGCGGGCGC
ATCGCCCTGCAGCTGTGGCACGTCGGCCGTGTCTCCCACGAGCTGGTGCAGCCCGACGGC
CAGCAGCCCGTGGCACCGAGCGCCCTCAAGGCCGAGGGGGCGGAATGCTTCGTCGAGTTC
GAGGACGGCACGGCGGGGCTGCACCCCACCAGCACGCCGCGGGCGCTTGAGACCGACGAG
ATCCCCGGCATCGTCGAGGACTACCGCCAGGCTGCGCAGCGCGCCAAGCGTGCCGGCTTC
GACATGGTCGAGGTCCACGCCGCCAACGCCTGCCTGCCCAACCAGTTCCTCGCCACCGGC
ACCAACCGGCGCACCGACCAGTACGGCGGCTCCATCGAGAACCGGGCGCGCTTCCCGCTG
GAGGTGGTCGACGCCGTGGCCGAGGTGTTCGGGCCCGAGCGGGTCGGCATCCGCCTGACC
CCCTTCCTCGAGCTCTTCGGCCTCACCGACGACGAGCCCGAGGCGATGGCCTTCTACCTG
GCCGGCGAGCTCGACCGCCGCGGCCTGGCCTACCTCCACTTCAACGAGCCCGACTGGATC
GGTGGCGATATCACCTACCCCGAAGGCTTCCGGGAGCAGATGCGCCAGCGCTTCAAGGGT
GGGCTGATCTACTGCGGCAACTACGATGCCGGGCGCGCCCAGGCCCGCCTGGATGACAAC
ACCGCCGACGCCGTGGCCTTCGGCCGCCCCTTCATCGCCAACCCCGATCTGCCCGAGCGC
TTCCGCCTGGGGGCCGCCCTCAACGAGCCCGACCCCAGCACCTTCTACGGCGGCGCCGAG
GTCGGCTACACCGACTACCCCTTCCTCGACAACGGCCACGACCGGCTCGGCTGA

# Drug_Target_4_General_Function:
Involved in FMN binding

# Drug_Target_4_General_References:
8037698	French CE, Bruce NC: Purification and characterization of morphinone reductase from Pseudomonas putida M10. Biochem J. 1994 Jul 1;301 ( Pt 1):97-103.
8554504	French CE, Bruce NC: Bacterial morphinone reductase is related to Old Yellow Enzyme. Biochem J. 1995 Dec 15;312 ( Pt 3):671-8.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
5191

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
41250

# Drug_Target_4_Name:
Morphinone reductase

# Drug_Target_4_Number_of_Residues:
377

# Drug_Target_4_PDB_ID:
1GWJ

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00724	Oxidored_FMN

# Drug_Target_4_Protein_Sequence:
>Morphinone reductase
MPDTSFSNPGLFTPLQLGSLSLPNRVIMAPLTRSRTPDSVPGRLQQIYYGQRASAGLIIS
EATNISPTARGYVYTPGIWTDAQEAGWKGVVEAVHAKGGRIALQLWHVGRVSHELVQPDG
QQPVAPSALKAEGAECFVEFEDGTAGLHPTSTPRALETDEIPGIVEDYRQAAQRAKRAGF
DMVEVHAANACLPNQFLATGTNRRTDQYGGSIENRARFPLEVVDAVAEVFGPERVGIRLT
PFLELFGLTDDEPEAMAFYLAGELDRRGLAYLHFNEPDWIGGDITYPEGFREQMRQRFKG
GLIYCGNYDAGRAQARLDDNTADAVAFGRPFIANPDLPERFRLGAALNEPDPSTFYGGAE
VGYTDYPFLDNGHDRLG

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Q51990

# Drug_Target_4_SwissProt_Name:
Q51990_PSEPU

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
4.67

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Not Available

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
Not Available

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
Not Available

# Drug_Target_50_GenBank_ID_Gene:
Y14079

# Drug_Target_50_GenBank_ID_Protein:
Not Available

# Drug_Target_50_GeneCard_ID:
Not Available

# Drug_Target_50_Gene_Name:
azr

# Drug_Target_50_Gene_Sequence:
>525 bp
ATGAACATGTTAGTCATAAATGGCACGCCAAGAAAACATGGCAGAACAAGAATTGCAGCA
TCCTATATTGCAGCTCTGTATCACACGGATTTGATTGATCTAAGCGAGTTTGTATTGCCC
GTTTTTAACGGTGAAGCGGAACAATCTGAACTGTTGAAAGTACAGGAGCTTAAGCAACGC
GTTACGAAAGCGGATGCGATTGTATTATTATCGCCTGAATATCACAGCGGCATGAGCGGC
GCTTTAAAAAATGCCTTGGATTTTCTAAGCAGCGAACAATTCAAATATAAGCCCGTTGCA
TTATTGGCAGTAGCGGGCGGCGGAAAAGGCGGCATCAATGCGCTGAACAATATGAGAACT
GTGATGCGGGGTGTCTACGCCAATGTCATTCCGAAGCAGCTGGTGCTTGATCCGGTGCAT
ATTGATGTTGAAAATGCTACAGTGGCTGAAAACATTAAGGAAAGCATAAAAGAGCTTGTC
GAAGAACTCAGCATGTTCGCAAAAGCAGGAAATCCCGGCGTCTAA

# Drug_Target_50_General_Function:
Not Available

# Drug_Target_50_General_References:
2846750	Pooley HM, Paschoud D, Karamata D: The gtaB marker in Bacillus subtilis 168 is associated with a deficiency in UDPglucose pyrophosphorylase. J Gen Microbiol. 1987 Dec;133(12):3481-93.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_50_HGNC_ID:
Not Available

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
5181

# Drug_Target_50_Locus:
Not Available

# Drug_Target_50_Molecular_Weight:
18904

# Drug_Target_50_Name:
Hypothetical protein yhdA

# Drug_Target_50_Number_of_Residues:
174

# Drug_Target_50_PDB_ID:
1NNI

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF03358	FMN_red

# Drug_Target_50_Protein_Sequence:
>Hypothetical protein yhdA
MNMLVINGTPRKHGRTRIAASYIAALYHTDLIDLSEFVLPVFNGEAEQSELLKVQELKQR
VTKADAIVLLSPEYHSGMSGALKNALDFLSSEQFKYKPVALLAVAGGGKGGINALNNMRT
VMRGVYANVIPKQLVLDPVHIDVENATVAENIKESIKELVEELSMFAKAGNPGV

# Drug_Target_50_Reaction:
Not Available

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Not Available

# Drug_Target_50_SwissProt_ID:
O07529

# Drug_Target_50_SwissProt_Name:
AZR_BACSU

# Drug_Target_50_Synonyms:
Azoreductase
YhdA protein

# Drug_Target_50_Theoretical_pI:
6.97

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Not Available

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
Not Available

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
Not Available

# Drug_Target_51_GenBank_ID_Gene:
AE001439

# Drug_Target_51_GenBank_ID_Protein:
Not Available

# Drug_Target_51_GeneCard_ID:
Not Available

# Drug_Target_51_Gene_Name:
fldA

# Drug_Target_51_Gene_Sequence:
>495 bp
TTAAGCGAAAGAACCTTTAACTTGTTCTACCCATTTTGCAATTCTTTCATCTGTCAAATC
GTCTTGATTGTCTTCATCAATCACTAGACCCACGAATTTACCGCCTTCTACCGCTTTAGA
AGCTTCAAAATGATAACCATCAGTGGGAGTTTGTCCTACCACTTTGCCGGCTTTAGCTTT
TTCATAAATGTGGAAAATGCCTTCCGCGAAAGTTTCGCTGTAAGTGTCTTGATCGCCCAA
GCCTACAAGCCCAATGGTTTTATTCGCAAAGTCGCTCGCTTCTAGTGTGCCTAAAAAGTC
TTCCCAATCTGTTTGCAAATCGCCCGCACCGGCTGTTGGAGCGACTAAAATAACCTTTGT
AAAGCCATTAAATTGCTCTTTAGAAGCTTTAGCCACATCAATCACTTCAGCATTACCAAT
AGCCTTGCTGATTTTTTCAGCGATAGCTTCAGCGTTCCCGCTGTCTGTCCCAAAAAAGAT
ACCAATTTTTCCCAT

# Drug_Target_51_General_Function:
Involved in FMN binding

# Drug_Target_51_General_References:
9923682	Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999 Jan 14;397(6715):176-80.

# Drug_Target_51_HGNC_ID:
Not Available

# Drug_Target_51_HPRD_ID:
Not Available

# Drug_Target_51_ID:
5182

# Drug_Target_51_Locus:
Not Available

# Drug_Target_51_Molecular_Weight:
17474

# Drug_Target_51_Name:
Flavodoxin

# Drug_Target_51_Number_of_Residues:
164

# Drug_Target_51_PDB_ID:
1FUE

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00258	Flavodoxin_1

# Drug_Target_51_Protein_Sequence:
>Flavodoxin
MGKIGIFFGTDSGNAEAIAEKISKAIGNAEVIDVAKASKEQFNGFTKVILVAPTAGAGDL
QTDWEDFLGTLEASDFANKTIGLVGLGDQDTYSETFAEGIFHIYEKAKAGKVVGQTPTDG
YHFEASKAVEGGKFVGLVIDEDNQDDLTDERIAKWVEQVKGSFA

# Drug_Target_51_Reaction:
Not Available

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Low-potential electron donor to a number of redox enzymes (By similarity)

# Drug_Target_51_SwissProt_ID:
Q9ZK53

# Drug_Target_51_SwissProt_Name:
FLAV_HELPJ

# Drug_Target_51_Synonyms:
Not Available

# Drug_Target_51_Theoretical_pI:
4.20

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Cytoplasm. Nucleus. Endoplasmic reticulum

# Drug_Target_52_Chromosome_Location:
6

# Drug_Target_52_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
Not Available

# Drug_Target_52_GenBank_ID_Gene:
Y10032

# Drug_Target_52_GenBank_ID_Protein:
1834511

# Drug_Target_52_GeneCard_ID:
SGK1

# Drug_Target_52_Gene_Name:
SGK1

# Drug_Target_52_Gene_Sequence:
>1296 bp
ATGACGGTGAAAACTGAGGCTGCTAAGGGCACCCTCACTTACTCCAGGATGAGGGGCATG
GTGGCAATTCTCATCGCTTTCATGAAGCAGAGGAGGATGGGTCTGAACGACTTTATTCAG
AAGATTGCCAATAACTCCTATGCATGCAAACACCCTGAAGTTCAGTCCATCTTGAAGATC
TCCCAACCTCAGGAGCCTGAGCTTATGAATGCCAACCCTTCTCCTCCACCAAGTCCTTCT
CAGCAAATCAACCTTGGCCCGTCGTCCAATCCTCATGCTAAACCATCTGACTTTCACTTC
TTGAAAGTGATCGGAAAGGGCAGTTTTGGAAAGGTTCTTCTAGCAAGACACAAGGCAGAA
GAAGTGTTCTATGCAGTCAAAGTTTTACAGAAGAAAGCAATCCTGAAAAAGAAAGAGGAG
AAGCATATTATGTCGGAGCGGAATGTTCTGTTGAAGAATGTGAAGCACCCTTTCCTGGTG
GGCCTTCACTTCTCTTTCCAGACTGCTGACAAATTGTACTTTGTCCTAGACTACATTAAT
GGTGGAGAGTTGTTCTACCATCTCCAGAGGGAACGCTGCTTCCTGGAACCACGGGCTCGT
TTCTATGCTGCTGAAATAGCCAGTGCCTTGGGCTACCTGCATTCACTGAACATCGTTTAT
AGAGACTTAAAACCAGAGAATATTTTGCTAGATTCACAGGGACACATTGTCCTTACTGAT
TTCGGACTCTGCAAGGAGAACATTGAACACAACAGCACAACATCCACCTTCTGTGGCACG
CCGGAGTATCTCGCACCTGAGGTGCTTCATAAGCAGCCTTATGACAGGACTGTGGACTGG
TGGTGCCTGGGAGCTGTCTTGTATGAGATGCTGTATGGCCTGCCGCCTTTTTATAGCCGA
AACACAGCTGAAATGTACGACAACATTCTGAACAAGCCTCTCCAGCTGAAACCAAATATT
ACAAATTCCGCAAGACACCTCCTGGAGGGCCTCCTGCAGAAGGACAGGACAAAGCGGCTC
GGGGCCAAGGATGACTTCATGGAGATTAAGAGTCATGTCTTCTTCTCCTTAATTAACTGG
GATGATCTCATTAATAAGAAGATTACTCCCCCTTTTAACCCAAATGTGAGTGGGCCCAAC
GAGCTACGGCACTTTGACCCCGAGTTTACCGAAGAGCCTGTCCCCAACTCCATTGGCAAG
TCCCCTGACAGCGTCCTCGTCACAGCCAGCGTCAAGGAAGCTGCCGAGGCTTTCCTAGGC
TTTTCCTATGCGCCTCCCACGGACTCTTTCCTCTGA

# Drug_Target_52_General_Function:
Involved in ATP binding

# Drug_Target_52_General_References:
10548550	Kobayashi T, Deak M, Morrice N, Cohen P: Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem J. 1999 Nov 15;344 Pt 1:189-97.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
18753299	Raikwar NS, Snyder PM, Thomas CP: An evolutionarily conserved N-terminal Sgk1 variant with enhanced stability and improved function. Am J Physiol Renal Physiol. 2008 Nov;295(5):F1440-8. Epub 2008 Aug 27.
9114008	Waldegger S, Barth P, Raber G, Lang F: Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4440-5.
9722955	Waldegger S, Erdel M, Nagl UO, Barth P, Raber G, Steuer S, Utermann G, Paulmichl M, Lang F: Genomic organization and chromosomal localization of the human SGK protein kinase gene. Genomics. 1998 Jul 15;51(2):299-302.

# Drug_Target_52_HGNC_ID:
GNC:10810

# Drug_Target_52_HPRD_ID:
Not Available

# Drug_Target_52_ID:
6608

# Drug_Target_52_Locus:
6q23

# Drug_Target_52_Molecular_Weight:
48942.0

# Drug_Target_52_Name:
Serine/threonine-protein kinase Sgk1

# Drug_Target_52_Number_of_Residues:
431

# Drug_Target_52_PDB_ID:
Not Available

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
PF00069	Pkinase
PF00433	Pkinase_C

# Drug_Target_52_Protein_Sequence:
>Serine/threonine-protein kinase Sgk1
MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKI
SQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAE
EVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYIN
GGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTD
FGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSR
NTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINW
DDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLG
FSYAPPTDSFL

# Drug_Target_52_Reaction:
Not Available

# Drug_Target_52_Signals:
None

# Drug_Target_52_Specific_Function:
Protein kinase that plays an important role in cellular stress response. Activates certain potassium, sodium, and chloride channels, suggesting an involvement in the regulation of processes such as cell survival, neuronal excitability and renal sodium excretion. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Mediates cell survival signals, phosphorylates and negatively regulates pro-apoptotic FOXO3A. Phosphorylates NEDD4L, which leads to its inactivation and to the subsequent activation of various channels and transporters such as ENaC, KCNA3/Kv1.3 or EAAT1. Isoform 2 exhibited a greater effect on cell plasma membrane expression of ENaC and Na(+) transport than isoform 1

# Drug_Target_52_SwissProt_ID:
O00141

# Drug_Target_52_SwissProt_Name:
SGK1_HUMAN

# Drug_Target_52_Synonyms:
Serum/glucocorticoid-regulated kinase 1

# Drug_Target_52_Theoretical_pI:
8.81

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Not Available

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
Not Available

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
Not Available

# Drug_Target_53_GenBank_ID_Gene:
M63808

# Drug_Target_53_GenBank_ID_Protein:
Not Available

# Drug_Target_53_GeneCard_ID:
Not Available

# Drug_Target_53_Gene_Name:
nfnB

# Drug_Target_53_Gene_Sequence:
>654 bp
ATGGATATCATTTCTGTCGCCCTGAAACGCCACTCTACCAAGGCGTTCGACGCAAGCAAA
AAACTGACCGCGGAAGAAGCGGAAAAAATCAAAACCCTGCTGCAGTACAGCCCGTCCAGC
ACCAACTCCCAGCCGTGGCACTTCATTGTAGCCAGCACCGAGGAAGGAAAAGCGCGCGTG
GCGAAGTCCGCTGCGGGCACCTATGTGTTCAACGAACGCAAAATGCTGGATGCTTCCCAC
GTGGTGGTGTTCTGCGCGAAAACCGCGATGGATGACGCCTGGCTGGAGCGCGTCGTGGAT
CAGGAAGAGGCCGATGGCCGTTTCAACACGCCGGAAGCCAAAGCCGCAAACCATAAGGGC
CGCACCTACTTCGCCGACATGCACCGCGTGGATCTGAAAGATGACGACCAGTGGATGGCG
AAGCAGGTTTACCTGAACGTCGGCAACTTCCTGCTGGGCGTGGGCGCGATGGGTCTGGAC
GCGGTACCAATTGAAGGTTTCGACGCCGCTATTCTCGACGAAGAGTTTGGCCTGAAAGAG
AAAGGCTTCACCAGCCTGGTGGTGGTACCGGTTGGGCACCACAGCGTGGAAGATTTCAAC
GCCACGCTGCCGAAATCTCGCCTGCCGCTGAGCACGATTGTGACCGAGTGCTGA

# Drug_Target_53_General_Function:
Involved in oxidoreductase activity

# Drug_Target_53_General_References:
1999405	Bryant C, DeLuca M: Purification and characterization of an oxygen-insensitive NAD(P)H nitroreductase from Enterobacter cloacae. J Biol Chem. 1991 Mar 5;266(7):4119-25.
1999406	Bryant C, Hubbard L, McElroy WD: Cloning, nucleotide sequence, and expression of the nitroreductase gene from Enterobacter cloacae. J Biol Chem. 1991 Mar 5;266(7):4126-30.

# Drug_Target_53_HGNC_ID:
Not Available

# Drug_Target_53_HPRD_ID:
Not Available

# Drug_Target_53_ID:
5184

# Drug_Target_53_Locus:
Not Available

# Drug_Target_53_Molecular_Weight:
23950

# Drug_Target_53_Name:
Oxygen-insensitive NAD(P)H nitroreductase

# Drug_Target_53_Number_of_Residues:
217

# Drug_Target_53_PDB_ID:
1KQD

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_53_Protein_Sequence:
>Oxygen-insensitive NAD(P)H nitroreductase
MDIISVALKRHSTKAFDASKKLTAEEAEKIKTLLQYSPSSTNSQPWHFIVASTEEGKARV
AKSAAGTYVFNERKMLDASHVVVFCAKTAMDDAWLERVVDQEEADGRFNTPEAKAANHKG
RTYFADMHRVDLKDDDQWMAKQVYLNVGNFLLGVGAMGLDAVPIEGFDAAILDEEFGLKE
KGFTSLVVVPVGHHSVEDFNATLPKSRLPLSTIVTEC

# Drug_Target_53_Reaction:
Not Available

# Drug_Target_53_Signals:
None

# Drug_Target_53_Specific_Function:
Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred

# Drug_Target_53_SwissProt_ID:
Q01234

# Drug_Target_53_SwissProt_Name:
NFNB_ENTCL

# Drug_Target_53_Synonyms:
EC 1.-.-.-
NR

# Drug_Target_53_Theoretical_pI:
5.61

# Drug_Target_53_Transmembrane_Regions:
None

# Drug_Target_54_Cellular_Location:
Not Available

# Drug_Target_54_Chromosome_Location:
Not Available

# Drug_Target_54_Drug_References:
Not Available

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
Not Available

# Drug_Target_54_GenBank_ID_Gene:
AF202316

# Drug_Target_54_GenBank_ID_Protein:
Not Available

# Drug_Target_54_GeneCard_ID:
Not Available

# Drug_Target_54_Gene_Name:
fprA

# Drug_Target_54_Gene_Sequence:
>1200 bp
ATGAGCCAGCCTGTCGCCATTACCGACGGCATCTACTGGGTAGGGGCCGTTGACTGGAAC
ATCCGCTACTTCCACGGTCCCGCTTTTTCCACCCACCGCGGTACAACTTATAATGCCTAT
CTGATTGTCGACGATAAAACCGCCCTGGTGGATACTGTCTATGAACCCTTTAAAGAAGAA
CTCATTGCCAAACTAAAGCAAATAAAAGATCCGGTTAAACTCGACTACCTGGTGGTCAAC
CATACCGAAAGCGATCATGCCGGCGCCTTCCCGGCCATCATGGAACTCTGTCCAGACGCC
CACGTCCTCTGCACCCAGCGGGCCTTTGACAGCCTGAAAGCCCATTATAGCCACATCGAT
TTCAACTATACCATTGTCAAAACTGGGACCAGCGTCAGCCTGGGTAAACGCTCCCTGACC
TTCATCGAGGCGCCCATGCTCCACTGGCCCGACAGCATGTTTACCTATGTACCGGAAGAA
GCCCTGCTCCTTCCCAATGATGCCTTCGGCCAGCATATCGCCACCAGCGTCCGCTTCGAC
GACCAGGTGGATGCCGGCCTGATTATGGACGAGGCGGCCAAGTACTATGCCAATATTCTC
ATGCCCTTCAGCAACCTGATTACCAAAAAGCTGGATGAAATCCAGAAGATAAACCTGGCC
ATCAAAACCATAGCCCCCAGCCACGGCATTATCTGGCGTAAAGATCCCGGCCGAATCATC
GAAGCTTACGCCCGCTGGGCCGAGGGTCAGGGTAAGGCCAAAGCCGTCATCGCCTACGAC
ACCATGTGGCTGAGCACAGAAAAGATGGCCCACGCCCTGATGGACGGCCTGGTGGCCGGC
GGCTGCGAGGTCAAGCTCTTCAAGCTGTCCGTATCCGACCGCAACGATGTGATCAAAGAA
ATTCTGGACGCCCGAGCCGTCCTGGTCGGCTCGCCGACGATCAATAACGATATCCTGCCG
GTGGTCTCGCCGCTCCTGGACGACCTGGTAGGATTAAGGCCCAAGAATAAAGTTGGCCTG
GCCTTCGGCGCCTATGGCTGGGGCGGCGGCGCCCAAAAGATCCTGGAAGAACGCTTGAAG
GCAGCTAAAATCGAACTGATAGCCGAGCCCGGCCCCACCGTCCAATGGGTTCCCCGTGGC
GAGGACCTGCAGCGCTGCTACGAGCTGGGCCGGAAAATCGCAGCGCGCATAGCCGATTAA

# Drug_Target_54_General_Function:
Involved in hydrolase activity

# Drug_Target_54_General_References:
11160086	Das A, Coulter ED, Kurtz DM Jr, Ljungdahl LG: Five-gene cluster in Clostridium thermoaceticum consisting of two divergent operons encoding rubredoxin oxidoreductase- rubredoxin and rubrerythrin-type A flavoprotein- high-molecular-weight rubredoxin. J Bacteriol. 2001 Mar;183(5):1560-7.
12627946	Silaghi-Dumitrescu R, Coulter ED, Das A, Ljungdahl LG, Jameson GN, Huynh BH, Kurtz DM Jr: A flavodiiron protein and high molecular weight rubredoxin from Moorella thermoacetica with nitric oxide reductase activity. Biochemistry. 2003 Mar 18;42(10):2806-15.

# Drug_Target_54_HGNC_ID:
Not Available

# Drug_Target_54_HPRD_ID:
Not Available

# Drug_Target_54_ID:
4405

# Drug_Target_54_Locus:
Not Available

# Drug_Target_54_Molecular_Weight:
44298

# Drug_Target_54_Name:
Nitric oxide reductase

# Drug_Target_54_Number_of_Residues:
399

# Drug_Target_54_PDB_ID:
1YCH

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF00258	Flavodoxin_1
PF00753	Lactamase_B

# Drug_Target_54_Protein_Sequence:
>Nitric oxide reductase
MSQPVAITDGIYWVGAVDWNIRYFHGPAFSTHRGTTYNAYLIVDDKTALVDTVYEPFKEE
LIAKLKQIKDPVKLDYLVVNHTESDHAGAFPAIMELCPDAHVLCTQRAFDSLKAHYSHID
FNYTIVKTGTSVSLGKRSLTFIEAPMLHWPDSMFTYVPEEALLLPNDAFGQHIATSVRFD
DQVDAGLIMDEAAKYYANILMPFSNLITKKLDEIQKINLAIKTIAPSHGIIWRKDPGRII
EAYARWAEGQGKAKAVIAYDTMWLSTEKMAHALMDGLVAGGCEVKLFKLSVSDRNDVIKE
ILDARAVLVGSPTINNDILPVVSPLLDDLVGLRPKNKVGLAFGAYGWGGGAQKILEERLK
AAKIELIAEPGPTVQWVPRGEDLQRCYELGRKIAARIAD

# Drug_Target_54_Reaction:
Not Available

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Has nitric oxide reductase activity in combination with Hrb; probably involved in nitrosative stress protection

# Drug_Target_54_SwissProt_ID:
Q9FDN7

# Drug_Target_54_SwissProt_Name:
FPRA_MOOTA

# Drug_Target_54_Synonyms:
EC 1.-.-.-
FMN- protein fprA
Flavoprotein A
Type A flavoprotein fprA

# Drug_Target_54_Theoretical_pI:
6.29

# Drug_Target_54_Transmembrane_Regions:
None

# Drug_Target_55_Cellular_Location:
Not Available

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
Not Available

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
Not Available

# Drug_Target_55_GenBank_ID_Gene:
AE017222

# Drug_Target_55_GenBank_ID_Protein:
Not Available

# Drug_Target_55_GeneCard_ID:
Not Available

# Drug_Target_55_Gene_Name:
fni

# Drug_Target_55_Gene_Sequence:
>999 bp
GTGAACATCCGGGAGAGGAAGCGGAAGCACCTCGAGGCCTGCCTGGAAGGCGAGGTGGCC
TACCAGAAGACCACCACGGGGCTGGAAGGCTTCCGCCTCCGCTACCAGGCCCTGGCGGGC
CTCGCCCTAGGCGAGGTGGACCTCACCACCCCCTTCCTGGGGAAGACCCTGAAGGCCCCC
TTCCTCATCGGGGCCATGACCGGGGGGGAGGAAAACGGGGAGAGGATCAACCTGGCCCTG
GCGGAGGCCGCGGAGGCCTTAGGGGTGGGGATGATGCTGGGCTCGGGCAGGATCCTTCTG
GAGCGCCCCGAGGCCCTAAGGAGCTTCCGGGTGCGGAAGGTGGCCCCAAAGGCGCTCCTC
ATCGCCAACCTGGGCCTCGCCCAGCTCAGGCGCTACGGGCGGGACGACCTCCTCCGGCTC
GTGGAGGCCCTGGAGGCGGACGCCCTCGCCTTCCACGTGAACCCCCTGCAGGAGGCGGTG
CAGCGGGGGGACACGGACTTCCGGGGCCTGGTGGAGAGGCTCGCCGAACTCCTCCCCCTC
CCCTTCCCCGTGATGGTGAAGGAGGTGGGGCACGGCCTCTCCCGGGAGGCGGCCTTGGCC
CTACGGGACCTCCCCTTGGCGGCGGTGGACGTGGCCGGGGCCGGGGGGACGAGCTGGGCC
CGGGTGGAGGAGTGGGTGCGCTTCGGGGAGGTGCGCCACCCGGAGCTCTGCGAGATCGGG
ATCCCCACGGCGAGGGCCATCCTCGAGGTGCGGGAGGTCCTGCCCCACCTCCCCCTCGTG
GCCTCCGGCGGGGTCTACACGGGGACGGACGGGGCCAAGGCCCTGGCCCTGGGGGCGGAC
CTCTTGGCGGTGGCGCGCCCCCTCCTCAGGCCCGCCCTGGAGGGGGCGGAAAGGGTGGCG
GCCTGGATCGGGGACTACCTGGAAGAACTTAGGACCGCCCTCTTCGCCATCGGGGCCAAG
AACCCGAAGGAAGCCCGGGGGCGGGTGGAGCGGGTGTAG

# Drug_Target_55_General_Function:
Involved in oxidoreductase activity

# Drug_Target_55_General_References:
Not Available

# Drug_Target_55_HGNC_ID:
Not Available

# Drug_Target_55_HPRD_ID:
Not Available

# Drug_Target_55_ID:
5187

# Drug_Target_55_Locus:
Not Available

# Drug_Target_55_Molecular_Weight:
35901

# Drug_Target_55_Name:
Isopentenyl-diphosphate delta-isomerase

# Drug_Target_55_Number_of_Residues:
332

# Drug_Target_55_PDB_ID:
1VCG

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
PF01070	FMN_dh

# Drug_Target_55_Protein_Sequence:
>Isopentenyl-diphosphate delta-isomerase
MNIRERKRKHLEACLEGEVAYQKTTTGLEGFRLRYQALAGLALGEVDLTTPFLGKTLKAP
FLIGAMTGGEENGERINLALAEAAEALGVGMMLGSGRILLERPEALRSFRVRKVAPKALL
IANLGLAQLRRYGRDDLLRLVEALEADALAFHVNPLQEAVQRGDTDFRGLVERLAELLPL
PFPVMVKEVGHGLSREAALALRDLPLAAVDVAGAGGTSWARVEEWVRFGEVRHPELCEIG
IPTARAILEVREVLPHLPLVASGGVYTGTDGAKALALGADLLAVARPLLRPALEGAERVA
AWIGDYLEELRTALFAIGAKNPKEARGRVERV

# Drug_Target_55_Reaction:
Not Available

# Drug_Target_55_Signals:
None

# Drug_Target_55_Specific_Function:
Not Available

# Drug_Target_55_SwissProt_ID:
Q746I8

# Drug_Target_55_SwissProt_Name:
Q746I8_THET2

# Drug_Target_55_Synonyms:
EC 5.3.3.2

# Drug_Target_55_Theoretical_pI:
7.07

# Drug_Target_55_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
U08996

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
frp

# Drug_Target_5_Gene_Sequence:
>723 bp
ATGAACAATACGATTGAAACCATTCTTGCTCATCGCTCTATCCGAAAATTCACCGCAGTT
CCTATTACTGATGAACAAAGACAAACCATCATTCAAGCAGGTTTAGCTGCGTCTTCTTCT
AGTATGCTTCAAGTCGTCTCAATCGTTCGAGTGACTGACTCTGAAAAGCGTAACGAATTG
GCTCAATTTGCTGGTAACCAAGCTTATGTTGAAAGTGCGGCTGAGTTCTTAGTGTTTTGT
ATTGATTATCAGCGCCATGCAACCATCAATCCTGATGTACAGGCAGACTTTACAGAACTA
ACTCTGATTGGAGCAGTAGATTCTGGAATCATGGCACAAAACTGCTTGCTTGCAGCCGAG
TCTATGGGATTAGGTGGCGTATATATTGGAGGACTAAGGAATAGCGCAGCTCAAGTTGAT
GAGCTATTGGGCTTACCGGAAAATAGCGCGGTGTTGTTTGGTATGTGCTTAGGGCATCCC
GATCAAAATCCCGAAGTAAAGCCACGCCTACCTGCACATGTGGTTGTTCATGAAAATCAA
TACCAAGAGCTAAATTTAGATGATATTCAGAGCTACGATCAAACTATGCAAGCGTATTAT
GCGAGCCGTACAAGCAATCAAAAACTGAGTACATGGTCGCAAGAAGTCACTGGGAAGCTT
GCTGGTGAGTCGCGACCTCATATTCTGCCGTACTTGAACAGTAAGGGGCTAGCAAAACGC
TAA

# Drug_Target_5_General_Function:
Involved in oxidoreductase activity

# Drug_Target_5_General_References:
8206832	Lei B, Liu M, Huang S, Tu SC: Vibrio harveyi NADPH-flavin oxidoreductase: cloning, sequencing and overexpression of the gene and purification and characterization of the cloned enzyme. J Bacteriol. 1994 Jun;176(12):3552-8.
8885832	Tanner JJ, Lei B, Tu SC, Krause KL: Flavin reductase P: structure of a dimeric enzyme that reduces flavin. Biochemistry. 1996 Oct 22;35(42):13531-9.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4503

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
26310

# Drug_Target_5_Name:
NADPH-flavin oxidoreductase

# Drug_Target_5_Number_of_Residues:
240

# Drug_Target_5_PDB_ID:
2BKJ

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_5_Protein_Sequence:
>NADPH-flavin oxidoreductase
MNNTIETILAHRSIRKFTAVPITDEQRQTIIQAGLAASSSSMLQVVSIVRVTDSEKRNEL
AQFAGNQAYVESAAEFLVFCIDYQRHATINPDVQADFTELTLIGAVDSGIMAQNCLLAAE
SMGLGGVYIGGLRNSAAQVDELLGLPENSAVLFGMCLGHPDQNPEVKPRLPAHVVVHENQ
YQELNLDDIQSYDQTMQAYYASRTSNQKLSTWSQEVTGKLAGESRPHILPYLNSKGLAKR

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Involved in bioluminescence. It is a good supplier of reduced flavin mononucleotide (FMNH2) to the bioluminescence reaction

# Drug_Target_5_SwissProt_ID:
Q56691

# Drug_Target_5_SwissProt_Name:
FRP_VIBHA

# Drug_Target_5_Synonyms:
EC 1.6.99.-
Flavin reductase P
NADPH- FMN oxidoreductase

# Drug_Target_5_Theoretical_pI:
5.06

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
Not Available

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
RPS6KA4

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
Not Available

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
7124

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
Not Available

# Drug_Target_6_Name:
Ribosomal protein S6 kinase alpha-4

# Drug_Target_6_Number_of_Residues:
0

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
Not Available

# Drug_Target_6_Protein_Sequence:
Not Available

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
Not Available

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
O75676

# Drug_Target_6_SwissProt_Name:
KS6A4_HUMAN

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
Not Available

# Drug_Target_6_Transmembrane_Regions:
Not Available

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
L48616

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
phzG

# Drug_Target_7_Gene_Sequence:
>669 bp
ATGAACGGCTCAATACAAGGCAAGCCGCTGTTGGGTAAAGGCATGTCGGAATCCCTCACC
GGCACATTGGATGCGCCCTTCCCCGAATATCAGACACTGCCCGCCGACCCCATGAGCGTG
CTGCACAATTGGCTGGAGCGTGCGCGCCGCGTGGGCATCCGCGAGCCCAGGGCGCTGGCG
CTGGCCACCGCCGACAGCCAGGGCCGGCCCTCCACGCGTATCGTGGTGATCAGCGAGATC
AGTGACGCCGGCGTGGTGTTCAGCACCCATGCCGGCAGCCAGAAAGGCCGTGAACTGCTC
CACAACCCCTGGGCTTCGGGCGTGCTGTATTGGCGCGAAACCAGTCAGCAAATCATCCTC
AATGGCCAGGCCGTGCGCTTGCCGAACGCCAAGGCCGATGATGCCTGGCTCAAGCGCCCT
TATGCCACGCACCCGATGTCATCGGTGTCTCGCCAGAGTGAAGAACTGCAGGACGTGCAG
GCCATGCGCAACGCCGCCAGGCAACTTGCCGAGCTGCAGGGTCCACTGCCGCGTCCGGAG
GGATATTGCGTGTTCGAGTTGCGCCTTGAATCGCTGGAGTTCTGGGGAAATGGGCAGGAG
CGCTTGCATGAGCGGTTGCGGTATGACCGCAGCGATACAGGCTGGAACGTGCGGCGTTTG
CAGCCCTGA

# Drug_Target_7_General_Function:
Involved in FMN binding

# Drug_Target_7_General_References:
9573209	Mavrodi DV, Ksenzenko VN, Bonsall RF, Cook RJ, Boronin AM, Thomashow LS: A seven-gene locus for synthesis of phenazine-1-carboxylic acid by Pseudomonas fluorescens 2-79. J Bacteriol. 1998 May;180(9):2541-8.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
5193

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
24935

# Drug_Target_7_Name:
Phenazine biosynthesis protein phzG

# Drug_Target_7_Number_of_Residues:
222

# Drug_Target_7_PDB_ID:
1TY9

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_7_Protein_Sequence:
>Phenazine biosynthesis protein phzG
MNGSIQGKPLLGKGMSESLTGTLDAPFPEYQTLPADPMSVLHNWLERARRVGIREPRALA
LATADSQGRPSTRIVVISEISDAGVVFSTHAGSQKGRELLHNPWASGVLYWRETSQQIIL
NGQAVRLPNAKADDAWLKRPYATHPMSSVSRQSEELQDVQAMRNAARQLAELQGPLPRPE
GYCVFELRLESLEFWGNGQERLHERLRYDRSDTGWNVRRLQP

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Involved in the biosynthesis of the antibiotic phenazine, a nitrogen-containing heterocyclic molecule having important roles in virulence, competition and biological control. Probably catalyzes the final step in the conversion of trans-2,3- dihydro-3-hydroxyanthranilic acid (DHHA) to phenazine-1-carboxylic acid (PCA)

# Drug_Target_7_SwissProt_ID:
Q51793

# Drug_Target_7_SwissProt_Name:
PHZG_PSEFL

# Drug_Target_7_Synonyms:
EC 1.4.-.-

# Drug_Target_7_Theoretical_pI:
9.05

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
Not Available

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
AE004091

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
PA1204

# Drug_Target_8_Gene_Sequence:
>558 bp
ATGAGCGACGACATCAAGGTATTGGGCATTTCCGGCAGCCTGCGCAGCGGCTCCTACAAC
AGCGCGGCGCTGCAGGAGGCGATTGGCCTGGTCCCGCCGGGCATGAGCATCGAGCTGGCG
GACATCTCCGGCATCCCGCTGTACAACGAGGACGTCTACGCCCTCGGCTTCCCGCCCGCG
GTGGAACGCTTCCGCGAGCAGATTCGCGCGGCGGACGCGCTGCTGTTCGCCACCCCGGAA
TACAACTATTCGATGGCCGGGGTGCTGAAGAATGCCATCGACTGGGCCTCGCGGCCGCCG
GAGCAGCCGTTCTCCGGCAAGCCGGCGGCGATCCTCGGCGCCAGCGCCGGGCGTTTCGGC
ACCGCGCGGGCGCAGTATCACTTGCGCCAGACGCTGGTGTTCCTCGACGTTCATCCGCTG
AACAAGCCGGAAGTGATGATCTCCAGCGCGCAGAACGCCTTCGATGCCCAGGGCCGGCTG
CTCGACGACAAGGCGCGCGAGCTGATCCAGCAGCAGTTGCAGGCCCTGCAGCTATGGGTG
CGCCGCCTGCGCGGTTGA

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
5194

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
20224

# Drug_Target_8_Name:
Hypothetical protein

# Drug_Target_8_Number_of_Residues:
185

# Drug_Target_8_PDB_ID:
1X77

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF03358	FMN_red

# Drug_Target_8_Protein_Sequence:
>Hypothetical protein
MSDDIKVLGISGSLRSGSYNSAALQEAIGLVPPGMSIELADISGIPLYNEDVYALGFPPA
VERFREQIRAADALLFATPEYNYSMAGVLKNAIDWASRPPEQPFSGKPAAILGASAGRFG
TARAQYHLRQTLVFLDVHPLNKPEVMISSAQNAFDAQGRLLDDKARELIQQQLQALQLWV
RRLRG

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
Q9I4D4

# Drug_Target_8_SwissProt_Name:
Q9I4D4_PSEAE

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
6.54

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
Not Available

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
HAO2

# Drug_Target_9_Gene_Sequence:
Not Available

# Drug_Target_9_General_Function:
Not Available

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
7087

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
Not Available

# Drug_Target_9_Name:
Hydroxyacid oxidase 2

# Drug_Target_9_Number_of_Residues:
0

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
Not Available

# Drug_Target_9_Protein_Sequence:
Not Available

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
Not Available

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
Q9NYQ3

# Drug_Target_9_SwissProt_Name:
HAOX2_HUMAN

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
Not Available

# Drug_Target_9_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB03247
